CA2245578A1 - Spiro-ketal derivatives and their use as therapeutic agents - Google Patents
Spiro-ketal derivatives and their use as therapeutic agents Download PDFInfo
- Publication number
- CA2245578A1 CA2245578A1 CA 2245578 CA2245578A CA2245578A1 CA 2245578 A1 CA2245578 A1 CA 2245578A1 CA 2245578 CA2245578 CA 2245578 CA 2245578 A CA2245578 A CA 2245578A CA 2245578 A1 CA2245578 A1 CA 2245578A1
- Authority
- CA
- Canada
- Prior art keywords
- dioxa
- aza
- decane
- fluorophenyl
- spiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims description 16
- 229940124597 therapeutic agent Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 242
- -1 phenoxy, benzyloxy Chemical group 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 34
- 150000002367 halogens Chemical class 0.000 claims abstract description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 29
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 28
- 208000002193 Pain Diseases 0.000 claims abstract description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 18
- 206010047700 Vomiting Diseases 0.000 claims abstract description 17
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 11
- 206010027599 migraine Diseases 0.000 claims abstract description 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims abstract description 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims abstract description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 12
- 206010061218 Inflammation Diseases 0.000 claims abstract 3
- 230000004054 inflammatory process Effects 0.000 claims abstract 3
- 239000000460 chlorine Substances 0.000 claims description 91
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 71
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 58
- 238000006243 chemical reaction Methods 0.000 claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 25
- 102000003141 Tachykinin Human genes 0.000 claims description 23
- 108060008037 tachykinin Proteins 0.000 claims description 23
- 229910052757 nitrogen Chemical group 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- 241000689227 Cora <basidiomycete fungus> Species 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 241000036848 Porzana carolina Species 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 150000002900 organolithium compounds Chemical class 0.000 claims description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 13
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 46
- 238000005481 NMR spectroscopy Methods 0.000 description 42
- 239000003921 oil Substances 0.000 description 41
- 235000019198 oils Nutrition 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 201000010099 disease Diseases 0.000 description 21
- 125000003003 spiro group Chemical group 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 239000011521 glass Substances 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 102100024304 Protachykinin-1 Human genes 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 239000006260 foam Substances 0.000 description 11
- 101150041968 CDC13 gene Proteins 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 9
- 101800003906 Substance P Proteins 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 208000033808 peripheral neuropathy Diseases 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229910003827 NRaRb Inorganic materials 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000008570 general process Effects 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- YFKBXYGUSOXJGS-UHFFFAOYSA-N 1,3-Diphenyl-2-propanone Chemical compound C=1C=CC=CC=1CC(=O)CC1=CC=CC=C1 YFKBXYGUSOXJGS-UHFFFAOYSA-N 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 101800000399 Neurokinin A Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 239000002249 anxiolytic agent Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 230000020341 sensory perception of pain Effects 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HEAUFJZALFKPBA-JPQUDPSNSA-N (3s)-3-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-JPQUDPSNSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 4
- 101800002813 Neurokinin-B Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 239000010779 crude oil Substances 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100033009 Tachykinin-3 Human genes 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000014 opioid analgesic Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 229910052701 rubidium Inorganic materials 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical group O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000027601 Inner ear disease Diseases 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100037342 Substance-K receptor Human genes 0.000 description 2
- 108010072901 Tachykinin Receptors Proteins 0.000 description 2
- 102000007124 Tachykinin Receptors Human genes 0.000 description 2
- 241000159243 Toxicodendron radicans Species 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000454 anti-cipatory effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- 229960004193 dextropropoxyphene Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 208000006275 fascioliasis Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical compound [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000008653 root damage Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 230000002455 vasospastic effect Effects 0.000 description 2
- 201000005539 vernal conjunctivitis Diseases 0.000 description 2
- 208000027491 vestibular disease Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- IOWGHQGLUMEZKG-UHFFFAOYSA-N (2-bromophenyl)methanol Chemical compound OCC1=CC=CC=C1Br IOWGHQGLUMEZKG-UHFFFAOYSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DLXNVSRGOHFBDV-UHFFFAOYSA-N (3Z)-3-amino-2-chloro-3-(methylhydrazinylidene)propanoic acid Chemical compound CNNC(C(Cl)C(=O)O)=N DLXNVSRGOHFBDV-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- GSZAAEJBPFTBKG-INIZCTEOSA-N (3s)-4-benzyl-3-(4-fluorophenyl)morpholin-2-one Chemical compound C1=CC(F)=CC=C1[C@H]1C(=O)OCCN1CC1=CC=CC=C1 GSZAAEJBPFTBKG-INIZCTEOSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- SVTKSKRNLMAUKF-HAIKCVHQSA-N (4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O SVTKSKRNLMAUKF-HAIKCVHQSA-N 0.000 description 1
- ZGSZBVAEVPSPFM-HYTSPMEMSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-HYTSPMEMSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BOLDZXRCJAJADM-AAXBYHQXSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid;trihydrate Chemical compound O.O.O.OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BOLDZXRCJAJADM-AAXBYHQXSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RCHDLEVSZBOHOS-UHFFFAOYSA-N 1,4-dichlorobut-2-yne Chemical compound ClCC#CCCl RCHDLEVSZBOHOS-UHFFFAOYSA-N 0.000 description 1
- CRRUGYDDEMGVDY-UHFFFAOYSA-N 1-bromoethylbenzene Chemical compound CC(Br)C1=CC=CC=C1 CRRUGYDDEMGVDY-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IGZGUYVVBABKOY-UHFFFAOYSA-N 1-iodo-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1I IGZGUYVVBABKOY-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 description 1
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- UMUJZUDPHBABQX-UHFFFAOYSA-N 2-iodo-1-methoxy-4-(trifluoromethyl)benzene Chemical compound COC1=CC=C(C(F)(F)F)C=C1I UMUJZUDPHBABQX-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- AWHIZLGSPNLJRO-UHFFFAOYSA-M CCCCO[Zr](Cl)(OCCCC)OCCCC Chemical compound CCCCO[Zr](Cl)(OCCCC)OCCCC AWHIZLGSPNLJRO-UHFFFAOYSA-M 0.000 description 1
- 101100279441 Caenorhabditis elegans egg-5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010049949 Intercostal neuralgia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 101100121960 Mus musculus Glis2 gene Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 102000046798 Neurokinin B Human genes 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 244000018764 Nyssa sylvatica Species 0.000 description 1
- 235000003339 Nyssa sylvatica Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- BCGJBQBWUGVESK-KCTCKCTRSA-N Oxymorphone hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BCGJBQBWUGVESK-KCTCKCTRSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 244000258044 Solanum gilo Species 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100121961 Xenopus laevis glis2 gene Proteins 0.000 description 1
- ADSXDBCZNVXTRD-UHFFFAOYSA-N [Mg]C1=CC=CC=C1 Chemical compound [Mg]C1=CC=CC=C1 ADSXDBCZNVXTRD-UHFFFAOYSA-N 0.000 description 1
- XNXNQLTYVZUMNM-UHFFFAOYSA-N [N].CCCCCCCCCC Chemical compound [N].CCCCCCCCCC XNXNQLTYVZUMNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229960005380 alfentanil hydrochloride Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 239000003152 bradykinin antagonist Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- 229960002705 dihydrocodeine bitartrate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- 238000011832 ferret model Methods 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960002764 hydrocodone bitartrate Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229960002738 hydromorphone hydrochloride Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- RWTWIZDKEIWLKQ-IWWMGODWSA-N levorphan tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 RWTWIZDKEIWLKQ-IWWMGODWSA-N 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960005157 levorphanol tartrate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CYSFUFRXDOAOMP-UHFFFAOYSA-M magnesium;prop-1-ene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C=C CYSFUFRXDOAOMP-UHFFFAOYSA-M 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960005189 methadone hydrochloride Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 229960003066 morphine tartrate Drugs 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- RYVLOOXFFIFQEN-UHFFFAOYSA-N n-[4-(1-oxo-3,4-dihydro-2h-pyrido[4,3-b]indol-5-yl)butyl]acetamide Chemical group C12=CC=CC=C2N(CCCCNC(=O)C)C2=C1C(=O)NCC2 RYVLOOXFFIFQEN-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 229960001513 nalbuphine hydrochloride Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- UAIXRPCCYXNJMQ-HPRIMLMLSA-N nih-8805 Chemical compound Cl.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 UAIXRPCCYXNJMQ-HPRIMLMLSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960005374 oxymorphone hydrochloride Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- OQGYMIIFOSJQSF-DTOXXUQYSA-N pentazocine hcl Chemical compound Cl.C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 OQGYMIIFOSJQSF-DTOXXUQYSA-N 0.000 description 1
- 229960003809 pentazocine hydrochloride Drugs 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000030062 persistent idiopathic facial pain Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940065347 propoxyphene hydrochloride Drugs 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical group C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to compounds of formula (I), wherein R represents hydroxy, C1-6alkoxy, C3-6alkenyloxy, C3-6alkynyloxy, fluoro C16alkoxy, C3-7cycloalkoxy, C3-7cycloalkylC1-4alkoxy, phenoxy, benzyloxy or halogen, wherein the phenyl moiety of said phenoxy or benzyloxy is optionally substituted by one, two or three of C1-6alkyl, C1-6alkoxy, halogen and trifluoromethyl; R1, R2, R3, R4, R5, R6, R9a and R9b are as defined in the specification; or R and R1 may be joined such that -R-R1- is a linkage selected from -O-CH2- and -O-CH2CH2-; m is zero, 1, 2 or 3; and n is zero, 1, 2 or 3; with the proviso that the sum total of m and n is 2 or 3; and pharmaceutically acceptable salts thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.
Description
CA 0224~78 1998-08-0~
~PIRO-K~TAL DERIVATIVES AND '1'~1~1~ USE AS
THERAPEUTIC AGENTS
This invention relates to a class of spiroketal compounds which are ~ 5 useful as tachykinin antagonists. The present invention also relates to processes for their preparation, pharmaceutical compositions Cont,S~ining them, and to their use in therapy.
The tachykinins are a group of naturally oc~ulrhlg peptides found widely distributed throughout m:~mm~ n tissues, both within the central nervous system and in peripheral nervous and circulatory systems.
The tachykinins are distinguished by a conserved carboxyl-terminal sequence:
Phe-X-Gly-Leu-Met-NH2 At present, there are three known m~mm~ n tachykinins referred to as substance P, neurokinin A (NKA, substance K, neuromedin L) and neurokinin B (NKB, neuromedin K) ~for review see J.E. Maggio, Peptides (1985) 6(suppl. 3), 237-242). The current nomenclature designates the three tachykinin receptors mediating the biological actions of substance P, NKA and NKB as the NKl, NK2 and NK3 receptors, respectively.
Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic infl~mmiqtory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, infl~mmatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular infl~mm~tory diseases, proliferative vitreoretinopathy, irritable bowel syndrome and disorders of bladder function including cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R.
CA 02245578 l998-08-05 Patacchini, P. Rovero .and A. Giachetti, J. Auton. Pharmacol. tl993) ~, 23-93.
For instance, substance P is believed inter alia to be involved in the neurotr~n.~mi~ion of pain sensations ~Otsuka et al, "Role of Substance P
5 as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia" in 1982 Substance P in the Nervous System, Ciba Foundation Symposium 91, 13-34 (published by Pitman) and Otsuka and Yanagisawa, "~oes Substance P Act as a Pain Transmitter?" TIPS (1987) ~, 506-510], spe~ific~lly in the tr~n~mi.~ion of pain in migraine (B.E.B. Sandberg et al, 10 eJ. Med Chem, (1982) 25, 1009) and in arthritis [Levine et al Science (1984) 226, 647-549]. Tachykinins have also been implicated in gastrointestinal (GI) disorders and diseases of the GI tract such as ;nfl~mm atory bowel disease [Mantyh et al Neuroscience (1988) ~~(3), 817-37 and D. Regoli in "Trends itl Cluster Headache" Ed. Sicuteri et al Elsevier Scientific Publishers, Amsterdam (1987) page 85)] and emesis ~F. D. Tattersall et al, Eur. cJ. Pharmacol., (1993) 250, R5-R6]. It is also hypothesised that there is a neurogenic mech~ni~m for arthritis in which substance P may play a role [Kidd et al "A Neurogenic Mech~ni.~m for. Symmetrical Arthritis" in The Lancet, 11 November 1989 and Gronblad et al, "Neuropeptides in 20 Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in J.
Rheurnatol. (1988) 15(12), 1807-10~. Therefore, substance P is believed to be involved in the infl~mmatory response in diseases such as rheumatoid arthritis and osteoarthritis, and ~lbrositis [O'Byrne et al, Arthritis and Rheumatism (1990) 33, 1023-8l. Other disease areas where tachykinin 25 antagonists are believed to be useful are allergic conditions [Hamelet et al,Can. ~J. Pharmacol. Physiol. (1988) 66, 1361-7], immunoregulation ~Lotz et al, Science (1988) 241~ 1218-21 and Kimball et al, ~J. Im~nu7l01. (1988) 141(10), 3564-9] vasodilation. bronchospasm, reflex or neuronal control of the viscera ~antyh et al, PNAS (1988) ~, 323~-9] andr possibly by 30 arresting or slowing B-amyloid-mediated neurodegenerative changes CA 0224~78 lsss-os-o~
wo 97/30056 PCT/Gs97/00404 ~Yankner et al, Science (1990) 250, 279-82] in senile dementia of the Alzheimer type, ~17h~imer~s disease and Down's Syndrome.
Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular snlall cell lung cancer (SCL~) ~Langdon et al, Cancer Research (1992) 52, 4554-7].
Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Luber-Narod et al, poster C.~.N.P. XVIIIth Congress, 28th June-2nd July 1992~, and in disorders of bladder function such as bladder detrusor hyper-reflexia (Lancet, 16th May 1992, 1239).
It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersen~ y disorders such as poison ivy, vasospastic diseases such as :~n~in:~ and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosus (European patent specification no. 0 436 334), ophth~lm~c disease such as conjuctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).
European patent specification no. 0 577 394 (published 5th January 26 1994) discloses morpholine and thiomorpholine tachykinin receptor antagonists of the general formula R~X~ R4a ~ R2a ~ R5a Rla wherein Rla is a large variety of substituents;
R2a and R3a are inter alia hydrogen;
R4a is inter alia R6Z~
, R
R5a is z,nter al~a optionally substituted phenyl;
5 R6a, R7a and R8a are a variety of substituents;
Xa is O, S, SO or SO2;
ya iS inter alia O; and za is hydrogen or C1 4alkyl.
We have now found a further class of non-peptides which are potent 10 antagonists of tachykinins, especially of substance P.
The present invention provides compounds of the formula (I):
R'~R3 o (C~"
R9b IN 1 RJ
Rs (I) wherein R represents hydroxy, C1 Galkoxy, C3 ¢alkenyloxy, C3.Galkynyloxy, fluoroCl 6alkoxy, C3 7cycloalkoxy, C3 7cycloalkylCI 4alkoxy, phenoxy, benzyloxy or halogen, wherein the phenyl moiety of said phenoxy Ol benzyloxy is optionally substituted by one, two or thrce substituents selected from Cl Galkyl, Cl Galkoxy, halogen and trifluoromethyl;
R1 represents hydrogen, halogen, C1 Galkyl, C~Galkenyl, C~Galkynyl, C3 7cycloalkyl, C3 7cycloalkylCl 4alkyl, Cl.Galkoxy, fluoroCl Galkyl, CA 0224~78 1998-08-0~
fi~uoroCl 6alkoxy, Cl.4alkyl substituted by a Cl ~lko~y or hydroxy group, hydroxy, trimethylsilyl, nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONRaRb, NRaRb, SO2NRaRb, or OCl 4alkylNRaRb, where Ra and Rb are each independently hydrogen or Cl 4alkyl;
R2 and R3 each independently represent hydrogen, halogen, Cl 6alkyl, Cl 6alkoxy substituted by Cl 4alkoxy or trifluoromethyl;
or R and R1 may be joined such that -R-Rl- is a linkage selected from -O-CH2- and -O-CH2CH2-;
or, where Rl and R2 are attached to adjacent carbon atoms, they 10 may be joined such that, together with the carbon atoms to which they are attached, there is formed a 5- or 6-membered ring optionally cont~inin~ ~
or 2 heteroatoms selected from oxygen, sulfur or nitrogen, or 1 or 2 groups selected from S(O), S(O)2 and NRa, which ring may also contain 1 or 2 double bonds, where Ra is as previously defined;
R4 represents hydrogen, halogen, Cl 6alkyl, C2 6alkenyl, C2 6alkynyl, C3 7cycloalkyl, C3 7cycloal~ylCl 4alkyl, Cl 6alkoxy, Cl.4alkyl substituted by a Cl 4alkoxy group, trifluoromethyl, nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONRaRb where Ra and Rb are as previously defined;
R5 represents hydrogen, halogen, C1 Galkyl, Cl Galkoxy substitutcd by Cl 4alkoxy or trifluoromethyl;
RG represents hydrogen, CORa, CO2Ra, COCONRaRb, COCO2Ra, Cl Galkyl optionally substituted by a group selected from (CO2Ra, CONRaRb, hydroxy, CN, CORa, NRaRb, C(NOH)NRaRb, CONHphenyl(Cl 4alkyl), COCO2Ra, CONHNRaRb, C(S)NRaRb, CONRaC1 GalkylRl2, CONRl3C2 Galkenyl, CONRl3C~ Galkynyl, COCONRaRb, CONRaC~NRb)NRaRb, CONRaheteroaryl, and phenyl optionally substituted by one, two or three substituents selected from C1 Galkyl, Cl (;alkoxy, halogen and trifluoromethyl);
or RG represents a group of the formula -CH2CsCCH2NR7R8 where R7 and R8 are as defined below;
CA 0224~78 1998-08-0~
or R6 represents Cl 6alkyl, optionally substituted by oxo, substituted by a 5-membered or 6-membered heterocyclic ring contS3ining 2 or 3 nitrogen atoms optionally substituted by =O or =S and optionally substituted by a group of the formula ZNR7R8 where Z is Cl 6alkylene or C3 6cycloaIkyl;
R7 is hydrogen or Cl 4alkyl, C3 7cycloalkyl, C3 7cycloalkylCl 4alkyl, or C2 4alkyl substituted by Cl 4alkoxy or hydroxyl;
R8 is hydrogen or Cl 4alkyl, C3 7cycloalkyl, C3 7cycloalkylCl 4alkyl, or C2 4alkyl substituted by Cl 4alkoxy, hydroxyl or a 4, 5 or 6 membered 10 heteroaliphatic ring cont~ining one or two heteroatoms selected from N, O
and S;
or R7, R8 and the nitrogen atom to which they are attached for~n a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or Cl 4alkoxy optionally substituted by a 1~ Cl~alkoxy or hydroxyl group, and optionally cont~ining a double bond, which ring ~ay optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH
or NRC moiety where Rc is Cl 4alkyl optionally substituted by hydroxy or Cl 4alkoxy;
or R7, R8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
or Z, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring to 4 to 7 ring atoms which may optionally contain an oxygen ring atom;
R9a and R9b each independently represent hydrogen or Cl 4alkyl, or R9a and R9b are joined so, together with the carbon atoms to which they are attached, there is formed a C6 7 ring;
Rl2 represents ORa, CONRaRb or heteroaryl;
Rl3 represents H or Cl ~;alkyl;
m is zero, 1, 2 or 3; and CA 0224~78 1998-08-0~
n is zero, 1, 2 or 3; with the proviso that the sum total of m and n is 2 or 3;
and pharmaceutically acceptable salts thereo~
A preferred class of compound of formula (I) is that wherein R
5 represents hydroxy, Cl 3alkoxy, C3 salkenyloxy, phenoxy or halogen.
Particularly preferred are those compounds where R represents hydroxy or Cl 3alkoxy, and especially those where R represents hydroxy or methoxy.
Where R represents a phenoxy or benzyloxy substituent the phenyl moiety of each substituent is preferably unsubstituted.
Where R represents a halogen atom, fluorine is preferred.
A preferred class of compound of formula (I) is that wherein represents hydrogen, halogen, Cl Galkyl, C2 6alkenyl, C2.~ialkynyl, C3 7cycloalkyl, C3 7cycloalkylC1 4alkyl, Cl 6alkoxy, Cl 4alkyl substituted by a Cl 4alkoxy group, OCF3, hydroxy, tri~1uoromethyl, trimethylsilyl, nitro, CN, SRa, SORa, SO2Ra, CORa, C02Ra, CONRaRb where Ra and Rb are each independently hydrogen or Cl 4alkyl; and R2 and R3 each independently represent hydrogen, halogen, Cl ~alkyl, Cl ~alkoxy substituted by Cl 4alkoxy or trifluoromethyl Certain particularly apt compounds of the present invention include those wherein Rl is hydrogen, Cl ~alkyl, Cl 4alkoxy, halogen, fluoroC
3alkyl or fluoroCl 3alkoxy.
Most aptly R2 is hydrogen, Cl ~alkyl, Cl 4alkoxy, halogen or CF3.
Most aptly R3 is hydrogen, fluorine, chlorine or CF3 Favourably Rl is hydrogen, Cl 4alkyl, especially methyl, Cl 4alkoxy, especially methoxy, OCF3 Ol CF3.
Favourably R2 is hydrogen, fluorine, chlorine, Cl 4alkyl or CF3, especially hydrogen or CF3.
Favourably R3 is hydrogen.
Preferably R'7 is in the ~-position on the phenyl ring.
Most aptly R~ is hydrogen.
Most aptly R~ is hydrogen, fluorine, chlorine or CF3 Preferably R4 is hydrogen and R5 is 4-fluoro.
Most aptly R9a and R9b are each independently hydrogen or methyl.
Preferably R9a is hydrogen. Preferably R9b is hydrogen. Most preferably R9a and R9b are both hydrogen.
Preferably n is 1.
Preferably m is 1 or 2, especially 1.
Favourably R~ is hydrogen, Cl 3alkyl, especially CHa and CH(CH3), substituted by phenyl wherein said phenyl ring is optionally substituted by Cl salkoxy (especially methoxy) or CF3, or R6 is a group of formula -CH2C--CCH2NR7R8, or R~i is Cl 3alkyl, in particular CH2, CH(CH3) and CH2CH2 and especially CH2, substituted by a 5-membered ring.
In particular, the 5-membered ring is a heterocyclic ring selected from:
H3~ H~ N3/
H i o =~ 7 8 ZNR R
N ZNR R N~/ ; and <~ .
ZNR R ZNR R
Particularly preferred heterocyclic rings are selected from:
CA 0224=,=,78 1998-08-0=, _ 9 _ H N N
0~ ~ i o=( ~ i ~~ ~ i N HN--N H ZNR R
N~/ ; HN~ ~ ; and <~
N ZNR R N ZNR R N--\
ZNR R
Most especially, the heterocyclic ring is selected from:
N ~/ ; and HN
N N ZNR R
One favoured group of compounds of the present invention are of the formula (Ia) and pharmaceutically acceptable salts thereof:
A ~'1 ~~~~ A
N~
6 ~A3 (I~) wherein R and R~ are as defined in relation to formula (I);
Al is hydrogen, Cl 3alkyl, Cl 3alkoxy, halogen, fluoroCl 3alkyl or fluoroCl 3alkoxy;
A2 is hydrogen, halogen, Cl 4alkyl or fluoroCl 3alkyl; and A3 is hydrogen or halogen.
CA 0224~78 1998-08-0~
In particular, Al is preferably hydrogen, methyl, methoxy, OC~F3 or CF3.
In particular A2 is hydrogen, ffuorine or trifiuoromethyl.
In particular A3 is hydrogen or fluorine.
With respect to compounds of the formulae (I) and (Ia), Z (where present), may be a linear, branched or cyclic group. Favourably Z contains 1 to 4 carbon atoms and most favourably 1 or 2 carbon atoms. A
particularly favourable group Z is CH2.
With respect to compounds of the formulae (I) and (Ia~, R7 may aptly be a Cl 4alkyl group or a C~4alkyl group substituted by a hydroxyl or Cl 2alkoxy group, R8 may aptly be a Cl 4alkyl group or a Cl 4alkyl group substituted by a hydroxyl or Cl 2alkoxy group, or R7 and R8 may be linked so that, together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl, piperidyl, morpholino, thiomorpholino, piperazino or piperazino group substituted on t~e nitrogen atom by a Cl 4alkyl group or a C2 4alkyl group substituted by a hydroxy or Cl 2alkoxy group.
Where the group NR7R8 represents a heteroaliphatic ring of 4 to 7 ring atoms and said ring contains a double bond, a particularly preferred group is 3-pyrroline Where the group NR7R8 represents a non-aromatic azabicyclic ring system, such a system may contain between 6 and 12, and preferabl~,~
between 7 and 10, ring atoms. Suitable rings include 5-azabicvclo[2.1.1]hexyl, 5-azabicyclo[2.2.1~heptyl, 6-azabicyclo[3.2.1]octyl, 2-azabicycloL2.2.2]octyl, 6-azabicyclo[3.2.2]nonyl, 6-azabicyclo[3.3.1~nonyl, 6-azabicyclo[3.2.2]decyl, 7-azabicyclo[4.3.1]decyl, 7-azabicycloL4.4. l]undecyl and 8-azabicyclo L5-4- l]dodecyl, especially 5-azabicyclo[2.2.1]heptyl and 6-azabicyclo[3.2.1]octyl.
Where R8 represents a C2 4alkyl glOup substituted by a 5 or 6 membered heteroaliphatic ring cont~ining one or two heteroatoms selected fiom N, O and S, suitable rings include pyrrolidino, piperidino, piperazino, CA 0224',',78 1998-08-0', morpholino, or thiomorpholino. Particularly preferred are nitrogen cont~ining heteroaliphatic rings, especially pyrrolidino and morpholino rings.
In the group ZNR7R8, Z is preferably CH2 or CH2CH2, and especially 5 CH2.
The group NR7R8 preferably represents amino, methyl~mino, dimethylamino, diethyl~mino, azetidinyl, pyrrolidino or morpholino.
In particular, NR7R8 is preferably dimethylamino, azetidinyl or pyrrolidino, especially dimethyl ~mino.
Where R and Rl are joined such that -R-Rl- is a linkage, this is preferably -O-CH2-, thereby forming a phthalan ring.
Where Rl and R2, together with the carbon atoms to which they are attached, form a 5- or 6-membered ring optionally cont~ining 1 or ~
heteroatoms selected from oxygen, sulfur or nitrogen, or 1 or 2 groups 15 selected from S(O~, ~(0)2 and NRa, and which ring may also contain 1 or 2 double bonds, it will be appreciated that the ring thus formed may be saturated, partially saturated or unsaturated. Thus, Rl and R2 may represent, for example, -OCH2CH2CH2-, -OCH2CH20-, -OCH2CH2-, -OCH20-, -NRaCH2CH2CH2-, -NRaCH2CH2-, -CH2CH2CH2CH2-, 20 -CH2CH2CH2-, -CH=CH-CH=CH-, -O-CH=CH-, -NRa-CH=CH-, -S-CH=CH-, -NRa-CH=N-, -O-CH=N-, -S-CH=N-, -N=CH-CH=CH-, -CH=N-CH=CH-. Particularly preferred linkages formcd by Rl and R2 include, -OCH2CH2CH~-,-OCH2CH20-,-OCH2CH2-,-OCH20-,-NRaCH CH2CH~-and -CH=CH-CH=CH- In these examples, Ra preferably represents a 25 hydrogen atom.
As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples o~ suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, 30 n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.
CA 0224~78 1998-08-0~
The cycloalkyl groups referred to herein may represent, ~or example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. A suitable cycloalkylalkyl group may be, for example, cyclopropylmethyl.
As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. ~,x~mI~les of suitable alkenyl groups include vinyl and allyl. A suitable alkynyl group is propar~yl.
As used herein, the terms "fluoroCl 6alkyl" and "fluoroCl 6alkoxy"
means a Cl 6alkyl or Cl 6alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by a fluorine atom.
Particularly preferred are fluoroC1 3alkyl and fluoroCl 3alkoxy groups, for example, CF3, CH2CH2F, CH2CHF2, CH2CF3, OCF3, OCH2CH2F, OCH2CHF2 or OCH2CF3, and most especially (~F3 and OCF3.
When used herein the term halogen means ~luorine, chlorine, ~5 bromine and iodine. The most apt halogens are ~Luorine and chlorine of which fluorine is preferred.
Specific compounds within the scope of this invention include:
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-phenyl-spiro[5.4]decane;
(2R, 3S,gR)-4-aza-4-benzyl- 1, 7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-f~uorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5 4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-~:~-(trifluoromethyVphenyl)spiro[5.4]decane;
(2R,3S,9S)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethoxy)phenyl)spiro[5.4]decane;
~PIRO-K~TAL DERIVATIVES AND '1'~1~1~ USE AS
THERAPEUTIC AGENTS
This invention relates to a class of spiroketal compounds which are ~ 5 useful as tachykinin antagonists. The present invention also relates to processes for their preparation, pharmaceutical compositions Cont,S~ining them, and to their use in therapy.
The tachykinins are a group of naturally oc~ulrhlg peptides found widely distributed throughout m:~mm~ n tissues, both within the central nervous system and in peripheral nervous and circulatory systems.
The tachykinins are distinguished by a conserved carboxyl-terminal sequence:
Phe-X-Gly-Leu-Met-NH2 At present, there are three known m~mm~ n tachykinins referred to as substance P, neurokinin A (NKA, substance K, neuromedin L) and neurokinin B (NKB, neuromedin K) ~for review see J.E. Maggio, Peptides (1985) 6(suppl. 3), 237-242). The current nomenclature designates the three tachykinin receptors mediating the biological actions of substance P, NKA and NKB as the NKl, NK2 and NK3 receptors, respectively.
Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic infl~mmiqtory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, infl~mmatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular infl~mm~tory diseases, proliferative vitreoretinopathy, irritable bowel syndrome and disorders of bladder function including cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R.
CA 02245578 l998-08-05 Patacchini, P. Rovero .and A. Giachetti, J. Auton. Pharmacol. tl993) ~, 23-93.
For instance, substance P is believed inter alia to be involved in the neurotr~n.~mi~ion of pain sensations ~Otsuka et al, "Role of Substance P
5 as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia" in 1982 Substance P in the Nervous System, Ciba Foundation Symposium 91, 13-34 (published by Pitman) and Otsuka and Yanagisawa, "~oes Substance P Act as a Pain Transmitter?" TIPS (1987) ~, 506-510], spe~ific~lly in the tr~n~mi.~ion of pain in migraine (B.E.B. Sandberg et al, 10 eJ. Med Chem, (1982) 25, 1009) and in arthritis [Levine et al Science (1984) 226, 647-549]. Tachykinins have also been implicated in gastrointestinal (GI) disorders and diseases of the GI tract such as ;nfl~mm atory bowel disease [Mantyh et al Neuroscience (1988) ~~(3), 817-37 and D. Regoli in "Trends itl Cluster Headache" Ed. Sicuteri et al Elsevier Scientific Publishers, Amsterdam (1987) page 85)] and emesis ~F. D. Tattersall et al, Eur. cJ. Pharmacol., (1993) 250, R5-R6]. It is also hypothesised that there is a neurogenic mech~ni~m for arthritis in which substance P may play a role [Kidd et al "A Neurogenic Mech~ni.~m for. Symmetrical Arthritis" in The Lancet, 11 November 1989 and Gronblad et al, "Neuropeptides in 20 Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in J.
Rheurnatol. (1988) 15(12), 1807-10~. Therefore, substance P is believed to be involved in the infl~mmatory response in diseases such as rheumatoid arthritis and osteoarthritis, and ~lbrositis [O'Byrne et al, Arthritis and Rheumatism (1990) 33, 1023-8l. Other disease areas where tachykinin 25 antagonists are believed to be useful are allergic conditions [Hamelet et al,Can. ~J. Pharmacol. Physiol. (1988) 66, 1361-7], immunoregulation ~Lotz et al, Science (1988) 241~ 1218-21 and Kimball et al, ~J. Im~nu7l01. (1988) 141(10), 3564-9] vasodilation. bronchospasm, reflex or neuronal control of the viscera ~antyh et al, PNAS (1988) ~, 323~-9] andr possibly by 30 arresting or slowing B-amyloid-mediated neurodegenerative changes CA 0224~78 lsss-os-o~
wo 97/30056 PCT/Gs97/00404 ~Yankner et al, Science (1990) 250, 279-82] in senile dementia of the Alzheimer type, ~17h~imer~s disease and Down's Syndrome.
Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular snlall cell lung cancer (SCL~) ~Langdon et al, Cancer Research (1992) 52, 4554-7].
Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Luber-Narod et al, poster C.~.N.P. XVIIIth Congress, 28th June-2nd July 1992~, and in disorders of bladder function such as bladder detrusor hyper-reflexia (Lancet, 16th May 1992, 1239).
It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersen~ y disorders such as poison ivy, vasospastic diseases such as :~n~in:~ and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosus (European patent specification no. 0 436 334), ophth~lm~c disease such as conjuctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).
European patent specification no. 0 577 394 (published 5th January 26 1994) discloses morpholine and thiomorpholine tachykinin receptor antagonists of the general formula R~X~ R4a ~ R2a ~ R5a Rla wherein Rla is a large variety of substituents;
R2a and R3a are inter alia hydrogen;
R4a is inter alia R6Z~
, R
R5a is z,nter al~a optionally substituted phenyl;
5 R6a, R7a and R8a are a variety of substituents;
Xa is O, S, SO or SO2;
ya iS inter alia O; and za is hydrogen or C1 4alkyl.
We have now found a further class of non-peptides which are potent 10 antagonists of tachykinins, especially of substance P.
The present invention provides compounds of the formula (I):
R'~R3 o (C~"
R9b IN 1 RJ
Rs (I) wherein R represents hydroxy, C1 Galkoxy, C3 ¢alkenyloxy, C3.Galkynyloxy, fluoroCl 6alkoxy, C3 7cycloalkoxy, C3 7cycloalkylCI 4alkoxy, phenoxy, benzyloxy or halogen, wherein the phenyl moiety of said phenoxy Ol benzyloxy is optionally substituted by one, two or thrce substituents selected from Cl Galkyl, Cl Galkoxy, halogen and trifluoromethyl;
R1 represents hydrogen, halogen, C1 Galkyl, C~Galkenyl, C~Galkynyl, C3 7cycloalkyl, C3 7cycloalkylCl 4alkyl, Cl.Galkoxy, fluoroCl Galkyl, CA 0224~78 1998-08-0~
fi~uoroCl 6alkoxy, Cl.4alkyl substituted by a Cl ~lko~y or hydroxy group, hydroxy, trimethylsilyl, nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONRaRb, NRaRb, SO2NRaRb, or OCl 4alkylNRaRb, where Ra and Rb are each independently hydrogen or Cl 4alkyl;
R2 and R3 each independently represent hydrogen, halogen, Cl 6alkyl, Cl 6alkoxy substituted by Cl 4alkoxy or trifluoromethyl;
or R and R1 may be joined such that -R-Rl- is a linkage selected from -O-CH2- and -O-CH2CH2-;
or, where Rl and R2 are attached to adjacent carbon atoms, they 10 may be joined such that, together with the carbon atoms to which they are attached, there is formed a 5- or 6-membered ring optionally cont~inin~ ~
or 2 heteroatoms selected from oxygen, sulfur or nitrogen, or 1 or 2 groups selected from S(O), S(O)2 and NRa, which ring may also contain 1 or 2 double bonds, where Ra is as previously defined;
R4 represents hydrogen, halogen, Cl 6alkyl, C2 6alkenyl, C2 6alkynyl, C3 7cycloalkyl, C3 7cycloal~ylCl 4alkyl, Cl 6alkoxy, Cl.4alkyl substituted by a Cl 4alkoxy group, trifluoromethyl, nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONRaRb where Ra and Rb are as previously defined;
R5 represents hydrogen, halogen, C1 Galkyl, Cl Galkoxy substitutcd by Cl 4alkoxy or trifluoromethyl;
RG represents hydrogen, CORa, CO2Ra, COCONRaRb, COCO2Ra, Cl Galkyl optionally substituted by a group selected from (CO2Ra, CONRaRb, hydroxy, CN, CORa, NRaRb, C(NOH)NRaRb, CONHphenyl(Cl 4alkyl), COCO2Ra, CONHNRaRb, C(S)NRaRb, CONRaC1 GalkylRl2, CONRl3C2 Galkenyl, CONRl3C~ Galkynyl, COCONRaRb, CONRaC~NRb)NRaRb, CONRaheteroaryl, and phenyl optionally substituted by one, two or three substituents selected from C1 Galkyl, Cl (;alkoxy, halogen and trifluoromethyl);
or RG represents a group of the formula -CH2CsCCH2NR7R8 where R7 and R8 are as defined below;
CA 0224~78 1998-08-0~
or R6 represents Cl 6alkyl, optionally substituted by oxo, substituted by a 5-membered or 6-membered heterocyclic ring contS3ining 2 or 3 nitrogen atoms optionally substituted by =O or =S and optionally substituted by a group of the formula ZNR7R8 where Z is Cl 6alkylene or C3 6cycloaIkyl;
R7 is hydrogen or Cl 4alkyl, C3 7cycloalkyl, C3 7cycloalkylCl 4alkyl, or C2 4alkyl substituted by Cl 4alkoxy or hydroxyl;
R8 is hydrogen or Cl 4alkyl, C3 7cycloalkyl, C3 7cycloalkylCl 4alkyl, or C2 4alkyl substituted by Cl 4alkoxy, hydroxyl or a 4, 5 or 6 membered 10 heteroaliphatic ring cont~ining one or two heteroatoms selected from N, O
and S;
or R7, R8 and the nitrogen atom to which they are attached for~n a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or Cl 4alkoxy optionally substituted by a 1~ Cl~alkoxy or hydroxyl group, and optionally cont~ining a double bond, which ring ~ay optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH
or NRC moiety where Rc is Cl 4alkyl optionally substituted by hydroxy or Cl 4alkoxy;
or R7, R8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
or Z, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring to 4 to 7 ring atoms which may optionally contain an oxygen ring atom;
R9a and R9b each independently represent hydrogen or Cl 4alkyl, or R9a and R9b are joined so, together with the carbon atoms to which they are attached, there is formed a C6 7 ring;
Rl2 represents ORa, CONRaRb or heteroaryl;
Rl3 represents H or Cl ~;alkyl;
m is zero, 1, 2 or 3; and CA 0224~78 1998-08-0~
n is zero, 1, 2 or 3; with the proviso that the sum total of m and n is 2 or 3;
and pharmaceutically acceptable salts thereo~
A preferred class of compound of formula (I) is that wherein R
5 represents hydroxy, Cl 3alkoxy, C3 salkenyloxy, phenoxy or halogen.
Particularly preferred are those compounds where R represents hydroxy or Cl 3alkoxy, and especially those where R represents hydroxy or methoxy.
Where R represents a phenoxy or benzyloxy substituent the phenyl moiety of each substituent is preferably unsubstituted.
Where R represents a halogen atom, fluorine is preferred.
A preferred class of compound of formula (I) is that wherein represents hydrogen, halogen, Cl Galkyl, C2 6alkenyl, C2.~ialkynyl, C3 7cycloalkyl, C3 7cycloalkylC1 4alkyl, Cl 6alkoxy, Cl 4alkyl substituted by a Cl 4alkoxy group, OCF3, hydroxy, tri~1uoromethyl, trimethylsilyl, nitro, CN, SRa, SORa, SO2Ra, CORa, C02Ra, CONRaRb where Ra and Rb are each independently hydrogen or Cl 4alkyl; and R2 and R3 each independently represent hydrogen, halogen, Cl ~alkyl, Cl ~alkoxy substituted by Cl 4alkoxy or trifluoromethyl Certain particularly apt compounds of the present invention include those wherein Rl is hydrogen, Cl ~alkyl, Cl 4alkoxy, halogen, fluoroC
3alkyl or fluoroCl 3alkoxy.
Most aptly R2 is hydrogen, Cl ~alkyl, Cl 4alkoxy, halogen or CF3.
Most aptly R3 is hydrogen, fluorine, chlorine or CF3 Favourably Rl is hydrogen, Cl 4alkyl, especially methyl, Cl 4alkoxy, especially methoxy, OCF3 Ol CF3.
Favourably R2 is hydrogen, fluorine, chlorine, Cl 4alkyl or CF3, especially hydrogen or CF3.
Favourably R3 is hydrogen.
Preferably R'7 is in the ~-position on the phenyl ring.
Most aptly R~ is hydrogen.
Most aptly R~ is hydrogen, fluorine, chlorine or CF3 Preferably R4 is hydrogen and R5 is 4-fluoro.
Most aptly R9a and R9b are each independently hydrogen or methyl.
Preferably R9a is hydrogen. Preferably R9b is hydrogen. Most preferably R9a and R9b are both hydrogen.
Preferably n is 1.
Preferably m is 1 or 2, especially 1.
Favourably R~ is hydrogen, Cl 3alkyl, especially CHa and CH(CH3), substituted by phenyl wherein said phenyl ring is optionally substituted by Cl salkoxy (especially methoxy) or CF3, or R6 is a group of formula -CH2C--CCH2NR7R8, or R~i is Cl 3alkyl, in particular CH2, CH(CH3) and CH2CH2 and especially CH2, substituted by a 5-membered ring.
In particular, the 5-membered ring is a heterocyclic ring selected from:
H3~ H~ N3/
H i o =~ 7 8 ZNR R
N ZNR R N~/ ; and <~ .
ZNR R ZNR R
Particularly preferred heterocyclic rings are selected from:
CA 0224=,=,78 1998-08-0=, _ 9 _ H N N
0~ ~ i o=( ~ i ~~ ~ i N HN--N H ZNR R
N~/ ; HN~ ~ ; and <~
N ZNR R N ZNR R N--\
ZNR R
Most especially, the heterocyclic ring is selected from:
N ~/ ; and HN
N N ZNR R
One favoured group of compounds of the present invention are of the formula (Ia) and pharmaceutically acceptable salts thereof:
A ~'1 ~~~~ A
N~
6 ~A3 (I~) wherein R and R~ are as defined in relation to formula (I);
Al is hydrogen, Cl 3alkyl, Cl 3alkoxy, halogen, fluoroCl 3alkyl or fluoroCl 3alkoxy;
A2 is hydrogen, halogen, Cl 4alkyl or fluoroCl 3alkyl; and A3 is hydrogen or halogen.
CA 0224~78 1998-08-0~
In particular, Al is preferably hydrogen, methyl, methoxy, OC~F3 or CF3.
In particular A2 is hydrogen, ffuorine or trifiuoromethyl.
In particular A3 is hydrogen or fluorine.
With respect to compounds of the formulae (I) and (Ia), Z (where present), may be a linear, branched or cyclic group. Favourably Z contains 1 to 4 carbon atoms and most favourably 1 or 2 carbon atoms. A
particularly favourable group Z is CH2.
With respect to compounds of the formulae (I) and (Ia~, R7 may aptly be a Cl 4alkyl group or a C~4alkyl group substituted by a hydroxyl or Cl 2alkoxy group, R8 may aptly be a Cl 4alkyl group or a Cl 4alkyl group substituted by a hydroxyl or Cl 2alkoxy group, or R7 and R8 may be linked so that, together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl, piperidyl, morpholino, thiomorpholino, piperazino or piperazino group substituted on t~e nitrogen atom by a Cl 4alkyl group or a C2 4alkyl group substituted by a hydroxy or Cl 2alkoxy group.
Where the group NR7R8 represents a heteroaliphatic ring of 4 to 7 ring atoms and said ring contains a double bond, a particularly preferred group is 3-pyrroline Where the group NR7R8 represents a non-aromatic azabicyclic ring system, such a system may contain between 6 and 12, and preferabl~,~
between 7 and 10, ring atoms. Suitable rings include 5-azabicvclo[2.1.1]hexyl, 5-azabicyclo[2.2.1~heptyl, 6-azabicyclo[3.2.1]octyl, 2-azabicycloL2.2.2]octyl, 6-azabicyclo[3.2.2]nonyl, 6-azabicyclo[3.3.1~nonyl, 6-azabicyclo[3.2.2]decyl, 7-azabicyclo[4.3.1]decyl, 7-azabicycloL4.4. l]undecyl and 8-azabicyclo L5-4- l]dodecyl, especially 5-azabicyclo[2.2.1]heptyl and 6-azabicyclo[3.2.1]octyl.
Where R8 represents a C2 4alkyl glOup substituted by a 5 or 6 membered heteroaliphatic ring cont~ining one or two heteroatoms selected fiom N, O and S, suitable rings include pyrrolidino, piperidino, piperazino, CA 0224',',78 1998-08-0', morpholino, or thiomorpholino. Particularly preferred are nitrogen cont~ining heteroaliphatic rings, especially pyrrolidino and morpholino rings.
In the group ZNR7R8, Z is preferably CH2 or CH2CH2, and especially 5 CH2.
The group NR7R8 preferably represents amino, methyl~mino, dimethylamino, diethyl~mino, azetidinyl, pyrrolidino or morpholino.
In particular, NR7R8 is preferably dimethylamino, azetidinyl or pyrrolidino, especially dimethyl ~mino.
Where R and Rl are joined such that -R-Rl- is a linkage, this is preferably -O-CH2-, thereby forming a phthalan ring.
Where Rl and R2, together with the carbon atoms to which they are attached, form a 5- or 6-membered ring optionally cont~ining 1 or ~
heteroatoms selected from oxygen, sulfur or nitrogen, or 1 or 2 groups 15 selected from S(O~, ~(0)2 and NRa, and which ring may also contain 1 or 2 double bonds, it will be appreciated that the ring thus formed may be saturated, partially saturated or unsaturated. Thus, Rl and R2 may represent, for example, -OCH2CH2CH2-, -OCH2CH20-, -OCH2CH2-, -OCH20-, -NRaCH2CH2CH2-, -NRaCH2CH2-, -CH2CH2CH2CH2-, 20 -CH2CH2CH2-, -CH=CH-CH=CH-, -O-CH=CH-, -NRa-CH=CH-, -S-CH=CH-, -NRa-CH=N-, -O-CH=N-, -S-CH=N-, -N=CH-CH=CH-, -CH=N-CH=CH-. Particularly preferred linkages formcd by Rl and R2 include, -OCH2CH2CH~-,-OCH2CH20-,-OCH2CH2-,-OCH20-,-NRaCH CH2CH~-and -CH=CH-CH=CH- In these examples, Ra preferably represents a 25 hydrogen atom.
As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples o~ suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, 30 n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.
CA 0224~78 1998-08-0~
The cycloalkyl groups referred to herein may represent, ~or example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. A suitable cycloalkylalkyl group may be, for example, cyclopropylmethyl.
As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. ~,x~mI~les of suitable alkenyl groups include vinyl and allyl. A suitable alkynyl group is propar~yl.
As used herein, the terms "fluoroCl 6alkyl" and "fluoroCl 6alkoxy"
means a Cl 6alkyl or Cl 6alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by a fluorine atom.
Particularly preferred are fluoroC1 3alkyl and fluoroCl 3alkoxy groups, for example, CF3, CH2CH2F, CH2CHF2, CH2CF3, OCF3, OCH2CH2F, OCH2CHF2 or OCH2CF3, and most especially (~F3 and OCF3.
When used herein the term halogen means ~luorine, chlorine, ~5 bromine and iodine. The most apt halogens are ~Luorine and chlorine of which fluorine is preferred.
Specific compounds within the scope of this invention include:
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-phenyl-spiro[5.4]decane;
(2R, 3S,gR)-4-aza-4-benzyl- 1, 7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-f~uorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5 4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-~:~-(trifluoromethyVphenyl)spiro[5.4]decane;
(2R,3S,9S)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethoxy)phenyl)spiro[5.4]decane;
3~) (+/-)-(2R*.3S*,9R*~-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9- (2-methylphenyl)spiro[5.4]decane;
CA 0224~78 1998-08-0~
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-hydroxy-spiro [5. 4~ decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-spiro[5.43decane;
~ 5 (2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-phenylspiro~5.4~ decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4~decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro [5 .4] decane;
(2R,3S,9S)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyVspiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(tri~luoromethoxy)phenyl)spiro~ 5.4]decane;
(+/-)-(2R~,3S*,9R~)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methylphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)-spiro~5.4]decane;
(2R,3S,9R)-4-aza-4~(4-(N,N-dimethylamino)-but-2-ynyl)-1" -dioxa-3-(4-fluorphenyl)-9-hydroxy-9-(2-methoxy-5-(tri~luoromethyl)phenyl)-spiro~5.4]decane;
(2R, 3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)- 1, 2, 3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydrox~J-9-(2-methoxy-5-(tri~luoromethyl)phenyl)spiro[o.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-(l(S)-phenylethyl)-9-(2-(trifluoromethyl)phenyl)spiro[;3.4]decane;
CA 0224~78 1998-08-0~
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-~luorophenyl)-9-hydroxy-4-(1(R)-phenylethyl)-9-(2-(trifluoromethyl)phenyVspirol5.41decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-((2-(tri~Luoromethyl)phenyVmethyl)-9-(2-(trifluoromethyVphenyl)-5 spiro[6.4]decane;
(+/-)-(2R~,3S*,9R~)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro[5.4~decane;
(2R, 3S,9R~-4-aza-4-benzyl- 1, 7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-Inethoxyphenyl)spiro[5.4]decane;
10 (2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-~1uorophenyV-9-methoxy-9-(2-(tri~1uoromethyl)phenyl)spiroL5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyVspiror5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-15 9-(2-methylphenyl)spiro~5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyV-9-methoxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-spiro[5.4]decane;
20 (+/-)-(2R~,3S*,9R*)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro[6.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxyphenyl)spiro[5.43decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-25 (trifluorom~thyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-~luorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methylphenyl)spiro[6.4]decane;
30 ~2R,3S,9R)-4-aza-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-methoxy-spiro [5.4] decane;
CA 0224~78 1998-08-0~
WO 97/30~)56 PCT/GB97/00404 (2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-tetrazol-4-yl)methyl- 1, 7-dioxa-3-(4-fluoropheny~)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5 .4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(S)-phenylethyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(R)-phenylethyl)-9-(2-methoxy-5-~trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyV-9-n:lethoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((2-(trifluoromethyl)phenyl)methyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-15i (triflu~r~n~eth~ll)phenyl)-4-((~-(tri~1uoromethyl)phenyl)meth~zl)-spiro[5.4]decane;
(2R, 3S,9R)-4-aza- 1, 7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((4-(trifluoromethyl)phenyl)methyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-((2-methoxyphenyl)methyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl) spirol5.4]decane;
(2R,3S,9R)-9-allyloxy-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl3-9-phenyl-spiro [5.4]decane;
(2R, 3S, 9R) -4-aza-4-benzyl- 1, 7-dioxa-3- (4-fluorophenyl)-9-p henyl-9-(phenylmethyloxy)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1, 7-dioxa-3-(4-fluorophenyl)-9-phenyl-9-propyloxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-fluoro-3-(4-fluorophenyl)-9-phenyl-spiro[5.4]decane;
CA 0224~i~i78 1998-08-O~i WO 97/3~056 PCT/GB97/00404 - 16 ~
(2R,3S,9R~-4-a~a-1,7-dioxa-g-~uoro-3-(4-fluorophenyl)-9-phenylspiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(hydroxymethyl)phenyl)spiro[~.4~decane;
~; [2'R- [2'a(S*), 4~CC]~ 3r~ -(4-fluorophenyl)-4"-(phenylmethyl)dispiro-[isobenzofuran- 1 (3H~, 4' (5rH)-furan-2' (3~:1), 2" -morpholine];
[2r~-[2'a(S*),4roc]]-3"-(4-fluorophenyl)dispiro[isobenzofuran- 1(3~),4'(5 furan-2' (3~ 2~r -morpholine~;
and pharmaceutically acceptable salts thereof.
In a further aspect of the present invention, the compounds of formula (I) will preferably be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.
For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention incluae acid addition salts which may, for example, be formed by mi~ing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, 2~ alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g.
sodium or potassium salts, and ~lk~3line earth metal salts, e.g. calcium or magnesium salts.
The salts may be formed by conventional means, such as by reacting the ~ree base form of the product with one or more cquivalents of the CA 0224~78 l998-08-0~
appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed i7?, vacuo or by freeze drying or by e~ h~nging the anions of an existing salt for another anion on a suitable ion exchange resin.
The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I).
Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for exa~nple, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation i7t vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.
The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.
The compounds according to the invention have at least three asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
The preferred compounds of the formula (I) and ~Ia) will have the preferred stereochemistry of the ~-, 3- and 9-positions that is possessed by the compound of 3xample 1 (2R,3S,9R). Thus for example as shown in formula (Ib) CA 0224~78 1998-08-0~
o (c~R3 ~ ~j~ (CH ~)m 9b J' N ~ ""'~ R4 (Ib) The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in 5 association with a pharmaceutically acceptable carrier or excipient.
Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal a~rnini.qtration, or administration by inhalation or insufflation.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a so~id preformulation 15 composition cont~3ining a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into 20 equally effective unit dosage forms such as tablets, pills and capsules.
This solid preformulation composition is then subdivided into unit dosage forms of the type described above cont~ining from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a CA 0224~78 1998 - 08 - o~
dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
The two components can be separated by an enteric layer which serves to 5 resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and simil~r pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
Preferred compositions for administration by injection include those comprising a compound of formula (I), as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).
Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g. ~weenTM 20, 40, 60, 80 or 85) and other sorbitans (e.g. SpanTM 20, 40, 60, 80 or 85~. Compositions with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
Suitable emulsions mav be prepared using commercially available fat emulsions, such as IntralipidTM, LiposynTM, InfonutrolTM, LipofundinTM
CA 0224C7C778 1998-08-0C, and LipiphysanT~. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almondoil) and an emulsion formed upon mi~inE~ with a phospholipid (e.g. egg 5 phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%. The fat emulsion will preferably comprise fat droplets between 0.1 and 1.0~Lm, particularly 0.1 and 0.5,um, and have a pH in the range of 5.5 to 8Ø
Particularly preferred emulsion compositions are those prepared by mi~in~ a compound of formula (I) with IntralipidTM or the components thereof (soybean oil, egg phospholipids, glycerol and water).
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
Preferably the compositions are a(1rnini~tered by the oral or nasal 20 respiratory route for local or systemic effect. C~ompositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directl~ fiom the neb~ in~ device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, 25 suspension or powder compositions may be administered, pleferably orallv or nasall~, from devices which deliver the formulation in an appropriate manner.
The present invention futher provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), 30 which process comprises bringing a compound of formula (I) into association with a pharmaceutically acceptable carrier or excipient CA 0224~78 l998-08-0~
The compounds o~ formula (I) are of value in the treatment of a wide variety of ~.linic~l conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity.
Thus, for example, an excess of tachykinin, and in particular 5 substance P, activity is implicated in a variety of disorders of the central nervous system. Such disorders include mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and 10 cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, .
speclfic phoblas, for example, speclfic ~nlmf.l phoblas, soclal phoblas, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety 15 disorders; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders and psychotic disorders with delusions or hallucinations; delerium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as 20 Alzheimer's disease, senile dementia, dementia of the Al~heimer's type, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; Parkinson's disease and other extra-pyrz3mi-1z3l movement disorders such as 2~ medication-induced movement disorders, for example, neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induccd acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; substance-related disorders arising ~rom the use of alcohol, amphetamines (or amphetamine-30 like substances) caffeine, cannabis, cocaine, hallucinogens, inh~l~nts andaerosol propellants, nicotine, opioids, phenylglycidine derivatives, CA 0224~78 1998-08-0~
sedatives, hypnotics, and anxiolytics, which substance-related disorders include dependence and abuse, intoxication, withdrawal, intoxication delerium, withdrawal delerium, persisting dementia, psychotic disorders, mood disorders, anxiety disorders, sexual dysfunction and sleep disorders;
5 epilepsy; Down's syndrome; demyelinating diseases such as MS and ALS
and other neuropathological disorders such as peripheral neuropathy, for example diabetic and chemotherapy-induced neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic 10 cerebrovascular damage such as cerebral infarction, subarachnoid haemorrhage or cerebral oedema.
Tachykinin, and in particular substance P, activity is also involved in nociception and pain. The compounds of the present invention will therefore be of use in the prevention or treatment of diseases and 15 conditions in which pain predominates, including soft tissue and peripheral fl~m~ge, such as acute trauma, osteoarthritis, rheumatoid arthritis, musculo-skeletal pain, particularly after trauma, spinal pain, dental pain, myofascial pain syndromes, headache, episiotomy pain, and burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, 20 orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorlhoea, and labour pain; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, 25 nerve root damage, and arachnoiditis; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage; low back pain; sciatica;
ankylosing spondylitis, gout: and scar p ain .
Tachykinin, and in particular substance P, antagonists may also be 30 of use in the treatment of respiratory diseases, particularly those associated with excess mucus secretion, such as chronic obstructive CA 0224~78 1998-08-0~
airways disease, bronchopneumonia, chronic bronchitis, cystic fi~rosis and asthma, adult respiratory distress syndrome, and bronchospasm;
infl~mmz~tory diseases such as infl~mm~tory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis, pruritis and sunburn;
5 allergies such as eczema and rhinitis; hypersen~i~ivi~y disorders such as poison ivy; ophth~lmi~ diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophth~lmi~ conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other 10 eczematoid dermatitis.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of neoplasms, including breast tumours, neuroganglioblastomas and small cell carcinomas such as small cell lung cancer.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of gastrointestinal (GI) disorders, including infl~mm~tory disorders and diseases of the GI tract such as gastritis, gastroduodenal ulcers, gastric carcinomas, gastric lymphomas, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's 20 disease, irritable bowel syndrome and emesis, including acute~ delayed or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, for example, motion sickness, vertigo, dizziness and Meniere's disease, surgery, migraine, variations in intercranial pressure, gastro-oesophageal 2O reflux disease, acid indigestion, over indulgence in food or drink, acid stomach, waterbrash or regurgitation, heartburn, for example, episodic, ~ nocturnal or meal-induced heartburn, and dyspepsia.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of a variety of other conditions including stress 30 related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; adverse immunological reactions such as CA 0224~78 1998-08-0~
rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus;
plasma extravasation resulting from cyto3~ine chemotherapy, disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as ~n~n~3, vascular headache, migraine and Reynaud's disease; and pain or nociception attributable to or associated with any of the foregoing conditions, especially the tr~n.~mi~ n of pain in 10 migraine.
The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.
The compounds of formula (I) are particularly useful in the 1~ treatment of emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intercranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis induced by antincoplastic (cytotoxic) 20 agents including those routinely used in cancer chemotherapy, and emesis induced by other pharmacological agents, for example, rolipram.
Examples of such chemotherapcutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as 26 nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, ~olic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophvllotoxin; and cytotoxic antibiotics.
Particular examples of chemotherapeutic agents are described, for 30 instance, by D. J Stewart in l~ausea a7~d Vol7titi7lg: Rece77,t Research and Cli7licaZ Adva7~ces, Eds. J. ~ucharczyk et al, CRC Press Inc., Boca Raton CA 0224~78 1998-08-0~
- 2~ -Florida, USA (1991) pages 177-203, especially page 188. Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC~, dactinomycin, mechloreth~mine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin 5 (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla et al in Cancer Tr~atment Reports (1984) 68(1),163-172~.
The compounds of formula (I) are also of use in the treatment of 10 emesis induced by radiation including radiation therapy such as in the treatment of cancer, or radiation sickness; and in the treatment of post-operative nausea and vomiting.
It will be appreciated that the compounds of formula (I) may be presented together with another therapeutic agent as a combined 15 preparation for simultaneous, separate or sequential use for the relief of emesis. ~uch combined preparations may be, for example, in the form of a twin pack.
A further aspect of the present invention comprises the compounds of formula (I) in combination with a 5-HT3 antagonist, such as 20 ondansetron, granisetron or tropisetron, or other anti-emetic medicaments, for example, a dopamine antagonist such as metoclopramide or GABAs receptor agonists such as baclofen. Additionally, a compound of formula (I) may be administered in combination with an anti-infl~mmatory corticosteroid, such as dexamethasone, triamcinolone, 2a triamcinolone acetonide, flunisolide, budesonide, or others such as those disclosed in ~S patent nos. 2,789,118,2,g90,401,3,048,581,3,126,375, 3,929,768,3,996,359,3,928,326 and 3,749,712. Dexamethasone (DecadronTM3 is particularly preferred. Furthermore, a compound of formula (I) may be administered in combination with a chemotherapeutic 30 agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available CA 0224~78 1998-08-0~
WO 97/300~;6 PCT/GB97/00404 dosage forms of the known therapeutic agents for use in such combinations will be suitable.
When tested in the ferret model of cisplatin-induced emesis described by F. D. Tattersall et al, in Eur. J. pharmacol., (1993) 250, R6-5 R6, the compounds of the present invention were found to attenuate theretching and vomiting induced by cisplatin.
The compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or infl~ m m ~tion and disorders associated therewith such as, for example, neuropathy, such as diabetic 10 and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteroarthritis, rheumatoid arthritis, headache and especially migraine.
The present invention further provides a compound of formula (I) for use in therapy.
According to a further or alterIlative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a me~ m.?nt for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.
The present invention also provides a method for the the treatment 20 O1 prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises at1ministration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).
2~ For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically acti~e agent. For example, for the treatment of respiratorY diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a ~2-adrenergic receptor 30 agonist or tachykinin antagonist which acts at NK-2 receptors. The CA 0224~78 1998-08-0~
compound of formula (I) and the bronchodilator may be arlmini~tered to a patient simultaneously, sequentially or in combination.
Likewise, a compound of the present invention _ay be employed with a leukotriene antagonists, such as a leukotriene D4 antagonist such as a compound selected from those disclosed in European patent specification nos. 0 480 717 and 0 604114 and in US patent nos. 4,859,692 and 5,270,324. This combination is particularly useful in the treatment of respiratory diseases such as asthma, chronic bronchitis and cough.
The present invention accordingly provides a method for the 10 treatment of a respiratory disease, such as asthma, which method comprises a(lmini.~tration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.
The present invention also provides a composition comprising a 16 compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.
It will be appreciated that for the treatment or prevention of migraine, a compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-~Tl agonists, 20 especially sumatriptan, naratriptan, zolmatriptan or rizatriptan.
Likewise, for the treatment of behavioural hyperalgesia, a compound of the present invention may be used in conjunction with an antagonist of N-methyl D-aspartate (NMDA), such as dizocilpine.
For the treatment or prevention of in~mm~tory conditions in the 2~ lower urinary tract, especially cystitis, a compound of the present invention may be used in conjunction with an antiinfl~3mmatory agent such as a bradykinin receptor antagonist.
It will be appreciated that for the treatment or prevention of pain or nociception, a compound of the present invention may be used in 30 conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs and. in particular, opioid analgesics, especially CA 0224~78 1998-08-0~
WO 97/30056 PCT/GB97/01~404 morphine. Specific anti-;nfl~mm~tory agents include diclofenac, ibuprofen, indometh~in, ketoprofen, naproxen, piroxicam and sulindac.
Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof. Preferred salts of these opioid analgesics include morphine sulphate, morphine 10 hydrochloride, morphine tartrate, codeine phosphate, codeine sulphate, dihydrocodeine bitartrate, diacetylmorphine hydrochloride, hydrocodone bitartrate, hydromorphone hydrochloride, levorphanol tartrate, oxymorphone hydrochloride, alfentanil hydrochloride, buprenorphine hydrochloride, butorphanol tartrate, fentanyl citrate, meperidine 15 hydrochloride, methadone hydrochloride, nalbuphine hydrochloride, propoxyphene hydrochloride, propoxyphene napsylate (2-naphthalenesulphonic acid (1:1) monohydrate), and pentazocine hydrochloride.
Therefore, in a further aspect of the present invention, there is 20 provided a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient.
In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an 25 analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of pain or nociception.
It will be appreciated that for the treatment of depression or anxiety, a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents.
Suitable classes of anti-depressant agent include norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), CA 0224=,=,78 1998-08-0=, ~nonoamine oxidase inhibitors ~MAOIs), reversible inhibitors of monoamine oxidase (RIMAs~, serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, a-adrenoreceptor antagonists and atypical anti-depressants.
Suitable norepinephrine reuptake inhibitors include tertiary amine tricyclics and secondary amine tricyclics. Suitable examples of tertiary amine tricyclics include: amitriptyline, clomipramine, doxepin, imipramine and trimipramine, and pharmaceutically acceptable salts thereof. Suitable examples of secondary amine tricyclics include:
10 amoxapine, desipramine, maprotiline, nortriptyline and protriptyline, and pharmaceutically acceptable salts thereof.
Suitable selective serotonin reuptake inhibitors include: fluoxetine, fluvo~ ine, paroxetine and sertraline, and pharmaceutically acceptable salts thereo~
16 Suitable monoamine oxidase inhibitors include: isocarboxazid, phenelzine, tranylcypromine and selegiline, and pharmaceutically acceptable salts thereof.
Suitable reversible inhibitors of monoamine oxidase include:
moclobemide, and pharmaceutically acceptable salts thereof.
Suitable serotonin and noradrenaline reuptake inhibitors of use in the present invention include: venl~f:~ine, and pharmaceutically acceptable salts thereof Suitable CRF antagonists include those compounds described in International Patent Specification Nos. WO 94/13643, WO 94/13644, WO
25 94/13661, WO 94/13676 and WO 94/13677.
Suitable atypical anti-depressants include: bupropion, lithium, nefazodone, trazodone and viloxazine, and pharmaceutically acceptable salts thereof.
Suitable classes of anti-anxiety agent include benzodiazepines and 30 5-HTIA agonists or antagonists, especially 5-HTlA partial agonists, and corticotropin releasing factor ((~RF) antagonists.
CA 0224~78 1998-08-0~
Suitable benzodiazepines include: alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam, and pharmaceutically acceptable salts thereof.
Suitable 5-HTlA receptor agonists or antagonists include, in particular, the 5-HTlA receptor partial agonists buspirone, ~le.sino~n, gepirone and ipsaperone, and pharmaceutically acceptable salts thereo~
Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention and an anti-depressant or anti-anxiety agent, together 10 with at least one pharmaceutically acceptable carrier or excipient.
In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an anti-depressant or anti-anxiety agent as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention 15 of depression and/or anxiety.
The excellent pharmacological profile of the compounds of the present invention offers the opportunity for their use in therapy at low doses thereby minimi.qing the risk of unwanted side effects.
In the treatment of the conditions associated with an excess of 20 tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.
For example, in the treatment of conditions involving the neurotr~n~mi.ssion of pain sensations, a suitable dosage level is about 25 0.001 to 25 mg/kg per day, preferably about 0.005 to 1~ mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be a(lmini.~tered on a regimen of 1 to 4 times per day, preferably once or twice per day.
In the treatment of emesis using an injectable formulation, a 30 suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 1 mg/kg per day. The CA 0224~78 l998-08-0~
compounds may be afln~ini.~tered on a regimen of 1 to 4 times per day, preferably once or twice per day.
It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular 5 compounds or composition selected but also with the route of a~lmini.~tration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.
According to a general process (A), compounds of formula (I) 10 wherein R is a hydroxy group, may be prepared from a compound of formula (II) o (CH2)"
R9a 0 ~ O
~ (CH2)m 9b J~ N '~~ ~ R4 (II) 15 wherein R~, R5, RG, R9a, R9b, m and n are as defined in relation to formula ~.
(I) by reaction with a Grignard or organolithium compound of formula ~IIIA) or (IIIB) ~M~Hal RZ
R R
(IIIA) (IIIB) wherein Rl, R2 and R3 are as defined in relation to formula (I) and Hal is a halogen atom, for example, chlorine, bromine or iodine, especially a bromine atom.
= ~
Both reactions are effected under conventional conditions, for instance, in a suitable solvent such as an ether, e.g. tetrahydrofuran, at a temperature between -90~ and -60~C, with subsequent quenching using, for example, saturated ammonium chloride solution.
According to a general process (B), compounds of formula (I) wherein R is a group selected from Cl ~alkoxy, C3 Galkenyloxy, C3.6alkynyloxy, fluoroCl 6alkoxy, C3 7cycloaIkoxy, C3 7cycloalkylCl 4alkoxy, phenoxy or benzyloxy, may be prepared from the corresponding compound of formula (I) in which R is a hydroxy group, hereinafter referred to as 10 compounds of formula (IV~
Rl~R3 o--(CH,/ ~, R9b 7 " R4 R
(I~
by reaction with a suitable alkyl halide, alkenyl halide, alkynyl halide, 15 ~luoroalkyl halide, c~Tcloalkyl halide, cycloalkylalkyl halide, phenyl halide or benzyl halide.
The reaction is conveniently effected in the presence of a base such as an alkali metal halide, for example, sodium hydride in a suitable solvent, for example an organic solvent such as N,N-dimethylformamide, 20 preferably at a temperature between 10~C and 50~C, conveniently at room temperature.
According to another general process (C), colnpounds of formula (I) wherein R is a halogen atom~ may be prepared from a corresponding compound of formula (IV) by reaction with a suitable halogenating CA 0224~78 1998-08-0~
reagent. Thus, for example, compounds wherein R is Muorine may be prepared by reaction with diethylaminosulfur trifluoride, the reaction being effected in a suitable organic solvent such as a halogenated hydrocarbon, for example, dichloromethane, at a temperature between -90~C and -60~C, for example, at about -78~C.
According to another general process (D), compounds of formula (I) wherein R6 is H may be prepared from the corresponding compound of formula (I) in which RG is a benzyl group. The reaction may be effected, for instance, under conventional conditions of catalytic hydrogenation using a palladium or platinum catalyst or an oxide thereof, the reaction being effected in a suitable solvent such as an alcohol, for example, methanol, conveniently at room temperature.
According to a further general process (E), compounds of formula (I) may be prepared from the corresponding compound of formula (I) in which R~ is H, hereinafter referred to as compounds of formula (V) Rl~R3 ~ (CH~)n~
9b ~ N ~ \~ R4 ~R5 (V) wherein R, Rl, R~, R3, R'l, R;~, R9a, R9b, m and n are as defined in relation to formula (I), by reaction with a compound of formula LG-RG~ (VI) where RG" is a group of the formula RG as defined in relation to formula (I) or a precursor therefor and LG is a leaving group such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or a halogen atom (e.g.
brornine, chlorine or iodine); and, if RGa is a precursor group, converting it to a group R6 (in which process any reactive group may be protected and thereafter deprotected if desired).
6 This reaction may be performed in a conventional ms~nn~r, for example in an organic solvent such as dimethylform~m;de in the presence of an acid acceptor such as potassium carbonate.
According to another process (F), compounds of formula (I) wherein R6 represents a 1,2,3-triazol-4-ylmethyl group substituted by C~2NR7R8, 10 may be prepared by reaction of a compound of formula (VII) Rl~R3 O (C>~
J ~ R4 ~/ R~
N3 (VII) with an amine of formula NHR7R8, in a suitable solvent such as an ether, 15 for example, dioxan, at elevated temperature, for example, between ~0~C
and 100~C~, in a sealed tube, or the like. This reaction is based upon that described in Chemische Berichte (1989) 122, p. 1963.
According to a further process (G), compounds of formula (I) wherein RG represents a Cl Galkyl group which is substituted by an unsubstituted 20 or substituted 1,2,4-triazolyl group, may be prepared by reaction of an intermediate of formula (V) with a compound of formula (VIII) CA 0224~78 1998-08-0~
lG J~ ~ ( CH, ) p H~ll (VIII~
-w-herein ~al is a halogen atom, foL example, bromille~ chloli~ïe o-l= iOuir~e, p is an integer from 1 to 6 and Rl8 is H, CONH2 or O~H3 (which is converted to an oxo substituent under the reaction conditions), in the presence of a ~; base, followed where necessary by conversion to a compound of formula (I), for example, by reduction of the CONH2 group to CH2N~I2.
Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate. The reaction is conveniently effected in an anhydrous organic solvent such as, for example, anhydrous 10 dimethylformamide, preferably at elevated temperature, such as about 140~C.
A suitable reducing agent for the group CONH2 is lithium aluminium hydride, used at between -10~C and room temperature.
According to a further process (H), compounds of formula (I) may 15 also be prepared from other compounds of formula (I) using suitable interconversion procedures. In particular, interconversion processes may be used to vary the group RG. For example, compounds of formuIa (I) wherein RG is other than H may be prepared from the corresponding compounds of formula (I) wherein RG is ~I by reaction with a reagent ~0 suitable to introduce the group RG, for example, compounds of formula (I) wherein RG is CORa may be prepared from compounds of formula (I) wherein RG is H by, for example, reaction with an appropriate acid - anhydride.
Compounds of formula (I) wherein RG is Cl ~,alkyl may be prepared 25 fiom corresponding compounds of formula (I) wherein RG is CORa by reduction using, for example~ borane or a boroh~dride such as sodium cyanoborohydride Compounds of formula (I) wherein R6 is Cl 6alkyl substituted by CONRaRb may be prepared from corresponding compounds of formula (T) wherein R6 is Cl 6alkyl substituted by CO2Ra by treatment with ammonia or an amine of formula NRaRb.
Compounds of formula (I) wherein R~ is Cl 6alkyl substituted by 5-oxadiazolyl may be prepared from compounds of formula (I) wherein R6 is Cl 6alkyl substituted by CO23~a, where Ra represents Cl 6alkyl, by reaction with a compound of formula (IX) NOH
(IX) wherein R32 represents H or a suitable substituent, in the presence of a base.
Suitable bases of use in the reaction include alkali metals, such as, 15 for example, sodium, and alkali metal hydrides, such as, for example, sodium hydride.
The reaction is conveniently effected in a suitable organic solvent.
Which solvents will bc appropriate will depend on the nature of the base used. For example, where the base used is an alkali metal, suitable 20 solvents will include alcohols, for example, ethanol, whereas where the base used is an alkali hydride, suitable solvents will include ethers, for example, tetrahydrofuran.
Preferably the reaction is conducted at elevated temperature, such as the reflux temperature of the chosen solvent Compounds of formula (I~ wherein RG is Cl Galkyl substituted by thiazolyl may be prepared from compounds of formula (I) wherein RG is Cl Galkyl substituted by CSNH2 by reaction with a compound of formula Hal-CH2C(O)-RG~, where Hal is a halogen atom, such as brornine, chlorine or iodine, and RG~ represents H Ol a suitable substituent.
Compounds of formula (I) wherein RG is Cl 6alkyl substituted by thioxotriazolyl may be prepared from compounds of formula (I) wherein R6 is Cl 6alkyl substituted by CONHNHa by reaction with a compound of formula R6lNCS, wherein R6l represents H or a suitable substituent such 5 as Cl 6alkyl, in the presence of a base Suitable bases of use in the reaction include organic bases such as, for example, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The reaction is conveniently effected in a suitable organic solvent, such as alcohol, e.g.
butanol.
According to another general process (J), compounds of formula (I) wherein R6 represents the group -CHaC_CCH2NR7R8, may be prepared from a compound of formula (X) 9a o (C~
~ (CHy)m Rgb~J ~ \~
~ R~
Hal wherein Hal is a halogen atom such as chlorine, bromine or iodine, by reaction with an amine of formula HNR7R8 in the presence of a base.
Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate. The reaction is conveniently effected in an organic solvent such as, for example, N,N-dimethylformamide, conveniently at room temperature.
Intermediates of formula (II~ may be preparcd by the oxidation of a compound of formula (XI) O (c~
~ (CHy)m R9~ ~ Nl / ~ R4 (XI) under conventional conditions for the oxidation of a secondary alcohol.
Particularly preferred are the conditions of the Swern oxidation, i.e.
dimethylsulfoxide and oxalyl chl~ride, which reaction is conveniently 5 effected in a halogenated hydrocarbon such as dichloromethane, preferably at a temperature below -70~C.
Compounds of formula (XI) may be prepared from a compound of formula (XII) HO
(CHy)n 9a OH
~ (CHy)m R9b N --~R4 (XII) 10 by an acid catalysed intramolecular cyclisation reaction.
Suitable acids of use in the reaction include mineral acids such as, for example, hydrochloric acid. The reaction is conveniently effected in a suitable organic solvent, such as an alcohol, for example, methanol, at elevated temeprature, for example, at the reflux temperature of the chosen 1 5 solvent.
Intermediates of formula (XII) wherein n is 1 may be prepared by the hydroxylation of a compound of formula (XIII):
CA 02245C~78 1998-08-05 R9a ~ ~ CH2 ~ (CH2),,~
R9b~7~ \~R4 R6 ~
RJ
(XIII) using conventional methodology, for instance, using osmium tetroxide and N-methylmorpholine-N-oxide, preferably in an inert solvent such as an ether, for example, tetrahydrofuran, or an alcohol, for example, isobutyl 5 alcohol, or water or a mixture thereof, conveniently at room temperature.
Compounds of formula (XIII~ may be prepared by the reaction of a compound of formula (XIV):
R~ O ~ O
R9b 1 ~ R4 (XLV) with a compound of formula (XV):
~ MgCl ~ (CH.~) ,, (XV) using conventional Grignard conditions, for example, the reaction being effected in a solvent such as an ether, e.g. tetrahydrofuran, at reduced temperature, for examplc, at -78~C.
Compounds of formula (XIV) may be prepared by methods described in European Patent Specification No. 0 577 394-A, or by analogous methods.
Compounds of formula (~1) are known compounds.
Intermediates of formula (~TII) may be prepared from a compound of formula (X) by reaction with an azide, for example, sodium azide in a CA 0224=,=,78 1998-08-0=, suitable solvent such as dimethylsulphoxide at or below room temperature.
Compounds of formula (X~ may be prepared by a dropwise addition of an intermediate of formula (V) to a dihaloacetylene of formula 5 Hal-CH2-C_C-CH2-Hal where each Hal is independently chlorine, bromine or iodine, especially chlorine. The reaction is conveniently effected in a suitable solvent such as dimethylform~mi-le in the presence of a base such as potassium carbonate.
Compounds of formula (VIII) may be prepared as described in cT. Med. Chem., (1984) 27, 849.
For compounds wherein R6 is a (:~l 6alkyl group substituted by a 5-membered heterocycle which in turn is substituted by a ZNR7R8 group where Z is (~H2, certain favoured compounds of for~ula (I) may be prepared from a corresponding compound with a hydrogen atom in place of 15 the ZNR7R8. Thus, for example a compound of the formula (I) wherein R~
is an imidazolinone group carrying a CH2NR7R8 moiety may be prepared from a corresponding compound lacking the CH2NR7R8 moiety by reaction with formaldehydc and an amine NHR7R8 under conventional M~nnich reaction conditions, for example in methanol with heating. If desired a 20 pre-formed reagent such as R7R8N+=CH2.I- may be employed and a tertiary amine such as triethylamine used as acid acceptor.
Alternatively a compound of formula ~I) wherein RG is a Cl ~,alkyl group substituted by an imi~l~701inone group may be reacted with paraformaldehyde and an amine for example a secondary amine such as 25 pyrrolidine or morpholine to give a compound wherein the imicl~olinone ring is substituted by CH2NR7R8 where R7, R8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of ~ to 7 ring atoms which may optionally contain an oxygen ring atom or a second nitrogen atom which will be part of a N~ or NRC moiety, where Rc is as previously 30 defined.
CA 0224~78 l998-08-0~
WO 97/30056 PCT/GBg7/00404 This reaction may be performed in a conventional manner, for instance, in a suitable solvent such as an alcohol, for example, methanol at an elevated temperature up to the boiling point of the solvent.
A further alternative method for the preparation of certain compounds of formula (I) involves the reaction of an intermediate of formula (-V) as de~ined above with one of the compounds of formuia (~vïj:
LG ~ G LC~
~ ~ ~ N N ,/ (CH2)"
(a) ~L~ ~= ~ z H (c) HN ~
LG LG LG
(XVI) wherein each LG, which may be the same or different, is a leaving group, 10 such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or, in particular, a halogen atom, (e.g. bromine, chlorine or iodine), q is an integer from 1 to 6 and Z are as defined in formula (I), followed by reaction of the resultant compound with an amine NHR7R8 to complete the ZNR7R8 moiety.
This reaction is conveniently effected in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate.
It will be appreciated that, whcre necessary, reactive groups may be protected, thus for example, the NH groups of an imidazolinone of formula 20 (XIIa) may be protected by any suitable amine protecting group such as an acetyl group.
- It will be further appreciated that ~imil~r methodology may be used for the preparation of compounds where the group ZNR7R8 is absent.
(~ompounds of formulae (IIIA) and (IIIB) are either known 2O compounds or may be prepared from a corresponding compound of formula (X~II) WO 97/300!;6 PCT/GB97/00404 ~R
Hal (XVII) wherein Hal is a halogen atom, for example, chlorine, bromine or iodine, especially bromine, using conventional conditions for the synthesis of Grignard reagents or organolithium reagents.
An alternative convenient method for the preparation of compounds of formula (II), in which n is 1, is that illustrated by Scheme A, below, or using methods analogous thereto:
Scheme A
Rsa OPh OPh R9bXNJ~ R4 ~ / IgCl R9~o~ ~=CH~
R (c.f. Louw et al .~\ ~
R5 TetrQhedrolt, (i992) R9b ~l ~ ~ --R4 48: ~087-(;104) R6 ~X
(XIV) R5 n-BuLi ZnCL>
(Ph3P)4.Pd(o) R ~O~ I ~>co ozone/O~~ O
R '~ ~ (CE13)~5 R ~ \ R4 (II) It will be appreciated that compounds of the formula (I) wherein RG
contains an =O or =S substituent can exist in tautomeric forms. All such CA 0224~78 1998-08-0~
tautomeric forms and mixtures thereof are included within this invention.
Most aptly the =O or =S substituent in R~; is the =O substituent.
- Where they are not commercially available, the intermediates offormula (VI) above may be prepared by the procedures described in the accompanying l~xamples or by alternative procedures which will be readily apparent to one skilled in the art.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protectiue Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Further methods suitable for adaptation to the preparation of the spiroketal compounds of the present invention are described by F. Perron and K.F. Albizati in Chem. ~ev., (1989) ~, 1617-1661.
The exemplified compounds of this invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No.
WO 93/01165 The compounds or, in the case of prodrugs, the parent compounds, were found to be active with IC50 at the NKI receptor of less than l~M on said test method.
For the avoidance of doubt, the nomenclature adhered to throughout this specification is based upon the following structures:
2~
3' - 2'~4' G' G nd ,~ G' r.
N ' ',, R"
The following non-limiting Examples serve to illustrate the preparation of compounds of the present invention:
(2R,3S)-4-Benzvl-3-(4-fluorophenvl)-2-hvdroxY-2-(Prop-2-envl)mor~holine (3S)-4-Benzyl-3-(4-fluorophenyl)-2-morpholinone (see International Patent Specification No. WO 95/18124) (13.6g, 47.6mmol) was dissolved in anhydrous tetrahydrofuran (200ml) and cooled to below -70~C under an inert atmosphere. Allyl magnesium chloride (26.2ml of a 2.0M solution in tetrahydrofuran; 52.4mmol) was added dropwise over 15 minutes, maint~inin~ the temperature below -70~C~. After 30 minutes, the reaction was quenched by the addition of a saturated solution of ammonium chloride and allowed to warm to room temperature. The resulting suspension was extracted with ethyl acetate (3xlOO~nl), and the combined organic extracts dried ~MgSO4) and concentrated in vacuo to yield the title compound in ~3:1 mixture of the lactols as a light yellow oil (15.3g, 98%), which was used without further purification. m/2~ (ES+) 328 (M+l, 22%), 310 (M-OH, 61), 269 (100).
(2R,3S) -4-BenzYl-2-(2,3-dihvdroxY~ProPYl-3-(4-fluorophenvl) -2-hydroxvmorpholine The alkene of Description 1 (18.9g, 57.7mmol) was stirred with 2~ osmium tetroxide (0.2g, 0.8mmol) and N-methylmorpholine N-oxide (7.78g, 6~.4mmol) in a solution of tetrahydrofulan (200mV, 2-methyl-2-propanol (120ml) and water (14ml) for 3 days at room temperature. Thc resulting black solution was diluted with ethyl acetate (200ml), water (200ml) and saturated brine (lOOml), separated and the organic fraction dried (MgSO4) and concentrated i7Z, vacllo. The resulting black oil (26g) was purified by flash silica gel chromatography eluting with ~0-100%
CA 0224=,=,78 1998-08-0=, ethyl acetate in hexane to yield the title compound as a mixture of isomers as a white foam (15.9g, 76%). Analysis Found: C, 65.22; H, 6.74; N, 3.68.
C20H24FNO4Ø5 H20 requires C, 64.84; H, 6.82; N, 3.78% m/z (ES+) 362 (M+1, 18%), 344 (l~-OH, 100).
DESCRIPTIONS 3A and 3B
(2R,3S ,9RO-4-Aza-4-benzvl- 1,7-dioxa-3-(4-fluorol~henyl) -9-hYdroxYspiro~5.41decane; and (2S,3S,9RS)-4-Aza-4-benzvl-1,7-dioxa-3-(4-fi uorophenYl) -9-hvdroxvspiro ~5.41 decane The mixture of triols of Description 2 (15.0g, 41.5mmoV was dissolved in hydrochloric acid (200ml, 6M), and methanol (lOOml) and heated at re~lux for 5 hours. The cooled solution was basified with 4N
sodium hydroxide solution and extracted with ethyl acetate (3x200ml).
The combined organic extracts were dried (MgS04) and concentrated i71 vacuo. The resulting black oil (18g) was purified by ~lash silica gel chromatography eluting with 33-66% ethyl acetate in hexane to yield the title compounds as pairs of diasteromers. The less polar isomer pair ~Description 3A), was obtained as an orange gum (7.1g, 50%). Rf 0.37 (50~/0 ethyl acetate/hexane). lH NMR (360MHz, CDCl3) ~ 0.42 (~l/2H, d, J=10.4Hz)*, 1.69 (l/2H, dd, J=13.5, 5.5Hz), 1.86 (l/2H, d, J=14.6Hz), 1.96 (l/2H, d, J=13.6Hz), 2.15 (l/2H, dd, J=14.6, 6.4Hz~, 2.30 (lH, dt, J-12.0, 3.6Hz), 2.76 (lH, d, J=13.1Hz), 2.79 (lH, d, J=13.2Hz), 3.11 (~l/2H, d, J=11.2Hz)*, 3.34 (lH, d, J=14.2Hz), 3.35-3.71 (3H, m), 3.91 (7/2H, dd, J=9.7, 3.6Hz), 3.98-4.24 (2l/2H, m), 7.01 (2xl/2H, t, J=8.8Hz), 7.08 (2xl/2H, t, J=8.7Hz~, 7.18-7.29 (5H, m), 7.54 and 7.63 (2H, 2xbr s) ~* exchanges in D~O); m,/~ (ES+) 344 (M+1, 100%).
The more polar isomer pair (Description 3B) was obtained as an orange glass (4.3g, 30%). Rf 0.25 (50% ethyl acetate/hexane). lH NMR
(360MHz, CDCl3) ~ 0.83 (2/3H, br d)*, 1.64 (l/3H, dd, J=14.0, 5.7Hz), 1.87 (2/3H, d, J=14.6Hz), 2.02 (l/3H, J=14.0Hz), 2.15 (2/3H, dd, J=14.6, 6.6Hz), 2.32-2.41 (lH, m), 2.74-2.82 (lH, m), 3.03 (l/3H, d, J=ll.OHz)*, 3.14 (2/3H, CA 0224~78 1998-08-0~
d, J=13.7Hz), 3.17 (l/3H, d, J=13.7Hz), 3.50 (l/3H, d, J=13.6Hz), 3.59 (2/3H, d, J=13.7Hz), 3.66-4.16 ({~l/3H, m), 4.33 (2/3H, br s), 7.00-7.09 (2H total, m),7.21-7.31 (5H, m), 7.41-7.52 (2H total, m) (* e~f~h~nges in D2O); m/z (ES+) 344 (M+~, 100%).
DESCRIPI'ION 4 (2R~3S)-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluoro~henYl)-9-oxospLro~5.4]decane Anhydrous dimethylsulphoxide (3.4ml, 47.8mmol) dissolved in dichloromethane (lOml) was added dropwise over 10 minutes to a solution of oxalyl chloride (2.0ml, 22.9mmol) dissolved in anhydrous dichloromethane (200ml) cooled to below -70~C. The temperature was m~int~ined below -60~C during the addition and the solution stirred for a further 15 minutes at below -70~C. The alcoho~ isomer pair A (Description 3A) (6.57g, l9.1mmol) dissolved in dichloromethane (40ml) was added dropwise over 10 minutes, maint~ining the temperature below -70~C, and then stirred at this temperature for one hour. Triethylamine (13.3ml, 95.5mmol) was added dropwise over 10 minutes, and the reaction allowed to warm to room tempcrature. The resulting mixture was washed with dilute sodium bicarbonate solution (0.2M) and water (200ml) and the organic fraction dried (MgSO4) and concentrated i71 ~acuo (7.9g). The crude product was purified by flash silica gel chromatograph~ eluting with 14-20% ethyl acetate in hexane to yield the title compound as a pale yellow glass which solidified to a buff coloured solid on standing (5.2g, 80%). Analysis Found: C~, 70.29; H, 5.83; N, 4.02. C70H20FNO3 requires C, 70.37; H. 5.91; N, 4.10%. La]22D=+125.6 (c=1.04, CH7~12); lH NMR
(360MHz, CDCl3) ~ 2.31 (2H, d, J=3.0Hz), 2.35 (lH, dt, J=12.0, 3.5Hz), 2.80 (lH, d, J=12.9Hz), 2-.~3 (lH, br d, J=ll.OHz), 3 a2 (lH, s), 3.59 (lH, dq, J=10.1, 1.6Hz), 3.68 (lH, d, J=13.2Hz), 3.88 (lH. d, J=16.6Hz), 4.03 (lH, d, J=16.6Hz), 4.18 (lH, dt, J=11.7, 2.aHz), 7.0a ~lH, t, J=8.7Hz), 7.19-7.32 (5H, m), 7.58 (2H, br s); 7lt/_ (~S+) 342 (M+l, 100%).
CA 0224~78 1998-08-0~
(2R,3S.9R)-4-Aza-4-(4-chlorobut-2-vnYl)- 1,7-dioxa-3-(4-fluorophenYl)-9-hvdroxY-9-(2-methoxy-5-(trifluoromethYl)phenYl~sPiro [5.4l decane A solution of 1,4-dichlorobutyne (l96~11 2.0mmol) in DM~ (30ml) and potassium carbonate (709mg, 5.13mmol) was heated to 60~C. The morpholine of Example 12 ~731mg, 1.71mmol) as a solution in DMF (lOml) was added dropwise over 5 minutes and the reaction stirred for 3 hours.
The cooled reaction mixture was diluted with water (lOOml), extracted with ether (3x40ml), dried (MgS04) and concentrated to an orange oil 10 which was purified by flash silica gel chromatography eluting with 2:1 to 1:1 hexane:ethyl acetate to yield the title compound as a yellow oil (326mg, 37%). m/z (ES+) 514/516 (3:1, M+1, 100%).
15 (2R,3S,9R~-4-Aza-4-(4-azidobut-2-vnvl)-1.7-dioxa-3-(4-fluorophenvl)-9-hvdroxv-9-(2-methoxv-5-(trifluoromethYl)~henYl)sPiro~5.41decane Sodium azide (97mg, 1.48mmol) was added to a solution of the chloride of Description 5 (255mg, 0.49mmol) dissolved in DMSO (lOml) and stirred for 18 hours. The reaction mixture was diluted with saturated 20 ammonium chloride solution (lOOml), extracted with ethyl acetate (3x40ml), dried (MgSO4) and concentrated to a crude oil which was purified by flash silica gel chromatography eluting with 4:1 hexane:ethyl acetate to yield the title compound as an oil (232mg, 91%); ~n/~ (ES+) 521 (M+1, 100%).
(2R,3S~9R)-4-Aza-4-(4-chlorobut-2-vnvl)-1.7-dioxa-3-(4-fluorophenyl)-9-methox~r-(2-methoxv-5-(trifluoromethvl~henvl)sPiro[5.41decane The title compound was prepared from the morpholine of Example 32 30 according to the mcthod of Description 5 to yield a glass (137mg, 44%).
lH NM:I~ (360MHz, CD(~13) ~ 2.25 (lH, d, J=14.0)~ 2.53 (lH, d, J=14 0), 2 78 CA 0224~78 1998-08-0~
(lH, dd, J=11 4, 1.4), 2.93-3.01 (lH, m), 2.98 (31E~, s), 3.07 (lH, dt, J=17.4, 1.9), 3.19 (1~, dt, J=17.5, 1.8), 3.63 (lH, s), 3.67 (3H, s), 3.76 (lH, dd, J=11.5, 2.7), 3.90 (lH, d, J=9.8), 4.17 (2H, s), 4.39 (lH, dt, J=11.8, 2.8), 4.4;4 (lH, d, J=9.8), 6.81 (lH, d, J=8.6), 6.87 (2H, t, J=8.1), 7.22 (lH, d, J=2.1), 7.44 (~2H, br s), 7.45 (lH, dd, J=8.7, 1.9); m/z (ES+) 528l530 (3:1, M+l, 100%).
(2R,3S ~ 9R)-4-Aza-4-(4-azidobut-2-vnYl~- 1,7-dioxa-3-(4-fluorophenyl)-9-10 methoxY-9-(2-methoxY-5-(trifluoromethYl)~henyl)spiror5~4ldecane The title compound was prepared from the chloride of I)escription 7 according to the method of Description 6 to yield an oil (104mg, 76%). m /z (ES+) 535 (M+l, 100%).
(2R.3S,9R)-4-Aza-4-(4-chlorobut-2-vnYl)-1.7-dioxa-3-(4-FluoroPhenyl~-9-methoxy-9-(~-(tri~luoromethyl)phenvl)spiro~5.41decane The title compound was prepared from the morpholine of Example 31 according to the method of Description 5 to yield an oil (193mg, 84%).
(2R,3S,9R)-4-Aza-4-(4-azidobut-2-YnYl)-1.7-dioxa-3-(4-fluoroPhenyl)-9-methoxy-9-(2-(trifluoromethyl)~henvl)spiro~5.41decane The title compound was prepared from the chloride of Description 9 25 according to the method of Description 6 to yield an oil (166mg, 86%).
2-Bromobenzyl triisoProPvlsil~-l ether Triisopropylsilyl chloride (8.0ml, 46.0mmol) was added dropwise to a 30 solution of 2-bromobenzyl alcohol (7.0g, 39.6mmol) and imidazole (5. lg, 75.0mmol) in DMF (25ml) and the resulting solution stirred at 20~C for 18 CA 0224~78 1998-08-0~
hours. The reaction mixture was diluted with water (400ml) and extracted with ethyl acetate (3x75ml). The combined organic extracts were washed with saturated brine (lx75ml), dried (MgSO4) and concentrated to yield the title compound as a clear oil (10.2g, 78%). lH NMR (250M~z, CDCl3) 1.05-1.24 (21~I, m), 4.8~ (2H, s), 7.11 (lH, dt, ~=7.5, 1.2), 7.34 (lH, t, J=7.6), 7.48 (lH, dd, J=7.9, 1.1), 7.63 (lH, d, J=6.7).
DES~RIPTION 12 (2R,3S,9~-4-Aza-benzvl-1.7-dioxa-3-(4-fluoroPhenvl)-9-hvdroxY-9-(2-((triisopropvlsilYloxY)methvllphenYl~spiror5~4ldecane Tert-butyl lithium (1.69ml, 1.7M solution in pentane, 2.87mmol) was added dropwise to a solution of the bromide of Description 11 (2.0g, 5.85mmol) in ether (5ml) cooled to -78~C, the temperature rising to -30~C
during the addition. The benzyl ketone of Description 4 (l.Og, 2.83mmol) as a solution in ether (3ml) was added dropwise over 20 minutes and the resulting solution allowed to warm to 20~~ over ll/2 hours. The reaction was quenched by the addition of saturated ammonium chloride solution, extracted with ethyl acetate (3x40ml) and the combined organic extracts washed with saturated brine (lx40ml), dried (MgSO~) and concentrated to a yellow oil. The crude concentrate was purified by flash silica gel chromatography eluting with 19:1 hexane:ethyl acctate to yield the title compound as an oil contaminatcd with an equal mass of unreacted benzyl ketone (350mg total) and was used without further purification in Example 47; 777 /:z (ES+) 606 (M+1, 100%).
2a (2R,3S,9R)-4-Aza-4-benzyl-1,7-dioxa-3-(4-:i~luorophenvl)-9-hvdroxy-9-Phenvl-spiror5.41decane Phenyl magnesium ~romide (750111 of a 3.0M solution in ethel~, 2.25mmol) was added dropwise over 10 minutes to an ice cold solution of the benzyl l~etone of Description 4 (512mg, 1.50mmol) in tetrahydrofuran (lOml). The reaction mixture was allowed to warm to 20~C over 2 hours before being quenched with saturated ammonium chloride solution (15ml), extracted with ethyl acetate (3xl5ml), dried (MgSO4) and concentrated to dryness. The resulting crude gum (852mg) was purified by flash silica gel chromatography eluting with 7:3 hexane:ether to yield the title compound as an o~E-white foam (232mg, 37%). Analysis Found: C, 74.77; H, 6.19; N, 3.21. C2~H2~FNO3 requires C, 74.43; H, 6.26; N, 3.34%. lH NMR (360MHz, CDCl3) ~ 2.18 (lH, d, J=13.5), 2.23 (lH, d, J=13.6), 2.36 (lH, dt, J=12.1, 3.3), 2.81 (2H, t, 3=12.1), 3 54 (lH, s), 3.66 (3H, m), 4.20 (2H, m), 4.34 (lH, dt, J=11.4, 3.0), 7.05-7.12 (4H, m~, 7.19-7.26 (8H, m), 7.62 (2H, br s); m/~
(~S+) 420 (M+l, 100%).
(2R,3$,9R)-4-Aza-4-benzvl-1,7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxy-9-(2-methoxvPhenvl)sPiro~5.41decane n-Butyl lithium (1.03ml, 1.6M in hexanes, 1.65mmol) was added dropwise over 2 ~ninutes to a solution of 2-hromoanisole (210~1, 1.70mmol) in tetrahydrofuran (5ml) cooled to below -70~C. The solution was maintained at this temperature and stirred for 40 minutes before the benzyl ketone of Description 4 (0.50g, 1.46mmol) as a solution in tetrahydrofuran (5ml) was added dropwise over 10 minutes maints-ining the temperature below -70~C. The solution was stirred for 10 minutes before warming to 20~C over 1 hour and quenchcd with a saturated ammonium chloride solution (20ml). The resulting suspension was extracted with ethyl acetate (3xl5ml), dried (MgSO4) and concentrated to a black gum (0.64g), which was further purified by flash silica chromatography eluting with 20% ethyl acetate in hexanc. The title compound was obtained as a pale yellow gum (0 21g, 32%) which solidified on standing. lH NMR (250MHz, CDCl3) ~ 2.03 (lH, d, J=13.0), 2.34 (lH, dt, J=11.9. 3.5), 2.61 (lH, d, J=13.0), 2.77 ~lH, d, J=13.2), 2.82 (lH, br d, J=13.5), 3.37 (3H, s), 3.55 (lH. s), 3.62-3.70 (2H, m), 4.13 (2H, d, J=1.4), CA 0224~78 1998-08-0~
CA 0224~78 1998-08-0~
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-hydroxy-spiro [5. 4~ decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-spiro[5.43decane;
~ 5 (2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-phenylspiro~5.4~ decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4~decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro [5 .4] decane;
(2R,3S,9S)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyVspiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(tri~luoromethoxy)phenyl)spiro~ 5.4]decane;
(+/-)-(2R~,3S*,9R~)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methylphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)-spiro~5.4]decane;
(2R,3S,9R)-4-aza-4~(4-(N,N-dimethylamino)-but-2-ynyl)-1" -dioxa-3-(4-fluorphenyl)-9-hydroxy-9-(2-methoxy-5-(tri~luoromethyl)phenyl)-spiro~5.4]decane;
(2R, 3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)- 1, 2, 3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydrox~J-9-(2-methoxy-5-(tri~luoromethyl)phenyl)spiro[o.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-(l(S)-phenylethyl)-9-(2-(trifluoromethyl)phenyl)spiro[;3.4]decane;
CA 0224~78 1998-08-0~
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-~luorophenyl)-9-hydroxy-4-(1(R)-phenylethyl)-9-(2-(trifluoromethyl)phenyVspirol5.41decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-((2-(tri~Luoromethyl)phenyVmethyl)-9-(2-(trifluoromethyVphenyl)-5 spiro[6.4]decane;
(+/-)-(2R~,3S*,9R~)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro[5.4~decane;
(2R, 3S,9R~-4-aza-4-benzyl- 1, 7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-Inethoxyphenyl)spiro[5.4]decane;
10 (2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-~1uorophenyV-9-methoxy-9-(2-(tri~1uoromethyl)phenyl)spiroL5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyVspiror5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-15 9-(2-methylphenyl)spiro~5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyV-9-methoxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-spiro[5.4]decane;
20 (+/-)-(2R~,3S*,9R*)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro[6.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxyphenyl)spiro[5.43decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-25 (trifluorom~thyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-~luorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methylphenyl)spiro[6.4]decane;
30 ~2R,3S,9R)-4-aza-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-methoxy-spiro [5.4] decane;
CA 0224~78 1998-08-0~
WO 97/30~)56 PCT/GB97/00404 (2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-tetrazol-4-yl)methyl- 1, 7-dioxa-3-(4-fluoropheny~)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5 .4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(S)-phenylethyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(R)-phenylethyl)-9-(2-methoxy-5-~trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyV-9-n:lethoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((2-(trifluoromethyl)phenyl)methyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-15i (triflu~r~n~eth~ll)phenyl)-4-((~-(tri~1uoromethyl)phenyl)meth~zl)-spiro[5.4]decane;
(2R, 3S,9R)-4-aza- 1, 7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((4-(trifluoromethyl)phenyl)methyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-((2-methoxyphenyl)methyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl) spirol5.4]decane;
(2R,3S,9R)-9-allyloxy-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl3-9-phenyl-spiro [5.4]decane;
(2R, 3S, 9R) -4-aza-4-benzyl- 1, 7-dioxa-3- (4-fluorophenyl)-9-p henyl-9-(phenylmethyloxy)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1, 7-dioxa-3-(4-fluorophenyl)-9-phenyl-9-propyloxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-fluoro-3-(4-fluorophenyl)-9-phenyl-spiro[5.4]decane;
CA 0224~i~i78 1998-08-O~i WO 97/3~056 PCT/GB97/00404 - 16 ~
(2R,3S,9R~-4-a~a-1,7-dioxa-g-~uoro-3-(4-fluorophenyl)-9-phenylspiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(hydroxymethyl)phenyl)spiro[~.4~decane;
~; [2'R- [2'a(S*), 4~CC]~ 3r~ -(4-fluorophenyl)-4"-(phenylmethyl)dispiro-[isobenzofuran- 1 (3H~, 4' (5rH)-furan-2' (3~:1), 2" -morpholine];
[2r~-[2'a(S*),4roc]]-3"-(4-fluorophenyl)dispiro[isobenzofuran- 1(3~),4'(5 furan-2' (3~ 2~r -morpholine~;
and pharmaceutically acceptable salts thereof.
In a further aspect of the present invention, the compounds of formula (I) will preferably be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.
For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention incluae acid addition salts which may, for example, be formed by mi~ing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, 2~ alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g.
sodium or potassium salts, and ~lk~3line earth metal salts, e.g. calcium or magnesium salts.
The salts may be formed by conventional means, such as by reacting the ~ree base form of the product with one or more cquivalents of the CA 0224~78 l998-08-0~
appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed i7?, vacuo or by freeze drying or by e~ h~nging the anions of an existing salt for another anion on a suitable ion exchange resin.
The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I).
Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for exa~nple, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation i7t vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.
The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.
The compounds according to the invention have at least three asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
The preferred compounds of the formula (I) and ~Ia) will have the preferred stereochemistry of the ~-, 3- and 9-positions that is possessed by the compound of 3xample 1 (2R,3S,9R). Thus for example as shown in formula (Ib) CA 0224~78 1998-08-0~
o (c~R3 ~ ~j~ (CH ~)m 9b J' N ~ ""'~ R4 (Ib) The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in 5 association with a pharmaceutically acceptable carrier or excipient.
Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal a~rnini.qtration, or administration by inhalation or insufflation.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a so~id preformulation 15 composition cont~3ining a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into 20 equally effective unit dosage forms such as tablets, pills and capsules.
This solid preformulation composition is then subdivided into unit dosage forms of the type described above cont~ining from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a CA 0224~78 1998 - 08 - o~
dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
The two components can be separated by an enteric layer which serves to 5 resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and simil~r pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
Preferred compositions for administration by injection include those comprising a compound of formula (I), as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).
Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g. ~weenTM 20, 40, 60, 80 or 85) and other sorbitans (e.g. SpanTM 20, 40, 60, 80 or 85~. Compositions with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
Suitable emulsions mav be prepared using commercially available fat emulsions, such as IntralipidTM, LiposynTM, InfonutrolTM, LipofundinTM
CA 0224C7C778 1998-08-0C, and LipiphysanT~. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almondoil) and an emulsion formed upon mi~inE~ with a phospholipid (e.g. egg 5 phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%. The fat emulsion will preferably comprise fat droplets between 0.1 and 1.0~Lm, particularly 0.1 and 0.5,um, and have a pH in the range of 5.5 to 8Ø
Particularly preferred emulsion compositions are those prepared by mi~in~ a compound of formula (I) with IntralipidTM or the components thereof (soybean oil, egg phospholipids, glycerol and water).
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
Preferably the compositions are a(1rnini~tered by the oral or nasal 20 respiratory route for local or systemic effect. C~ompositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directl~ fiom the neb~ in~ device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, 25 suspension or powder compositions may be administered, pleferably orallv or nasall~, from devices which deliver the formulation in an appropriate manner.
The present invention futher provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), 30 which process comprises bringing a compound of formula (I) into association with a pharmaceutically acceptable carrier or excipient CA 0224~78 l998-08-0~
The compounds o~ formula (I) are of value in the treatment of a wide variety of ~.linic~l conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity.
Thus, for example, an excess of tachykinin, and in particular 5 substance P, activity is implicated in a variety of disorders of the central nervous system. Such disorders include mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and 10 cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, .
speclfic phoblas, for example, speclfic ~nlmf.l phoblas, soclal phoblas, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety 15 disorders; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders and psychotic disorders with delusions or hallucinations; delerium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as 20 Alzheimer's disease, senile dementia, dementia of the Al~heimer's type, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; Parkinson's disease and other extra-pyrz3mi-1z3l movement disorders such as 2~ medication-induced movement disorders, for example, neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induccd acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; substance-related disorders arising ~rom the use of alcohol, amphetamines (or amphetamine-30 like substances) caffeine, cannabis, cocaine, hallucinogens, inh~l~nts andaerosol propellants, nicotine, opioids, phenylglycidine derivatives, CA 0224~78 1998-08-0~
sedatives, hypnotics, and anxiolytics, which substance-related disorders include dependence and abuse, intoxication, withdrawal, intoxication delerium, withdrawal delerium, persisting dementia, psychotic disorders, mood disorders, anxiety disorders, sexual dysfunction and sleep disorders;
5 epilepsy; Down's syndrome; demyelinating diseases such as MS and ALS
and other neuropathological disorders such as peripheral neuropathy, for example diabetic and chemotherapy-induced neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic 10 cerebrovascular damage such as cerebral infarction, subarachnoid haemorrhage or cerebral oedema.
Tachykinin, and in particular substance P, activity is also involved in nociception and pain. The compounds of the present invention will therefore be of use in the prevention or treatment of diseases and 15 conditions in which pain predominates, including soft tissue and peripheral fl~m~ge, such as acute trauma, osteoarthritis, rheumatoid arthritis, musculo-skeletal pain, particularly after trauma, spinal pain, dental pain, myofascial pain syndromes, headache, episiotomy pain, and burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, 20 orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorlhoea, and labour pain; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, 25 nerve root damage, and arachnoiditis; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage; low back pain; sciatica;
ankylosing spondylitis, gout: and scar p ain .
Tachykinin, and in particular substance P, antagonists may also be 30 of use in the treatment of respiratory diseases, particularly those associated with excess mucus secretion, such as chronic obstructive CA 0224~78 1998-08-0~
airways disease, bronchopneumonia, chronic bronchitis, cystic fi~rosis and asthma, adult respiratory distress syndrome, and bronchospasm;
infl~mmz~tory diseases such as infl~mm~tory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis, pruritis and sunburn;
5 allergies such as eczema and rhinitis; hypersen~i~ivi~y disorders such as poison ivy; ophth~lmi~ diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophth~lmi~ conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other 10 eczematoid dermatitis.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of neoplasms, including breast tumours, neuroganglioblastomas and small cell carcinomas such as small cell lung cancer.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of gastrointestinal (GI) disorders, including infl~mm~tory disorders and diseases of the GI tract such as gastritis, gastroduodenal ulcers, gastric carcinomas, gastric lymphomas, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's 20 disease, irritable bowel syndrome and emesis, including acute~ delayed or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, for example, motion sickness, vertigo, dizziness and Meniere's disease, surgery, migraine, variations in intercranial pressure, gastro-oesophageal 2O reflux disease, acid indigestion, over indulgence in food or drink, acid stomach, waterbrash or regurgitation, heartburn, for example, episodic, ~ nocturnal or meal-induced heartburn, and dyspepsia.
Tachykinin, and in particular substance P, antagonists may also be of use in the treatment of a variety of other conditions including stress 30 related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; adverse immunological reactions such as CA 0224~78 1998-08-0~
rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus;
plasma extravasation resulting from cyto3~ine chemotherapy, disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as ~n~n~3, vascular headache, migraine and Reynaud's disease; and pain or nociception attributable to or associated with any of the foregoing conditions, especially the tr~n.~mi~ n of pain in 10 migraine.
The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.
The compounds of formula (I) are particularly useful in the 1~ treatment of emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intercranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis induced by antincoplastic (cytotoxic) 20 agents including those routinely used in cancer chemotherapy, and emesis induced by other pharmacological agents, for example, rolipram.
Examples of such chemotherapcutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as 26 nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, ~olic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophvllotoxin; and cytotoxic antibiotics.
Particular examples of chemotherapeutic agents are described, for 30 instance, by D. J Stewart in l~ausea a7~d Vol7titi7lg: Rece77,t Research and Cli7licaZ Adva7~ces, Eds. J. ~ucharczyk et al, CRC Press Inc., Boca Raton CA 0224~78 1998-08-0~
- 2~ -Florida, USA (1991) pages 177-203, especially page 188. Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC~, dactinomycin, mechloreth~mine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin 5 (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla et al in Cancer Tr~atment Reports (1984) 68(1),163-172~.
The compounds of formula (I) are also of use in the treatment of 10 emesis induced by radiation including radiation therapy such as in the treatment of cancer, or radiation sickness; and in the treatment of post-operative nausea and vomiting.
It will be appreciated that the compounds of formula (I) may be presented together with another therapeutic agent as a combined 15 preparation for simultaneous, separate or sequential use for the relief of emesis. ~uch combined preparations may be, for example, in the form of a twin pack.
A further aspect of the present invention comprises the compounds of formula (I) in combination with a 5-HT3 antagonist, such as 20 ondansetron, granisetron or tropisetron, or other anti-emetic medicaments, for example, a dopamine antagonist such as metoclopramide or GABAs receptor agonists such as baclofen. Additionally, a compound of formula (I) may be administered in combination with an anti-infl~mmatory corticosteroid, such as dexamethasone, triamcinolone, 2a triamcinolone acetonide, flunisolide, budesonide, or others such as those disclosed in ~S patent nos. 2,789,118,2,g90,401,3,048,581,3,126,375, 3,929,768,3,996,359,3,928,326 and 3,749,712. Dexamethasone (DecadronTM3 is particularly preferred. Furthermore, a compound of formula (I) may be administered in combination with a chemotherapeutic 30 agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available CA 0224~78 1998-08-0~
WO 97/300~;6 PCT/GB97/00404 dosage forms of the known therapeutic agents for use in such combinations will be suitable.
When tested in the ferret model of cisplatin-induced emesis described by F. D. Tattersall et al, in Eur. J. pharmacol., (1993) 250, R6-5 R6, the compounds of the present invention were found to attenuate theretching and vomiting induced by cisplatin.
The compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or infl~ m m ~tion and disorders associated therewith such as, for example, neuropathy, such as diabetic 10 and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteroarthritis, rheumatoid arthritis, headache and especially migraine.
The present invention further provides a compound of formula (I) for use in therapy.
According to a further or alterIlative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a me~ m.?nt for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.
The present invention also provides a method for the the treatment 20 O1 prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises at1ministration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).
2~ For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically acti~e agent. For example, for the treatment of respiratorY diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a ~2-adrenergic receptor 30 agonist or tachykinin antagonist which acts at NK-2 receptors. The CA 0224~78 1998-08-0~
compound of formula (I) and the bronchodilator may be arlmini~tered to a patient simultaneously, sequentially or in combination.
Likewise, a compound of the present invention _ay be employed with a leukotriene antagonists, such as a leukotriene D4 antagonist such as a compound selected from those disclosed in European patent specification nos. 0 480 717 and 0 604114 and in US patent nos. 4,859,692 and 5,270,324. This combination is particularly useful in the treatment of respiratory diseases such as asthma, chronic bronchitis and cough.
The present invention accordingly provides a method for the 10 treatment of a respiratory disease, such as asthma, which method comprises a(lmini.~tration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.
The present invention also provides a composition comprising a 16 compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.
It will be appreciated that for the treatment or prevention of migraine, a compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-~Tl agonists, 20 especially sumatriptan, naratriptan, zolmatriptan or rizatriptan.
Likewise, for the treatment of behavioural hyperalgesia, a compound of the present invention may be used in conjunction with an antagonist of N-methyl D-aspartate (NMDA), such as dizocilpine.
For the treatment or prevention of in~mm~tory conditions in the 2~ lower urinary tract, especially cystitis, a compound of the present invention may be used in conjunction with an antiinfl~3mmatory agent such as a bradykinin receptor antagonist.
It will be appreciated that for the treatment or prevention of pain or nociception, a compound of the present invention may be used in 30 conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs and. in particular, opioid analgesics, especially CA 0224~78 1998-08-0~
WO 97/30056 PCT/GB97/01~404 morphine. Specific anti-;nfl~mm~tory agents include diclofenac, ibuprofen, indometh~in, ketoprofen, naproxen, piroxicam and sulindac.
Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof. Preferred salts of these opioid analgesics include morphine sulphate, morphine 10 hydrochloride, morphine tartrate, codeine phosphate, codeine sulphate, dihydrocodeine bitartrate, diacetylmorphine hydrochloride, hydrocodone bitartrate, hydromorphone hydrochloride, levorphanol tartrate, oxymorphone hydrochloride, alfentanil hydrochloride, buprenorphine hydrochloride, butorphanol tartrate, fentanyl citrate, meperidine 15 hydrochloride, methadone hydrochloride, nalbuphine hydrochloride, propoxyphene hydrochloride, propoxyphene napsylate (2-naphthalenesulphonic acid (1:1) monohydrate), and pentazocine hydrochloride.
Therefore, in a further aspect of the present invention, there is 20 provided a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient.
In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an 25 analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of pain or nociception.
It will be appreciated that for the treatment of depression or anxiety, a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents.
Suitable classes of anti-depressant agent include norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), CA 0224=,=,78 1998-08-0=, ~nonoamine oxidase inhibitors ~MAOIs), reversible inhibitors of monoamine oxidase (RIMAs~, serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, a-adrenoreceptor antagonists and atypical anti-depressants.
Suitable norepinephrine reuptake inhibitors include tertiary amine tricyclics and secondary amine tricyclics. Suitable examples of tertiary amine tricyclics include: amitriptyline, clomipramine, doxepin, imipramine and trimipramine, and pharmaceutically acceptable salts thereof. Suitable examples of secondary amine tricyclics include:
10 amoxapine, desipramine, maprotiline, nortriptyline and protriptyline, and pharmaceutically acceptable salts thereof.
Suitable selective serotonin reuptake inhibitors include: fluoxetine, fluvo~ ine, paroxetine and sertraline, and pharmaceutically acceptable salts thereo~
16 Suitable monoamine oxidase inhibitors include: isocarboxazid, phenelzine, tranylcypromine and selegiline, and pharmaceutically acceptable salts thereof.
Suitable reversible inhibitors of monoamine oxidase include:
moclobemide, and pharmaceutically acceptable salts thereof.
Suitable serotonin and noradrenaline reuptake inhibitors of use in the present invention include: venl~f:~ine, and pharmaceutically acceptable salts thereof Suitable CRF antagonists include those compounds described in International Patent Specification Nos. WO 94/13643, WO 94/13644, WO
25 94/13661, WO 94/13676 and WO 94/13677.
Suitable atypical anti-depressants include: bupropion, lithium, nefazodone, trazodone and viloxazine, and pharmaceutically acceptable salts thereof.
Suitable classes of anti-anxiety agent include benzodiazepines and 30 5-HTIA agonists or antagonists, especially 5-HTlA partial agonists, and corticotropin releasing factor ((~RF) antagonists.
CA 0224~78 1998-08-0~
Suitable benzodiazepines include: alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam, and pharmaceutically acceptable salts thereof.
Suitable 5-HTlA receptor agonists or antagonists include, in particular, the 5-HTlA receptor partial agonists buspirone, ~le.sino~n, gepirone and ipsaperone, and pharmaceutically acceptable salts thereo~
Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention and an anti-depressant or anti-anxiety agent, together 10 with at least one pharmaceutically acceptable carrier or excipient.
In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an anti-depressant or anti-anxiety agent as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention 15 of depression and/or anxiety.
The excellent pharmacological profile of the compounds of the present invention offers the opportunity for their use in therapy at low doses thereby minimi.qing the risk of unwanted side effects.
In the treatment of the conditions associated with an excess of 20 tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.
For example, in the treatment of conditions involving the neurotr~n~mi.ssion of pain sensations, a suitable dosage level is about 25 0.001 to 25 mg/kg per day, preferably about 0.005 to 1~ mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be a(lmini.~tered on a regimen of 1 to 4 times per day, preferably once or twice per day.
In the treatment of emesis using an injectable formulation, a 30 suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 1 mg/kg per day. The CA 0224~78 l998-08-0~
compounds may be afln~ini.~tered on a regimen of 1 to 4 times per day, preferably once or twice per day.
It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular 5 compounds or composition selected but also with the route of a~lmini.~tration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.
According to a general process (A), compounds of formula (I) 10 wherein R is a hydroxy group, may be prepared from a compound of formula (II) o (CH2)"
R9a 0 ~ O
~ (CH2)m 9b J~ N '~~ ~ R4 (II) 15 wherein R~, R5, RG, R9a, R9b, m and n are as defined in relation to formula ~.
(I) by reaction with a Grignard or organolithium compound of formula ~IIIA) or (IIIB) ~M~Hal RZ
R R
(IIIA) (IIIB) wherein Rl, R2 and R3 are as defined in relation to formula (I) and Hal is a halogen atom, for example, chlorine, bromine or iodine, especially a bromine atom.
= ~
Both reactions are effected under conventional conditions, for instance, in a suitable solvent such as an ether, e.g. tetrahydrofuran, at a temperature between -90~ and -60~C, with subsequent quenching using, for example, saturated ammonium chloride solution.
According to a general process (B), compounds of formula (I) wherein R is a group selected from Cl ~alkoxy, C3 Galkenyloxy, C3.6alkynyloxy, fluoroCl 6alkoxy, C3 7cycloaIkoxy, C3 7cycloalkylCl 4alkoxy, phenoxy or benzyloxy, may be prepared from the corresponding compound of formula (I) in which R is a hydroxy group, hereinafter referred to as 10 compounds of formula (IV~
Rl~R3 o--(CH,/ ~, R9b 7 " R4 R
(I~
by reaction with a suitable alkyl halide, alkenyl halide, alkynyl halide, 15 ~luoroalkyl halide, c~Tcloalkyl halide, cycloalkylalkyl halide, phenyl halide or benzyl halide.
The reaction is conveniently effected in the presence of a base such as an alkali metal halide, for example, sodium hydride in a suitable solvent, for example an organic solvent such as N,N-dimethylformamide, 20 preferably at a temperature between 10~C and 50~C, conveniently at room temperature.
According to another general process (C), colnpounds of formula (I) wherein R is a halogen atom~ may be prepared from a corresponding compound of formula (IV) by reaction with a suitable halogenating CA 0224~78 1998-08-0~
reagent. Thus, for example, compounds wherein R is Muorine may be prepared by reaction with diethylaminosulfur trifluoride, the reaction being effected in a suitable organic solvent such as a halogenated hydrocarbon, for example, dichloromethane, at a temperature between -90~C and -60~C, for example, at about -78~C.
According to another general process (D), compounds of formula (I) wherein R6 is H may be prepared from the corresponding compound of formula (I) in which RG is a benzyl group. The reaction may be effected, for instance, under conventional conditions of catalytic hydrogenation using a palladium or platinum catalyst or an oxide thereof, the reaction being effected in a suitable solvent such as an alcohol, for example, methanol, conveniently at room temperature.
According to a further general process (E), compounds of formula (I) may be prepared from the corresponding compound of formula (I) in which R~ is H, hereinafter referred to as compounds of formula (V) Rl~R3 ~ (CH~)n~
9b ~ N ~ \~ R4 ~R5 (V) wherein R, Rl, R~, R3, R'l, R;~, R9a, R9b, m and n are as defined in relation to formula (I), by reaction with a compound of formula LG-RG~ (VI) where RG" is a group of the formula RG as defined in relation to formula (I) or a precursor therefor and LG is a leaving group such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or a halogen atom (e.g.
brornine, chlorine or iodine); and, if RGa is a precursor group, converting it to a group R6 (in which process any reactive group may be protected and thereafter deprotected if desired).
6 This reaction may be performed in a conventional ms~nn~r, for example in an organic solvent such as dimethylform~m;de in the presence of an acid acceptor such as potassium carbonate.
According to another process (F), compounds of formula (I) wherein R6 represents a 1,2,3-triazol-4-ylmethyl group substituted by C~2NR7R8, 10 may be prepared by reaction of a compound of formula (VII) Rl~R3 O (C>~
J ~ R4 ~/ R~
N3 (VII) with an amine of formula NHR7R8, in a suitable solvent such as an ether, 15 for example, dioxan, at elevated temperature, for example, between ~0~C
and 100~C~, in a sealed tube, or the like. This reaction is based upon that described in Chemische Berichte (1989) 122, p. 1963.
According to a further process (G), compounds of formula (I) wherein RG represents a Cl Galkyl group which is substituted by an unsubstituted 20 or substituted 1,2,4-triazolyl group, may be prepared by reaction of an intermediate of formula (V) with a compound of formula (VIII) CA 0224~78 1998-08-0~
lG J~ ~ ( CH, ) p H~ll (VIII~
-w-herein ~al is a halogen atom, foL example, bromille~ chloli~ïe o-l= iOuir~e, p is an integer from 1 to 6 and Rl8 is H, CONH2 or O~H3 (which is converted to an oxo substituent under the reaction conditions), in the presence of a ~; base, followed where necessary by conversion to a compound of formula (I), for example, by reduction of the CONH2 group to CH2N~I2.
Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate. The reaction is conveniently effected in an anhydrous organic solvent such as, for example, anhydrous 10 dimethylformamide, preferably at elevated temperature, such as about 140~C.
A suitable reducing agent for the group CONH2 is lithium aluminium hydride, used at between -10~C and room temperature.
According to a further process (H), compounds of formula (I) may 15 also be prepared from other compounds of formula (I) using suitable interconversion procedures. In particular, interconversion processes may be used to vary the group RG. For example, compounds of formuIa (I) wherein RG is other than H may be prepared from the corresponding compounds of formula (I) wherein RG is ~I by reaction with a reagent ~0 suitable to introduce the group RG, for example, compounds of formula (I) wherein RG is CORa may be prepared from compounds of formula (I) wherein RG is H by, for example, reaction with an appropriate acid - anhydride.
Compounds of formula (I) wherein RG is Cl ~,alkyl may be prepared 25 fiom corresponding compounds of formula (I) wherein RG is CORa by reduction using, for example~ borane or a boroh~dride such as sodium cyanoborohydride Compounds of formula (I) wherein R6 is Cl 6alkyl substituted by CONRaRb may be prepared from corresponding compounds of formula (T) wherein R6 is Cl 6alkyl substituted by CO2Ra by treatment with ammonia or an amine of formula NRaRb.
Compounds of formula (I) wherein R~ is Cl 6alkyl substituted by 5-oxadiazolyl may be prepared from compounds of formula (I) wherein R6 is Cl 6alkyl substituted by CO23~a, where Ra represents Cl 6alkyl, by reaction with a compound of formula (IX) NOH
(IX) wherein R32 represents H or a suitable substituent, in the presence of a base.
Suitable bases of use in the reaction include alkali metals, such as, 15 for example, sodium, and alkali metal hydrides, such as, for example, sodium hydride.
The reaction is conveniently effected in a suitable organic solvent.
Which solvents will bc appropriate will depend on the nature of the base used. For example, where the base used is an alkali metal, suitable 20 solvents will include alcohols, for example, ethanol, whereas where the base used is an alkali hydride, suitable solvents will include ethers, for example, tetrahydrofuran.
Preferably the reaction is conducted at elevated temperature, such as the reflux temperature of the chosen solvent Compounds of formula (I~ wherein RG is Cl Galkyl substituted by thiazolyl may be prepared from compounds of formula (I) wherein RG is Cl Galkyl substituted by CSNH2 by reaction with a compound of formula Hal-CH2C(O)-RG~, where Hal is a halogen atom, such as brornine, chlorine or iodine, and RG~ represents H Ol a suitable substituent.
Compounds of formula (I) wherein RG is Cl 6alkyl substituted by thioxotriazolyl may be prepared from compounds of formula (I) wherein R6 is Cl 6alkyl substituted by CONHNHa by reaction with a compound of formula R6lNCS, wherein R6l represents H or a suitable substituent such 5 as Cl 6alkyl, in the presence of a base Suitable bases of use in the reaction include organic bases such as, for example, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The reaction is conveniently effected in a suitable organic solvent, such as alcohol, e.g.
butanol.
According to another general process (J), compounds of formula (I) wherein R6 represents the group -CHaC_CCH2NR7R8, may be prepared from a compound of formula (X) 9a o (C~
~ (CHy)m Rgb~J ~ \~
~ R~
Hal wherein Hal is a halogen atom such as chlorine, bromine or iodine, by reaction with an amine of formula HNR7R8 in the presence of a base.
Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate. The reaction is conveniently effected in an organic solvent such as, for example, N,N-dimethylformamide, conveniently at room temperature.
Intermediates of formula (II~ may be preparcd by the oxidation of a compound of formula (XI) O (c~
~ (CHy)m R9~ ~ Nl / ~ R4 (XI) under conventional conditions for the oxidation of a secondary alcohol.
Particularly preferred are the conditions of the Swern oxidation, i.e.
dimethylsulfoxide and oxalyl chl~ride, which reaction is conveniently 5 effected in a halogenated hydrocarbon such as dichloromethane, preferably at a temperature below -70~C.
Compounds of formula (XI) may be prepared from a compound of formula (XII) HO
(CHy)n 9a OH
~ (CHy)m R9b N --~R4 (XII) 10 by an acid catalysed intramolecular cyclisation reaction.
Suitable acids of use in the reaction include mineral acids such as, for example, hydrochloric acid. The reaction is conveniently effected in a suitable organic solvent, such as an alcohol, for example, methanol, at elevated temeprature, for example, at the reflux temperature of the chosen 1 5 solvent.
Intermediates of formula (XII) wherein n is 1 may be prepared by the hydroxylation of a compound of formula (XIII):
CA 02245C~78 1998-08-05 R9a ~ ~ CH2 ~ (CH2),,~
R9b~7~ \~R4 R6 ~
RJ
(XIII) using conventional methodology, for instance, using osmium tetroxide and N-methylmorpholine-N-oxide, preferably in an inert solvent such as an ether, for example, tetrahydrofuran, or an alcohol, for example, isobutyl 5 alcohol, or water or a mixture thereof, conveniently at room temperature.
Compounds of formula (XIII~ may be prepared by the reaction of a compound of formula (XIV):
R~ O ~ O
R9b 1 ~ R4 (XLV) with a compound of formula (XV):
~ MgCl ~ (CH.~) ,, (XV) using conventional Grignard conditions, for example, the reaction being effected in a solvent such as an ether, e.g. tetrahydrofuran, at reduced temperature, for examplc, at -78~C.
Compounds of formula (XIV) may be prepared by methods described in European Patent Specification No. 0 577 394-A, or by analogous methods.
Compounds of formula (~1) are known compounds.
Intermediates of formula (~TII) may be prepared from a compound of formula (X) by reaction with an azide, for example, sodium azide in a CA 0224=,=,78 1998-08-0=, suitable solvent such as dimethylsulphoxide at or below room temperature.
Compounds of formula (X~ may be prepared by a dropwise addition of an intermediate of formula (V) to a dihaloacetylene of formula 5 Hal-CH2-C_C-CH2-Hal where each Hal is independently chlorine, bromine or iodine, especially chlorine. The reaction is conveniently effected in a suitable solvent such as dimethylform~mi-le in the presence of a base such as potassium carbonate.
Compounds of formula (VIII) may be prepared as described in cT. Med. Chem., (1984) 27, 849.
For compounds wherein R6 is a (:~l 6alkyl group substituted by a 5-membered heterocycle which in turn is substituted by a ZNR7R8 group where Z is (~H2, certain favoured compounds of for~ula (I) may be prepared from a corresponding compound with a hydrogen atom in place of 15 the ZNR7R8. Thus, for example a compound of the formula (I) wherein R~
is an imidazolinone group carrying a CH2NR7R8 moiety may be prepared from a corresponding compound lacking the CH2NR7R8 moiety by reaction with formaldehydc and an amine NHR7R8 under conventional M~nnich reaction conditions, for example in methanol with heating. If desired a 20 pre-formed reagent such as R7R8N+=CH2.I- may be employed and a tertiary amine such as triethylamine used as acid acceptor.
Alternatively a compound of formula ~I) wherein RG is a Cl ~,alkyl group substituted by an imi~l~701inone group may be reacted with paraformaldehyde and an amine for example a secondary amine such as 25 pyrrolidine or morpholine to give a compound wherein the imicl~olinone ring is substituted by CH2NR7R8 where R7, R8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of ~ to 7 ring atoms which may optionally contain an oxygen ring atom or a second nitrogen atom which will be part of a N~ or NRC moiety, where Rc is as previously 30 defined.
CA 0224~78 l998-08-0~
WO 97/30056 PCT/GBg7/00404 This reaction may be performed in a conventional manner, for instance, in a suitable solvent such as an alcohol, for example, methanol at an elevated temperature up to the boiling point of the solvent.
A further alternative method for the preparation of certain compounds of formula (I) involves the reaction of an intermediate of formula (-V) as de~ined above with one of the compounds of formuia (~vïj:
LG ~ G LC~
~ ~ ~ N N ,/ (CH2)"
(a) ~L~ ~= ~ z H (c) HN ~
LG LG LG
(XVI) wherein each LG, which may be the same or different, is a leaving group, 10 such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or, in particular, a halogen atom, (e.g. bromine, chlorine or iodine), q is an integer from 1 to 6 and Z are as defined in formula (I), followed by reaction of the resultant compound with an amine NHR7R8 to complete the ZNR7R8 moiety.
This reaction is conveniently effected in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate.
It will be appreciated that, whcre necessary, reactive groups may be protected, thus for example, the NH groups of an imidazolinone of formula 20 (XIIa) may be protected by any suitable amine protecting group such as an acetyl group.
- It will be further appreciated that ~imil~r methodology may be used for the preparation of compounds where the group ZNR7R8 is absent.
(~ompounds of formulae (IIIA) and (IIIB) are either known 2O compounds or may be prepared from a corresponding compound of formula (X~II) WO 97/300!;6 PCT/GB97/00404 ~R
Hal (XVII) wherein Hal is a halogen atom, for example, chlorine, bromine or iodine, especially bromine, using conventional conditions for the synthesis of Grignard reagents or organolithium reagents.
An alternative convenient method for the preparation of compounds of formula (II), in which n is 1, is that illustrated by Scheme A, below, or using methods analogous thereto:
Scheme A
Rsa OPh OPh R9bXNJ~ R4 ~ / IgCl R9~o~ ~=CH~
R (c.f. Louw et al .~\ ~
R5 TetrQhedrolt, (i992) R9b ~l ~ ~ --R4 48: ~087-(;104) R6 ~X
(XIV) R5 n-BuLi ZnCL>
(Ph3P)4.Pd(o) R ~O~ I ~>co ozone/O~~ O
R '~ ~ (CE13)~5 R ~ \ R4 (II) It will be appreciated that compounds of the formula (I) wherein RG
contains an =O or =S substituent can exist in tautomeric forms. All such CA 0224~78 1998-08-0~
tautomeric forms and mixtures thereof are included within this invention.
Most aptly the =O or =S substituent in R~; is the =O substituent.
- Where they are not commercially available, the intermediates offormula (VI) above may be prepared by the procedures described in the accompanying l~xamples or by alternative procedures which will be readily apparent to one skilled in the art.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protectiue Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Further methods suitable for adaptation to the preparation of the spiroketal compounds of the present invention are described by F. Perron and K.F. Albizati in Chem. ~ev., (1989) ~, 1617-1661.
The exemplified compounds of this invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No.
WO 93/01165 The compounds or, in the case of prodrugs, the parent compounds, were found to be active with IC50 at the NKI receptor of less than l~M on said test method.
For the avoidance of doubt, the nomenclature adhered to throughout this specification is based upon the following structures:
2~
3' - 2'~4' G' G nd ,~ G' r.
N ' ',, R"
The following non-limiting Examples serve to illustrate the preparation of compounds of the present invention:
(2R,3S)-4-Benzvl-3-(4-fluorophenvl)-2-hvdroxY-2-(Prop-2-envl)mor~holine (3S)-4-Benzyl-3-(4-fluorophenyl)-2-morpholinone (see International Patent Specification No. WO 95/18124) (13.6g, 47.6mmol) was dissolved in anhydrous tetrahydrofuran (200ml) and cooled to below -70~C under an inert atmosphere. Allyl magnesium chloride (26.2ml of a 2.0M solution in tetrahydrofuran; 52.4mmol) was added dropwise over 15 minutes, maint~inin~ the temperature below -70~C~. After 30 minutes, the reaction was quenched by the addition of a saturated solution of ammonium chloride and allowed to warm to room temperature. The resulting suspension was extracted with ethyl acetate (3xlOO~nl), and the combined organic extracts dried ~MgSO4) and concentrated in vacuo to yield the title compound in ~3:1 mixture of the lactols as a light yellow oil (15.3g, 98%), which was used without further purification. m/2~ (ES+) 328 (M+l, 22%), 310 (M-OH, 61), 269 (100).
(2R,3S) -4-BenzYl-2-(2,3-dihvdroxY~ProPYl-3-(4-fluorophenvl) -2-hydroxvmorpholine The alkene of Description 1 (18.9g, 57.7mmol) was stirred with 2~ osmium tetroxide (0.2g, 0.8mmol) and N-methylmorpholine N-oxide (7.78g, 6~.4mmol) in a solution of tetrahydrofulan (200mV, 2-methyl-2-propanol (120ml) and water (14ml) for 3 days at room temperature. Thc resulting black solution was diluted with ethyl acetate (200ml), water (200ml) and saturated brine (lOOml), separated and the organic fraction dried (MgSO4) and concentrated i7Z, vacllo. The resulting black oil (26g) was purified by flash silica gel chromatography eluting with ~0-100%
CA 0224=,=,78 1998-08-0=, ethyl acetate in hexane to yield the title compound as a mixture of isomers as a white foam (15.9g, 76%). Analysis Found: C, 65.22; H, 6.74; N, 3.68.
C20H24FNO4Ø5 H20 requires C, 64.84; H, 6.82; N, 3.78% m/z (ES+) 362 (M+1, 18%), 344 (l~-OH, 100).
DESCRIPTIONS 3A and 3B
(2R,3S ,9RO-4-Aza-4-benzvl- 1,7-dioxa-3-(4-fluorol~henyl) -9-hYdroxYspiro~5.41decane; and (2S,3S,9RS)-4-Aza-4-benzvl-1,7-dioxa-3-(4-fi uorophenYl) -9-hvdroxvspiro ~5.41 decane The mixture of triols of Description 2 (15.0g, 41.5mmoV was dissolved in hydrochloric acid (200ml, 6M), and methanol (lOOml) and heated at re~lux for 5 hours. The cooled solution was basified with 4N
sodium hydroxide solution and extracted with ethyl acetate (3x200ml).
The combined organic extracts were dried (MgS04) and concentrated i71 vacuo. The resulting black oil (18g) was purified by ~lash silica gel chromatography eluting with 33-66% ethyl acetate in hexane to yield the title compounds as pairs of diasteromers. The less polar isomer pair ~Description 3A), was obtained as an orange gum (7.1g, 50%). Rf 0.37 (50~/0 ethyl acetate/hexane). lH NMR (360MHz, CDCl3) ~ 0.42 (~l/2H, d, J=10.4Hz)*, 1.69 (l/2H, dd, J=13.5, 5.5Hz), 1.86 (l/2H, d, J=14.6Hz), 1.96 (l/2H, d, J=13.6Hz), 2.15 (l/2H, dd, J=14.6, 6.4Hz~, 2.30 (lH, dt, J-12.0, 3.6Hz), 2.76 (lH, d, J=13.1Hz), 2.79 (lH, d, J=13.2Hz), 3.11 (~l/2H, d, J=11.2Hz)*, 3.34 (lH, d, J=14.2Hz), 3.35-3.71 (3H, m), 3.91 (7/2H, dd, J=9.7, 3.6Hz), 3.98-4.24 (2l/2H, m), 7.01 (2xl/2H, t, J=8.8Hz), 7.08 (2xl/2H, t, J=8.7Hz~, 7.18-7.29 (5H, m), 7.54 and 7.63 (2H, 2xbr s) ~* exchanges in D~O); m,/~ (ES+) 344 (M+1, 100%).
The more polar isomer pair (Description 3B) was obtained as an orange glass (4.3g, 30%). Rf 0.25 (50% ethyl acetate/hexane). lH NMR
(360MHz, CDCl3) ~ 0.83 (2/3H, br d)*, 1.64 (l/3H, dd, J=14.0, 5.7Hz), 1.87 (2/3H, d, J=14.6Hz), 2.02 (l/3H, J=14.0Hz), 2.15 (2/3H, dd, J=14.6, 6.6Hz), 2.32-2.41 (lH, m), 2.74-2.82 (lH, m), 3.03 (l/3H, d, J=ll.OHz)*, 3.14 (2/3H, CA 0224~78 1998-08-0~
d, J=13.7Hz), 3.17 (l/3H, d, J=13.7Hz), 3.50 (l/3H, d, J=13.6Hz), 3.59 (2/3H, d, J=13.7Hz), 3.66-4.16 ({~l/3H, m), 4.33 (2/3H, br s), 7.00-7.09 (2H total, m),7.21-7.31 (5H, m), 7.41-7.52 (2H total, m) (* e~f~h~nges in D2O); m/z (ES+) 344 (M+~, 100%).
DESCRIPI'ION 4 (2R~3S)-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluoro~henYl)-9-oxospLro~5.4]decane Anhydrous dimethylsulphoxide (3.4ml, 47.8mmol) dissolved in dichloromethane (lOml) was added dropwise over 10 minutes to a solution of oxalyl chloride (2.0ml, 22.9mmol) dissolved in anhydrous dichloromethane (200ml) cooled to below -70~C. The temperature was m~int~ined below -60~C during the addition and the solution stirred for a further 15 minutes at below -70~C. The alcoho~ isomer pair A (Description 3A) (6.57g, l9.1mmol) dissolved in dichloromethane (40ml) was added dropwise over 10 minutes, maint~ining the temperature below -70~C, and then stirred at this temperature for one hour. Triethylamine (13.3ml, 95.5mmol) was added dropwise over 10 minutes, and the reaction allowed to warm to room tempcrature. The resulting mixture was washed with dilute sodium bicarbonate solution (0.2M) and water (200ml) and the organic fraction dried (MgSO4) and concentrated i71 ~acuo (7.9g). The crude product was purified by flash silica gel chromatograph~ eluting with 14-20% ethyl acetate in hexane to yield the title compound as a pale yellow glass which solidified to a buff coloured solid on standing (5.2g, 80%). Analysis Found: C~, 70.29; H, 5.83; N, 4.02. C70H20FNO3 requires C, 70.37; H. 5.91; N, 4.10%. La]22D=+125.6 (c=1.04, CH7~12); lH NMR
(360MHz, CDCl3) ~ 2.31 (2H, d, J=3.0Hz), 2.35 (lH, dt, J=12.0, 3.5Hz), 2.80 (lH, d, J=12.9Hz), 2-.~3 (lH, br d, J=ll.OHz), 3 a2 (lH, s), 3.59 (lH, dq, J=10.1, 1.6Hz), 3.68 (lH, d, J=13.2Hz), 3.88 (lH. d, J=16.6Hz), 4.03 (lH, d, J=16.6Hz), 4.18 (lH, dt, J=11.7, 2.aHz), 7.0a ~lH, t, J=8.7Hz), 7.19-7.32 (5H, m), 7.58 (2H, br s); 7lt/_ (~S+) 342 (M+l, 100%).
CA 0224~78 1998-08-0~
(2R,3S.9R)-4-Aza-4-(4-chlorobut-2-vnYl)- 1,7-dioxa-3-(4-fluorophenYl)-9-hvdroxY-9-(2-methoxy-5-(trifluoromethYl)phenYl~sPiro [5.4l decane A solution of 1,4-dichlorobutyne (l96~11 2.0mmol) in DM~ (30ml) and potassium carbonate (709mg, 5.13mmol) was heated to 60~C. The morpholine of Example 12 ~731mg, 1.71mmol) as a solution in DMF (lOml) was added dropwise over 5 minutes and the reaction stirred for 3 hours.
The cooled reaction mixture was diluted with water (lOOml), extracted with ether (3x40ml), dried (MgS04) and concentrated to an orange oil 10 which was purified by flash silica gel chromatography eluting with 2:1 to 1:1 hexane:ethyl acetate to yield the title compound as a yellow oil (326mg, 37%). m/z (ES+) 514/516 (3:1, M+1, 100%).
15 (2R,3S,9R~-4-Aza-4-(4-azidobut-2-vnvl)-1.7-dioxa-3-(4-fluorophenvl)-9-hvdroxv-9-(2-methoxv-5-(trifluoromethYl)~henYl)sPiro~5.41decane Sodium azide (97mg, 1.48mmol) was added to a solution of the chloride of Description 5 (255mg, 0.49mmol) dissolved in DMSO (lOml) and stirred for 18 hours. The reaction mixture was diluted with saturated 20 ammonium chloride solution (lOOml), extracted with ethyl acetate (3x40ml), dried (MgSO4) and concentrated to a crude oil which was purified by flash silica gel chromatography eluting with 4:1 hexane:ethyl acetate to yield the title compound as an oil (232mg, 91%); ~n/~ (ES+) 521 (M+1, 100%).
(2R,3S~9R)-4-Aza-4-(4-chlorobut-2-vnvl)-1.7-dioxa-3-(4-fluorophenyl)-9-methox~r-(2-methoxv-5-(trifluoromethvl~henvl)sPiro[5.41decane The title compound was prepared from the morpholine of Example 32 30 according to the mcthod of Description 5 to yield a glass (137mg, 44%).
lH NM:I~ (360MHz, CD(~13) ~ 2.25 (lH, d, J=14.0)~ 2.53 (lH, d, J=14 0), 2 78 CA 0224~78 1998-08-0~
(lH, dd, J=11 4, 1.4), 2.93-3.01 (lH, m), 2.98 (31E~, s), 3.07 (lH, dt, J=17.4, 1.9), 3.19 (1~, dt, J=17.5, 1.8), 3.63 (lH, s), 3.67 (3H, s), 3.76 (lH, dd, J=11.5, 2.7), 3.90 (lH, d, J=9.8), 4.17 (2H, s), 4.39 (lH, dt, J=11.8, 2.8), 4.4;4 (lH, d, J=9.8), 6.81 (lH, d, J=8.6), 6.87 (2H, t, J=8.1), 7.22 (lH, d, J=2.1), 7.44 (~2H, br s), 7.45 (lH, dd, J=8.7, 1.9); m/z (ES+) 528l530 (3:1, M+l, 100%).
(2R,3S ~ 9R)-4-Aza-4-(4-azidobut-2-vnYl~- 1,7-dioxa-3-(4-fluorophenyl)-9-10 methoxY-9-(2-methoxY-5-(trifluoromethYl)~henyl)spiror5~4ldecane The title compound was prepared from the chloride of I)escription 7 according to the method of Description 6 to yield an oil (104mg, 76%). m /z (ES+) 535 (M+l, 100%).
(2R.3S,9R)-4-Aza-4-(4-chlorobut-2-vnYl)-1.7-dioxa-3-(4-FluoroPhenyl~-9-methoxy-9-(~-(tri~luoromethyl)phenvl)spiro~5.41decane The title compound was prepared from the morpholine of Example 31 according to the method of Description 5 to yield an oil (193mg, 84%).
(2R,3S,9R)-4-Aza-4-(4-azidobut-2-YnYl)-1.7-dioxa-3-(4-fluoroPhenyl)-9-methoxy-9-(2-(trifluoromethyl)~henvl)spiro~5.41decane The title compound was prepared from the chloride of Description 9 25 according to the method of Description 6 to yield an oil (166mg, 86%).
2-Bromobenzyl triisoProPvlsil~-l ether Triisopropylsilyl chloride (8.0ml, 46.0mmol) was added dropwise to a 30 solution of 2-bromobenzyl alcohol (7.0g, 39.6mmol) and imidazole (5. lg, 75.0mmol) in DMF (25ml) and the resulting solution stirred at 20~C for 18 CA 0224~78 1998-08-0~
hours. The reaction mixture was diluted with water (400ml) and extracted with ethyl acetate (3x75ml). The combined organic extracts were washed with saturated brine (lx75ml), dried (MgSO4) and concentrated to yield the title compound as a clear oil (10.2g, 78%). lH NMR (250M~z, CDCl3) 1.05-1.24 (21~I, m), 4.8~ (2H, s), 7.11 (lH, dt, ~=7.5, 1.2), 7.34 (lH, t, J=7.6), 7.48 (lH, dd, J=7.9, 1.1), 7.63 (lH, d, J=6.7).
DES~RIPTION 12 (2R,3S,9~-4-Aza-benzvl-1.7-dioxa-3-(4-fluoroPhenvl)-9-hvdroxY-9-(2-((triisopropvlsilYloxY)methvllphenYl~spiror5~4ldecane Tert-butyl lithium (1.69ml, 1.7M solution in pentane, 2.87mmol) was added dropwise to a solution of the bromide of Description 11 (2.0g, 5.85mmol) in ether (5ml) cooled to -78~C, the temperature rising to -30~C
during the addition. The benzyl ketone of Description 4 (l.Og, 2.83mmol) as a solution in ether (3ml) was added dropwise over 20 minutes and the resulting solution allowed to warm to 20~~ over ll/2 hours. The reaction was quenched by the addition of saturated ammonium chloride solution, extracted with ethyl acetate (3x40ml) and the combined organic extracts washed with saturated brine (lx40ml), dried (MgSO~) and concentrated to a yellow oil. The crude concentrate was purified by flash silica gel chromatography eluting with 19:1 hexane:ethyl acctate to yield the title compound as an oil contaminatcd with an equal mass of unreacted benzyl ketone (350mg total) and was used without further purification in Example 47; 777 /:z (ES+) 606 (M+1, 100%).
2a (2R,3S,9R)-4-Aza-4-benzyl-1,7-dioxa-3-(4-:i~luorophenvl)-9-hvdroxy-9-Phenvl-spiror5.41decane Phenyl magnesium ~romide (750111 of a 3.0M solution in ethel~, 2.25mmol) was added dropwise over 10 minutes to an ice cold solution of the benzyl l~etone of Description 4 (512mg, 1.50mmol) in tetrahydrofuran (lOml). The reaction mixture was allowed to warm to 20~C over 2 hours before being quenched with saturated ammonium chloride solution (15ml), extracted with ethyl acetate (3xl5ml), dried (MgSO4) and concentrated to dryness. The resulting crude gum (852mg) was purified by flash silica gel chromatography eluting with 7:3 hexane:ether to yield the title compound as an o~E-white foam (232mg, 37%). Analysis Found: C, 74.77; H, 6.19; N, 3.21. C2~H2~FNO3 requires C, 74.43; H, 6.26; N, 3.34%. lH NMR (360MHz, CDCl3) ~ 2.18 (lH, d, J=13.5), 2.23 (lH, d, J=13.6), 2.36 (lH, dt, J=12.1, 3.3), 2.81 (2H, t, 3=12.1), 3 54 (lH, s), 3.66 (3H, m), 4.20 (2H, m), 4.34 (lH, dt, J=11.4, 3.0), 7.05-7.12 (4H, m~, 7.19-7.26 (8H, m), 7.62 (2H, br s); m/~
(~S+) 420 (M+l, 100%).
(2R,3$,9R)-4-Aza-4-benzvl-1,7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxy-9-(2-methoxvPhenvl)sPiro~5.41decane n-Butyl lithium (1.03ml, 1.6M in hexanes, 1.65mmol) was added dropwise over 2 ~ninutes to a solution of 2-hromoanisole (210~1, 1.70mmol) in tetrahydrofuran (5ml) cooled to below -70~C. The solution was maintained at this temperature and stirred for 40 minutes before the benzyl ketone of Description 4 (0.50g, 1.46mmol) as a solution in tetrahydrofuran (5ml) was added dropwise over 10 minutes maints-ining the temperature below -70~C. The solution was stirred for 10 minutes before warming to 20~C over 1 hour and quenchcd with a saturated ammonium chloride solution (20ml). The resulting suspension was extracted with ethyl acetate (3xl5ml), dried (MgSO4) and concentrated to a black gum (0.64g), which was further purified by flash silica chromatography eluting with 20% ethyl acetate in hexanc. The title compound was obtained as a pale yellow gum (0 21g, 32%) which solidified on standing. lH NMR (250MHz, CDCl3) ~ 2.03 (lH, d, J=13.0), 2.34 (lH, dt, J=11.9. 3.5), 2.61 (lH, d, J=13.0), 2.77 ~lH, d, J=13.2), 2.82 (lH, br d, J=13.5), 3.37 (3H, s), 3.55 (lH. s), 3.62-3.70 (2H, m), 4.13 (2H, d, J=1.4), CA 0224~78 1998-08-0~
4.34 (lH, dt, J=12.0, 2.5), 4.60 (lH, s), 6.73 (lH, d, J=8.2), 6.90 (lH, dt, J=7.5, 1.1), 7.05 (lH, t, J=8.8), 7.16-7.28 (7H, m), 7.52 (lH, dd, J=7.8, 1.8), 7.62 (2H, br s); m/z (ES+) 450 (M+l, 100%), 432 (M-OH, 20).
EXA~PLL 3 (2R.3S.9R)-4-Aza-4-benzvl- 1,7-dioxa-3-(4-fluorophenvl)-9-hvdroxy-9-(2-(tri~luoromethYl)PhenYl)spiro~r5.4~decane n-Butyl lithium (3.5ml of a 1.6M solution in hexanes, 5.6mmol) was added dropwise over 15 minutes to a solution of 2-(trifluoromethyl)-iodobenzene (1.47g, 5.4mmol) in ether (15mV cooled to -10~C. A~ter stirring for 1 hour, a 1.2M solution of tributoxyzirconium chloride in ether (4.7ml, 5.6}nmol) (Helv. Chr;m. Acta, 1981, 64, 1552) was added and stirring continued at 0~C for 2.5 hours. Benzyl ketone of Description 4 (616mg, 1.8mmol) as a solution in dichloromethane (6ml) was added and the reaction mixture allowed to warm to 20~C overnight. The reaction was quenched by the addition of 1.0M HCl solution (50ml), extracted with ether (3x30ml), dried (MgSO4) and concentrated to dryness. The crude oil (200mg) was purified by flash silica gel chromatography eluting with 2:1 hexane:ether to yield the title compound as a yellow oil (55mg, 6%).
lH Nl~R (CDC13) ~ 2.28 (lH, d, J=13.3), 2.22-2 40 (2H, m), 2.45 (lH, d, J=13.3), 2.81 (2H, t, J=11.8), 3.54 (lH, s), 3.66 (2H, d, J=12.8), 3.77 (lH, d, J=9.3), 4.32 (2H, m), 4.43 (l~I, d, J=9.2), 7.00 (2H, t, J-8.7), 7.13 (lH, d, J=7.4), 7.21-7.38 (7H, m), 7.58 (2H, br s), 7.68 (lH, d, J=7.3); r~l/3 (:E~S+) 488 (M+l, 100%).
EXAMPLES 4A and 4B
(2R~3S,9R)-4-Aza-4-benzvl-1,7-dioxa-3-(4-~uoroPhenYl)-9-hYdroxY-9-(2 ~ methoxv-6-(tri~1uoromethYl)PhenYl)sPiro~5 4~dccane; and ¢2R,3$,9S~-4-Aza-4-benzvl-1,7-dioxa-3-(4-~luQrophenvl)-9-hYdroxv-9-(2-methoxY-6-30 (tri~1uoromethvl)phenvl)sPiror6.4~decane CA 0224~78 1998-08-0~
2-Methoxy-5-(trifluoromethyl)iodobenzene (1.51g, 5.0mmol) and the benzyl ketone of Description 4 (1.53g, 4.5mmol) were reacted according to the method of Example 2 which gave after work up a crude oil (2.2g). The crude concentrate was purified by flash silica gel chromatography eluting 5 with 6:1 to 4:1 hexane:ethyl acetate to yield the title compound (~"rz~m~le 4A) as a white foam (846mg, 36%); lH NMR (360MHz, CDCl3) ~ 1.92 (lH, d, J=13.0), 2.33 (lH, dt, J=12.0, 3.5), 2.65 (lH, d, J=13.0), 2.76 (lH, d, J=13.2), 2.82 (lH, d, J=11.5), 3.30 (3H, s), 3.54 (lH, s), 3.64 (lH, d, J=13.0), 4.03 (lH, d, J=8.8), 4.18 (lH, d, J=8.8), 4.33 (lH, dt, J=11.8, 2.3), 4.66 (lH, s), 6.72 (lH, d, J=8.6), 7.07 (2H, t, J=8.7), 7.16-7.28 (5H, m~, 7.42 (lH, dd, J=8.9, 2.2), 7.63 (2H, br s), 7.98 (lH, d, J=2.3); 7n/z (ES+) 518 (M+l, 100%);
and the title compound (F',~mple 4B) as an oil ~170mg, 7%); 'H NMR
(360MHz, CI~Cl3) ~ 2.22 (lH, dd, J=14.3, 1.2), 2.33 (lH, dt, J=ll.9, 3.5), 2.73 (lH, d, J=14.3), 2.81 (lH, d, J=13.2), 3.52 (lH, s), 3.57 (lH, m), 3.70 (lH, d, J=13.2), 3.84 (3H, s), 3.85 (lH, d, J=9.0), 4.22 (lH, dt, J=11.8, 2.4), 4.35 (lH, d, J=9.0), 6.88 (lH, d, J=8.6), 7.12 (2H, t, J=8.7), 7.18-7.30 (5H, m), 7.48 (lH, dd, J=8.4, 1.8), 7.65 (lH, d, J=2.1), 7.71 (2H, br s); ~7t/~ (ES+)518 (M+l, 100%).
EXAMPI,E 5 (2R,3S,9R)-4-Aza-4-benzvl-1.7-dioxa-3-(4-fluoroPhenYl)-9-hvdroxy-9-(2-(trifluoromethoxy)phenyl)spiro ~5.41 decane The title compound was prepared according to the method of Example 3 to yield a yellow oil (9lmg, 10%). IH NMR (360MHz, CDCl3) ~ 2.21 (lH, d, J=13.0), 2.35 (lH, dt, J=ll.9, 3.3), 2.40 (lH, d, J=13.2), 2.77 (lH, d, J=13.3), 2.83 (lH, d, J=11.7), 3.56 (lH, s), 3.62-3.70 (2H, m~, 3.83 (lH, d, J=9.3), 4.34 (lH, dt, J=11.6, 2.1), 4.47 (lH, d, J=9.3), 4.55 (lH, s), 7.00 (2H,t, J=8.7), 7.14-7.35 (9H, m~, 7.57 (2H, br s); 77t/~ (E~+) 504 (M+l, 100%).
CA 02245578 l998-08-05 (+/-)-(2R~,3S*,9R*)-4-Aza-4-benzvl-1~7-dioxa-3-(4-fluoroPhenYl)-9-hYdroxy-~ 9-(2-methylphenyl~spiro~5.41decane The title compound was prepared according to the method of ~,~mI)le 1 to yield a white foam (355mg, 47%). Analysis Found: C, 74.64; H, 6.39;
N, 3.40. C27H2sFN03 requires C, 74.81; H, 6.51; N, 3.23%. lH NMR
(360MHz, CDC13) ~ 2.14 (3H, s), 2.27 (lH, d, J=13.2), 2.33 (lH, d, J=13.6), 2.35 (lH, dt, J=ll.9, 3.3), 2.80 (lH, d, J=13.4), 2.83 (lH, d, J=14.4), 3.57 (lH, s), 3.67 (lH, d, J=13.3), 3.86 (lH, d, J=9.3), 4.28 (lH, s), 4.33 (lH, dt, J=11.8, 2.4), 4.43 (lH, d, J=9.3), 7.00 (2H, t, J=8.8), 7.04-7.31 (9H, m), 7.58 (2H, br s); m/z (ES+) 434 (M+l, 100%).
(2R,3S.9R)-4-Aza-4-benzvl- 1,7-dioxa-9-(2-ethYlPhenYl)-3-(4-fluoroPhenyl) -9-hydroxY-spiro~5.41decane The title compound was prepared according to the method of Example 2 to yield an oil (180mg, 28%). IH NMR (360MHz, ~DCl3) ~ 1.07 (3H, t, J=7.5), 2.26-2.48 (4H, m), 2.77-2.88 (2H, m), 3.57 (lH,s), 3.64-3.72 (2H, m), 3.82 (lH, d, J=9.3), 4.32-4.38 (2~, m), 4.41 (lH, d, J=9.3), 6.98-7.08 (3H, m), 7.14-7.30 (8H, m), 7.54-7.64 (2H, br s); m/z (ES+) 449 (M+l, 100%).
(2R.3S,9R)-4-Aza-4-benzYl-9-t2-chlorophenYl)-1.7-dioxa-3-(4-fluoroPhenyl)-9-hvdroxy-spiror5.4~decane The title compound was prepared according to the method of Example 1 to yield an oil (280mg, 51%). ~ (ES+) 454 (M+l, 100%).
(2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxy-9-Phenylspirol5.41decane CA 02245C~78 1998-08-05 The benzylamine of h'.~mple 1 (255mg, 0.61mmol) as a solution in methanol (15ml) was hydrogenated at 40 psi of hydrogen with 10% Pd-C
catalyst (160mg) for 2l/2 hours The reaction mixture was filtered through a pad of Hyflo~M and concentrated to a crude gum which was purified by flash silica gel chromatography eluting with 5% methanol in dichloromethane to yield the title compound as a glass ~76mg, 38%).
lH NMR (360MHz, CDCl3) ~i 1.7-1.9 (~2H, br s), 2.09 (lH, d, J=13.5), 2.20 (lH, dd, J--13.5, 0.9), 3.06 (lH, dd, J=12.4, 2.4), 3.22 (lH, dt, J=12.3, 3.6), 3.73 (lH, dd, J=11.2, 3 0), 3 78 (lH, d, J=9 3), 4 03 (lH, s), 4.27 (lH, d, 10 J=9.3), 4.36 (lH, dt, J=11.7, 2.7), 7.03 (2H, t, J=8.7), 7.12 (2H, m), 7.16-7.26 (3H, m), 7.47 (2H, m); m/z (E:S+) 330 (M+l, 100%), 312 (M-17, 30).
EXAMPLl~ 10 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorophenvl)-9-hYdroxv-9-(2-15 methox~henvl)sPiro~;.41decane The benzyl~mine o~~ mple 2 was hydrogenated according to the method of Example 9 to yield the title compound as a glass (9Omg, 68%).
~H NMR (360MHz, CDCl3) ~ 1.98 (lH, d, J=13.1), 2.56 (lH, d, J=13.1), 3.04 (lH, dd, J=11.6, 2.1), 3.20 ~lH, dt, 3=12.3, 3.7), 3.34 (3H, s), 3.71 (lH, dd, 20 J=ll.O, 2.6), 4.03 (lH, s), 4.17 (2H, s), 4.33 (lH, dt, 3=11.6, 3.1), 6.72 (lH, dd, J=8.2, 0.9), 6.89 (lH, dt, J=7.6, 1.1), 7.02 (2H, t, J=8.7), 7.18 (lH, dt, J=7.8, 1.8), 7.44-7.55 (3H, m); m/~ (ES+) 360 (M+1, 100%), 342 (M-17, 72), 192 (75).
(2R,3S.9R)-4-A~a-1.7-dioxa-3-(4-fluorophenvl)-9-hYdroxy-9-(2-(trifluoromethyl)phenvl~spiror5.41decane The benzylamine of Example 3 was hydrogenated according to the method of l~xample 9 to yield the title compound as a glass (21mg, 53%).
30 lH NMR (360MHz, CDCl3) ~ 2.21 (lH, d, J=13.3), 2.42 (lH, d, J=13.3), 3.0 (lH, dd, J=12.4, 2 0), 3.22 (lH, dt, J=12.3, 3.6), 3.73 (lH, dd, ~=11.2, 2.8), CA 0224~78 1998-08-0~
- 55 - .
3.89 (~H, d, J=9.4), 4.05 (lH, s), 4.34 (lH, dt, J=11.7, 2.6), 4.48 (lH, d, J=9.4), 6.94-7.00 (2H, m), 7.20 (lH, d, J=7.3), 7.31-7.47 (4H, m), 7.68 (lH, dd, J=7.5, 1.6); m/z (ES+) 398 (M+l, 100%).
(2R,3$~9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxY-9-(2-methoxY-5 (trifluoromethyl)phenYl)sPiro ~5.4l decane The benzylamine of Example 4A was hydrogenated according to the method of Example 9 to yield the title compound as an oil (80mg, 70%).
lH NMR (360MHz, CDC13) ~ 1.7-2.1 (~lH, br s), 1.91 (lH, d, J=13.1), 2.59 (lH, d, J=13.0), 3.06 (lH, dd, J=12.4, 2.0), 3.22 (lH, dt, J=12.3, 3.6), 3.32 (3H, s), 3.73 (lH, dd, J=ll.l, 2.7), 4.04 (lH, s), 4.07 (lH, d, J=8.9), 4.34 (lH, dt, J=11.7, 2.9), 6.75 (lH, d, J=8.6), 7.04 (2H, t, J=8.6), 7.43-7.52 (3H, m), 7.92 (lH, d, J=2.3); m/z (ES+) 428 (M+l, 100%).
(2R.3S,9$)-4-Aza-1,7-dioxa-3-~4-fluorophenYl)-9-hvdroxY-9-(2-methoxY-5-(trifluoromethyl3phenyl)spiror5.41decane The benzylamine of Example 4B was hydrogenated according to the mthod of ~xample 9 to yield the title compound as an oil (79mg, 68%).
H NMR (360MHz, CDCl3) ~ 2.14 (lH, d, J=14.3), 2.16 (~lH, br s), 2.64 (lH, d, J=14.4), 3.02 (lH, dd, J=12.3, 2.2), 3.18 (lH, dt, J=12.2, 3.6), 3.62 (lH, dd, J=11.4, 2.8), 3.86 (3H, s), 3.91 (lH, dd, J=9.2, 1.3), 3.99 (lH, s), 4.22 (lH, dt, J=11.8, 2.6), 4.36 (lH, d, J=9.0), 6.90 (lH, d, J=8.6), 7.07 (2H, t, J=8.7), 7.49 (lH, dd, J=8.2, 1.8), 7.54-7.63 (3H, m); m/z (ES+) 428 (M+l, 100%).
E~MPLE 14 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-~luorophenvl3-9-hvdroxY-9-(2-(tri~luoromethoxY)Phcnvl)sPiror5~4ldecane The benzyl~3mine of ~,~mple 5 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (46mg, 66%).
lH NMR (360MHz, CDCls) ~ 1.7-2.1 (lH, br s), 2.18 (lH, d, J=13.1), 2.33 (lH, d, J=13.2), 3.06 (lH, dd, ~=I2.4, 2.2), 3.22 (lH, dt, J=12.3, 3.6), 3.74 (lH, dd, J=11.3, 2.9), 3.97 (lH, d, J=9.4), 4.06 (lH, s), 4.35 (lH, dt, J=11.7, 2.4), 4.48 (lH, d, J=9.5), 6.97 (2H, t, J=8.8), 7.14-7.19 (2H, m), 7.24-7.30 (lH, m), 7.39-7.46 (3H, m); m/z (ES+) 414 (M+1, 100%).
(+/-)-(2R~,3S~.9R*)-4-Aza-1.7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxv-9-(2-methylphenvl)sl)iror5.4~decane The benzyl~mine of ~"c:~m~le 6 was hydrogenated according to the method~of F,~r~m~le 9 to yield the title compound as glass (105mg, 78%).
lH NMR (360MHz, CDCl3) ~ 2.19 (lH, d, J=12.9), 2.21 (3H, s), 2.31 (lH, d, 15 J=13.2), 2.9-3.3 (~2H, br s), 3.06 (lH, dd, J=11.7, 2.0), 3.21 (lH, dt, J=12.3, 3.6~, 3.72 (lH, dd, J=10.5, 2.7), 3.95 (1E~, d, J=9.3), 4.06 (lH, s), 4.34 (lH, dt, J=11.7, 3.0), 4.49 (1H, d, J=9.2~, 6.94-7.18 (6H, m), 7.42-7.47 (2H, m);
m /z (ES+) 344 (M+ 1, 100%) .
EXAMPLl~ 16 (2R,3S,9R)-4-Aza-4-(2,3-dihvdro-3-oxo-1.2.4-triazol-5-YllmethYl-1,7-dioxa-3-(4-fluoro~henYl)-9-hYdroxY-9-(2-methoxvPhen~l)spiro~5.4ldecane The morpholine of Example 10 (81mg, 0.23mmol) was heated with N-methylcarboxy-2-chloroacetamidrazone (see European Patent 25 Specification No. 0 577 394-A) (45mg, 0.271mmol) and potassium carbonate (125mg, 0.904mmol) in DMF (5ml) at 60~C for 1 hour. The cooled solution was diluted with water (25ml), extracted with ethyl acetate (3xl5ml), dried (MgSO~) and concentrated to dryness. The crude gum (110mg) was purified by flash silica gel chromatog~aph~r eluting with 6-8%
30 methanol in dichloromethane to yield the intermcdiate imidiazone, which was redissolved in xylene (2ml~ and heated at reflux for 2 hours. The CA 0224~78 1998-08-0~
crude concentrate was purified by flash silica gel chromatography eluting with 6% methanol in dichloromethane to yield the title compound as a glass (42mg, 41%). IH NMR (360MHz, CDCl3) ~ 2.05 (lH, d, J=13.1), 2.57 (lH, d, J=13.2), 2.61 (lH, m), 2.89 (lH, br d, ~=11.2), 2.95 (lH, d, J=14.~;), 3.35 (3H, s~, 3.45 (lH, d, J=14.5), 3.62 (lH, s), 3.75 (lH, br d, J=8.9), 4.14 (lH, d, J=9.0), 4.18 (lH, d, J=9.0), 4.36 (lH, dt, J=11.7, 2.1), 4.47 (lH, s), 6.71 (lH, d, J=8.2), 6.89 (lH, t, J=7.5), 7.05 (2H, t, J=8.6), 7.19 (lH, t, J=7.5), 7.50 (lH, dd, J=7.8, 1.6), 7.56 (2H, vbr s), 9.90 (lH, br s), 10.45 (lH, br s); m/z (ES+) 457 (M:~l, 32%), 439 (M-17, 15), 382 (100).
(2R,3S,9R)-4-Aza-4-(2,3-dihvdro-3-oxo-1.2.4-triazol-5-Yl)methYl-1,7-dioxa-3-(4-fluoro~henyl)-9-hYdroxY-9-(2-(trifluoromethvl)phenYl)-spiro r5.4] decane The title compound was prepared from the morpholine of ~z~mple 11 according to the method of Example 16 to yield a glass (60mg, 48%).
H NMR (360MHz, CDCl3) ~ 2.2-2.5 (lH, br s), 2.23 (lH, d, J=13.5), 2.47 (lH, d, J=13.4), 2.61 (lH, dt, J=ll 9, 3.3), 2.90 (lH, d, ~=11.3), 3.00 (lH, d, J=14.4), 3.47 (lH, d, ~=14.5), 3.61 (lH, s), 3.75 (lH, d, J=8.9), 3.81 (lH, d, J=9.3), 4.26 (lH, s), 4.35 (lH, dt, J=11.7, 2.0), 4.45 (lH, d, J=9.3), 6.99 (2H,t, J=8.6), 7.11 (lH, d, J=8.6), 7.31-7.37 (2H, m), 7.52 (2H, br s), 7.67 (lH, d,J=9.3), 10.41 (lH, s), 10.95 (lH, br s); ~ (ES+) 495 (M~l, 100%).
~2R,3S,9R)-4-~za-4-(4-(N.N-dimethYlamino)-but-2-vnvl)-1.7-dioxa-3-(4-fluorphenyl)-9-hYdroxy-9-(2-methoxv-5-(trifluoromethvl)~henvl)-spiror{;.4~decane The chloride of Description 5 (60mg, 0.12mmol) dissolved in dioxan (3mV was added to condensed dimethylamine (3ml) in a sealed tube and 30 heated at 90~C for 7 hours. The crude concentrate was purified by flash silica gel chromatography eluting with 5% methanol in dichloromethane to yield the title compound as an oil (42mg, 69%). IH NMR (360MHz, CD~13) o 1.92 (lH, d, J=13.0), 2.31 (6H, s), 2.32 (2H, s), 2.~6 (lH, d, J=13.1), 2.83 (lH, br d, J=11.6), 3.03 (lH, dt, J=12.0, 3.7), 3.29 f2H, s), 3.32 (3H, s), 3.75 (lH, s), 3.79 (lH, dd, J=11.3, 3.7), 4.06 (lH, d, J=8.9), 4.19 (lH, d, J=8.9), 4.46 (lH, dt, J=ll.~i, 2.3), 4.61 (~lH, br s), 6.75 (lH, d, J=8.6), 7.05 (2H, t, J=8.5), 7.44 (lH, dd, J=9.0, 2.6), 7.53 (2H, br s), 7.92 (lH, d, J=2.2); m/z (ES+) ~23 (M+l, 100%).
(2R.3S.9R)-4-Aza-4-(~-(N.N-dimethYlaminomethYl)-1.2~3-triazol-4-yl)methyl- 1.7-dioxa-3-(4-fluoro~henYl)-9-hvdroxY-9-(2-methoxY-5-(trifluoromethYl)phenvl)spiror5.41decane The azide of Description 6 (230mg, 0.44mmol) dissolved in tli~ n (6ml) was added to condensed dimethylamine (6ml) in a sealed tube and heated at 90~C for 7 hours. The crude concentrate was purified by ~lash silica gel chromatography eluting with 10% methanol in dichloromethane to yield the ~itle compound as a foam (155mg, 62%). lH NMR (360MHz, CDCl3) o 1.94 (lH, d, J=13.0), 2.23 ~6H, s), 2.55 (lH, m), 2.58 (lH, d, J=13.1), 2.87 (lH, d, J=11.5), 3.20 (lH, d, J=13.8), 3.34 (3H, s), 3.51 (2H, s), 3.61 (2H, t, J=6.9), 3.71 (lH, dd, J=11.3, 2.1), 4.05 (lH, d, J=8.9), 4.18 (lH, d, J=8.9), 4.32 (lH, dt, J=11.7, 2.0), 6.75 (lH, d, J=8.6), 7.09 (2H, t, J=8.6), 7.45 (lH, dd, J=8.3, 2.1), 7.62 (2H, br s). 7.91 (lH, d, J=2.2); 77~/-fES+) 566 fM+l~ 82%), 165 (100).
EXAMPLES 20A and 20B
(2R,3S,9R)-4-Aza-1~7-dioxa-3-f4-fluoloPhenYl)-9-hYdrox~r-4-(1($)-~henvlethYl)-9-(2-(trifluoromethYl)~henYl)spilor~4ldecane; and (2R,3S,9R)-4-Aza-1,7-dioxa-3-f4-fluoloPhenYl)-9-hYdroxv-4-(l(R)-phenylethvl)-9-(2-(trifluoromethvl)phenYl)sPiro~5.41decane (l-Bromoethyl)benzene (103,ul, 0.76mmol) and potassium carbonate (208mg, 1.5mmol) were added to the mo~pholine of Example 11 (150mg, CA 0224~78 1998-08-0~
0.38mmol) as a solution in DMF (7ml) and stirred for 18 hours at 20~C, then 4 hours at 75~C. The cooled reaction mixture was diluted with water (50ml), extracted with ether (3x25ml), dried (MgS04) and concentrated to a yellow oil (194mg). The crude isomers were separated by medium pressure chromatography eluting with 2:1 hexane:ether to yield the less polar title compound (Example 20A) as a white solid (39mg, 21%);
lH NMR (360MHz, CDC13) ~ 1.17 (3H, d, J=6.8), 2.24 (lH, d, J=13.3), 2.41 (lH, d, J=11.6), 2.45 (lH, d, ~=13.3), 2.65 (lH, dt, J=11.8, 3.3), 3.6~ (lH, m), 3.75 (1~, ~, J=6.8), 3.77 (lH, d, J=9.2), 3.93 (lH, s), 4.24 (lH, dt, 10 J=11.4, 1.9), 4.3~ (lH, s), 4.44 (lH, d, J=9.2), 6.99 (2H, t, J=8.8), 7.15 (lH, d, J=7.3), 7.18-7.40 (4H, m), 7.43 (2H, d, J=8.0), 7.64 (2H, br s), 7.68 (lH, dd, J=7.6, 1.6); m/z (ES~) 502 (M+1, 100%); and the morepolar title compound (Example 20B) as a glass (68mg, 36%); lH NMR (360MHz, CDCl3) ~ 1.39 (3H, d, J=7.1), 2.20 (lH, d, J=13.5), 2.30 (lH, d, J=13.4), 2.30 15 (lH, m), 3.00 (lH, d, J=11.5), 3.48 (lH, s), 3.66 (lH, d, J=9.3), 3.71 (l~I, dd, J=ll.O, 1.4), 3.82 (lH, q, ~=7.1), 4.21 (lH, s), 4.36 (2H, m), 6.95 (2H, dd, J=8.0, 1.6), 7.04 (2H, t, J=8.7), 7.05 (lH, m), 7.23-7.36 (5H, m), 7.51 (2H, br s), 7.65 (lH, dd, J=7.3, 2.0); m/~ (ES+) 502 (M+l, 100%).
EXAMPLE ~1 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-hvdroxy-4-((2-(trifluoromethyl)phenyl)methvl)-9-(2-(trifluoromethYl)phenyl)-spiro r5.4l decane The morpholine of Example 11 (lOOmg, 0.25mmol), 2-25 (tri~Luoromethyl)bcnzyl bromide (120mg, 0.50mmol) and potassium carbonate (138mg, l.OOmmol) were stirred in DMF (5ml) for 4 hours. The reaction mixture was diluted with water (50ml), extracted with ether, (3x25mI), dried (MgSO~) and concentrated to a crude oil (244mg) which was purified by ~lash silica gel chromatography eluting with 4:1 30 hexane:ethyl acetate to vield the title compound as a glass (99mg, 71%) WO 97/300~;6 PCT/GB97/00404 lH NMR (360MHz, CDCl3) ~ 2.29 (lH, d, J=13.3), 2.44 (lH, dt, J=12.0, 3.2), 2.47 (lH, d, J=13.3), 2.75 (lH, d, J=11.8), 3.23 (lH, dd, J=14.8, 1.8), 3.58 (lH, d, J=14.8), 3.66 (lH, s), 3.67 (lH, m), 3.79 (lH, d, J=9.3), 4.32 (lH, s), 4.36 (lH, dt, J=11.7, 2.4), 4.46 (lH, d, J=9.3), 6.95 (2H, t, J=8.8), 7.15 (lH, d, J=7.3), 7.24-7.39 (3H, m), 7.51-7.65 (~4H, m), 7.68 (lH, dd, J=7.5, 1.6), 7.96 (lH, dd, J=7.7); m/z (ES+) 556 (M+l, 100%).
EXAMPL:~ 22 (+/-)-(2R*,3S~9R~)-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluorophenYl)-9-methoxY-9-PhenYl-spiro[5.41decane Sodium hydride (80mg, 60% dispersion in oil, 2.0mmol) was added to a racemic mixture of the alcohol of F,~mple 1 (250mg, 0.60mmol) dissolved in DMF (5mV. After stirring for 30 minutes, methyl iodide (370,u1, 5.96mmoV was added and the reaction stirred for between 2 and 24 hours. The reaction mixture was quenched by the addition of water (50ml, care!) extracted with ether (3x25ml), dried (MgSO4) and concentrated to a yellow solid (254mg) which was purified by flash silica gel chromatography eluting with 5:1 hexane: ethyl acetate to yield the title compound as a glass (197mg, 76%). Analysis Found: C, 75.10; H, 6.51; N, 3.38.
Cz7H2gFNO3 requ~res C, 74.81; H, 6.51; N, 3.23%~. IH NMR (360MHz, ~DGl3) ~ 2.22 (lH, d, J=14.2), 2.33 (lH, dt, J=11.9, 3.4), 2.45 (lH, d, J=14.2), 2.79 (2H, m), 3.09 (3H, s), 3.45 (lH, s), 3 64-3.70 (3H, m), 4.24 (lH, dt, J=11.7, 2.2), 4.28 (lH, d, J=9.3), 6.77-6.83 (2H, m), 6.97 (2H, t, J=8.7), 7.11-7.26 (8H, m), 7.57 (~2H, br s); m/~ (ES+) 434 (M+l, 100%), 402 (M-31, 42).
(2R.3S.9R~-4-Aza-4-benzyl- 1.7-dioxa-3-(4-fluoroPhenvl)-9-methoxv-9-(2- .
methoxvphenyl~spiror5.41decane The alcohol of Example 2 was reacted accol-ding to the method of Example 22 to yield the title compound as a pale vellow foam (466mg, CA 0224~78 1998-08-0~
71%). lH NMR (360MHz, CDC13) ~ 2.25 (lH, d, J=13.9), 2.31 (lH, dt, J=ll.9, 3.4), 2.58 (lH, dd, J=13.8, 1.0), 2.75 (lH, d, J=13.1), 2.78 (lH, br d, J=11.3), 2.97 (3H, s), 3.45 (lH, s), 3.60 (lH, d, J=13.3), 3.62-3.69 (2H, m), 3.66 (3H, s), 4 28 (lH, dt, J=11.8, 2.2), 4.52 (lH, dd, J=9.8, 0.8), 6.77-6.83 (2H, m), 6.88-6.97 (3H, m), 7.17-7.27 (6H, m), 7.56 (~2H, br s); m/z (ES+) 464 (M+l, 100%).
EXAMPL~ 4 (2R,3S.9R)-4-Aza-4-benzYl-1.7-dioxa-3-(4-iluoroPhenYl)-9-methoxv-9-(2-(trifluoromethYl)phenvl)spiror5.41decane The alcohol of ~ m~le 3 was reacted according to the method of Example 22 to yield the title compound as a solid after recrystallisation from 60/80 petrol (9lOmg, 82%). Mp. 155-157~C (petrol). lH NMR
(360MHz, CDCl3) ~ 2.29 (lH, d, J=14.7), 2.27-2.41 (lH, m), 2.56 (lH, d, J=14.7), 2.72-2.83 (2H, m), 2.96 (3H, s), 3.35 (lH, s), 3.69-3.70 (2H, m), 4.18 (lH, br t, J=11.8), 4.27 (2H, s), 6.63 (lH, d, J=7.9), 6.75 (lH, br s), 7.08 (lH, t, J=7.4), 7.16-7.46 (8H, m), 7.59 (lH, d, J=7.9).
(2R,3S,9R)-4-Aza-4-benzvl-1~7-dioxa-3-(4-fluoroPhenvl)-9-methoxv-9-(2-methoxy-a-(trifluoromethYl)phenYl)s~iroL5.4~dccane The alcohol of Example 4A was reacted according to the method of Example 22 to yield the title compound as a foam (430mg, 67%). lH NMR
(360MHz, CDCl3) ~ 2.32 (lH, dt, J=ll.9, 3.5), 2.35 (lH, d, J=14.0), 2.53 (lH, d, J=14.0), 2.75 (lH, d, J=13.1), 2.79 (IH, d, J=ll.O), 2.97 (3H, s), 3.43 (lH, s), 3.a9 (lH, d, J=13.3), 3.64 (lH, m), 3.69 (3H, s), 3.82 (lH, d, J=8.6), 6.88 (2H. t, J=8.7), 7.17-7.29 (6H, m), 7.46 (lH, dd, J=8.4, 1.6), 7.51 (~2H, br s); r7t/~ (ES+) 532 (M+l, 100%).
(+/-)-(2R~,3S*,9R~)-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluorophenvl)-9-methoxY-9-(2-methvlphenyl)spiror5.41decane The alcohol of ~,~m~le 6 was reacted according to the method of Example 22 to yield the title compound as an oil (175mg, 39%) IH NMR
(360~Hz, CDCl3) ~ 2.28-2.36 (2H, m~, 2.31 (3H, s), 2.54 (lH, d, J=13.8), 2.76 (lH, d, J=13.1~, 2.79 (lH, d, J=1~.6), 2.87 (3H, s), 3.42 (lH, s), 3.63 (lH, d, J=13.2), 3.65 (lH, m), 3.89 (lH, d, J=9.3~, 4.26 (lH, dt, J=11.8, 2.5), 4.42 (lH, d, J=9.3), 6.65 (lH, d, J=7.7), 6.84 (2H, t, J=8.9), 6.90 (lH, m), 7.05 (2H, m), 7.15-7.27 (5H,m), 7.49 (~2H, br s); m/z (~S+) 448 (M+l, 100%).
(2R,3S,9R)-4-Aza-4-benzvl-1.7-dioxa-9-(2-ethvlphenvl)-3-(4-iluoro~henvl)-9-methoxy-spiro[5.41decane The alcohol of Example 7 was reacted according to the method of Example 22 to yield the title compound as a white solid (135mg, 77%).
lH NMR (360MHz, CDCl3) ~ 1.14 (l~I, t, J=7.5), 2.28-2.37 (2H, m), 2.54 (lH, d, J=13.8), 2.67-2.84 (4H, m), 2.89 (3H, s), 3.42 (lH, s), 3.60-3.69 (2H, m), 3.85 (lH, d, J=9.4), 4 25 (lH, td, J=10.6, 2.2), 4 ~1 (lH, d. J=9.4), 6.67 (lH, d, J=7.9), 6.80-6.93 (3H, m), 7.11-7.28 (7H, m), 7.47 (2H~ br s); m/_ (ES+) 462 (M~1, 100%) (2R~3S~9R)-4-Aza-4-benzvl-9-(2-chloroPhen~7l)-1.7-dioxa-3-(4-fluoroPhen~rl)-9-~ethoxy-s~iro r5.4~ decane The alcohol of F.~,qm~le 8 was reacted according to the method of ml?le 22 to yield the title compound as an oil (150mg, 51%). lH N~IR
(360MHz, CDCl3) ~ 2.31 (lH, td. J=11.9, 3.3), 2.45 (lH, d, J=1~.1), 2~68 (lH, d, J=14.1), 2.73-2~84 (2H, ~ , 2~92 (3H, s), 3.41 (lH, s), 3.60-3.69 (2H, m), 4.05 (lH, d, J=9.7), 4.23 (lH. td, J=11.7, 2.2), 4.45 (lH, d. J=9.7), 6.78-CA 02245578 lsss-os-05 wo 97/300s6 PCT/GB97/Oû404 6.86 (2H, m), 6.98 ~lH, td, J=7.5, 1.3), 7.10 (lH, td, J=7.7, 1.6), 7.16-7.28 (7H, m), 7.41-7.54 (2H, m); m/z (ES+) 468 (M+l, 100%).
(+/-)-(2R* .3S~,9R*)-4-Aza- 1,7-dioxa-3-(4-fluoroPhenYl)-9-methoxY-9-phenyl-spiror5.41decane The (+/-)-benzyl~min~? of Example 22 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (138mg, 100%). lH ~MR (360MHz, CDC13) ~ 2.14 (lH, d, ~=14.2), 2.40 (lH, d, J=14 2), 3.03 (lH, dd, J=12.3, 2.2), 3.08 (3H, s), 3.20 (lH, dt, J=12.2, 3.6), 3.72 (lH, br d, J=12.1), 3.75 (lH, d, J=9.3), 3.95 (lH, s), 4.26 (lH, dt, J=12.0, 2.7), 4.31 (lH, d, J=9.7), 6.81-6.86 (2H, m), 6.90-6.96 (2H, m), 7.11-7.15 (3H, m), 7.39-7.45 (2H, m); m/z (ES+) 344 (M+l, 60%), 312 (M-31, 100).
EXAMPI,E 30 2R,3S,9R)-4-Aza-1~7-dioxa-3-~4-fluorophenvl)-9-methoxy-9-(2-methoxyphenYl)spiro ~5.4~decane The benzylamine of E~xample 23 was hydrogenated according to the method of Example 9 to yield the title compound as a yellow oil (265mg, 84%). lH NMR (360MHz, CDC13) ~ 2.18 (lH, s), 2.18 (lH, d, J=13.9), 2.54 (lH, d, J=13.9), 2.99 (3H, s), 3.00 (lH, m), 3.16 (lH, dt, J=12.2, 3.6), 3.63 (3H, s), 3.70 (lH, dd, J=11.4, 2.9), 3.82 ~lH, d, J=9.8), 3.95 (lH, s), 4.30 (lH, dt, J=11.8, 2.7), 4.55 (lH, d, J=9.8), 6.77-6.93 (4H, m), 6.98 (lH, dd, J=7.6, 1.6), 7.19 (lH, dt, J=7.8, 1.7), 7.39-7.45 (2H, m); m/~ ~ES+) 374 (M~l, 100%), 342 (M-31, 93).
(2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl~-9-methoxY-9-(2-30 (trifluoromethyl)phenYl)sPiror5.4~decane WO 97/300!;6 PCT/GB97/00404 The benzylamine of Example 24 was hydrogenated according to the mthod of ~,~m~le 9 to yield the title compound as a white solid (603mg, 90 %3. l H N M R (360 M H z, C D Cl3) ~ 2.01 (lH, br s, NH), 2.26 (lH, d, J=14.6), 2.52 (lH, d, J=14.6), 2.96 (3H, s), 3.03 (lH, dt, J=14.0, 2.0), 3.17 (lH, td, J=12.1, 4.0), 3.70 (lH, dd, J=11.4, 3.0), 3.46 (lH, s), 4.21 (lH, td, J=ll.9, 2.9), 4.30 (2H, s), 6.66-6.78 (3H, m), 7.06 (lH, t, J=7.6), 7.18-7.31 (3H, m), 7.58 (lH, d, J=7.9); m/z (ES+) 412 (M+l, 100%).
E~AMPLE 32 10 ~2R~3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorophenYl)-9-methoxv-9-(2-methoxy-5-(trifluoromethylh~henyl)sPiro ~5.41 decane The benzylamine of F"r~mple 25 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (272mg, 88%).
lH NMR (360MHz, CDCl3) ~ 2.26 (lH, d, J=13.9), 2.2-2.5 (~2H, br s), 2.49 15 (lH, d, J=13.7), 3.00 (3H, s), 3.03 (lH, m), 3.16 (lH, dt, J=12.2, 3.7), 3.64(3H, s), 3.71 (lH, dd, J=11.5, 2.8), 3.93 (lH, d, J=9.8), 3.96 (lH, s), 4.31 (lH, dt, J=ll.9, 2.9), 4.44 (lH, d, J=9.7), 6.81 (lH, d, J=8.6), 6.88 (2H, t, J=8.7), 7.25 (lH, d, J=2.1), 7.39-7.47 (3H, m); 771/Z ~ES+) 442 (M+l, 100%).
(2R~3S,9R)-4-Aza-1,7-dioxa-3-~4-fluorophenyl)-9-methoxy-9-(2-rnethvlphenyl)sT)iro~5.41decane The benzylamine of 33xarnple 26 was hydrogenated accor ding to the method of Example 9 to yield the title compound as a glass (35mg, 47%).
25 lH NMR (360MHz, CDCl3) ~ 2.14 (lH, d, J=13.9), 2.16 (lH, m), 2.28 (3H, s), 2.56 (lH, d, J=13.9), 2.86 (3H, s), 3.05-3.20 (2H, m), 3.76 (lH, dd, J=12.2, 2.9), 4.05 (lH, d, J=9.a), 4.13 (lH, m), 4.46 (lH, m), 4.49 (lH, d, J=9.5), 6.64 ~lH, d, J=7.6), 6.84 (2H, t, J=8.5), 6.88- ~lH, m), 7.03-7.10 (2H, m), 7.49 (2H, dd, J=8.5, 5.3); ~71/~, (ES+) 358 (M+l, 100%).
CA 0224~78 1998-08-0~
EXAMPI.E 34 (2R,3S,9R)-4-Aza-1.7-dioxa-9-(2-ethYlphenyl)-3-(4-fluorophenvl)-9-methoxv-sPiror6.41decane The benzylz~lmine of Example 27 was hydrogenated according to the method of Example 9 to yield the title compo~nd as an oil (85mg, 81%).
lH NMR (250MHz, CDCl3) ~ 1.14 (3H, t, J=10.7), 2.07 (lH, br s), 2.22 (lH, d, J=l9.9), 2.49 (lH, d, J=l9.9), 2.68 ~2H, q, J=10 8), 2.90 (3H, s), 3.02 (lH, dd, J=17.5, 3.4), 3.18 (lH, td, .,T=17.3, 5.0), 3.72 (lH, td, J=16.5, 4.2), 3.92-3.99 (2H, m), 4.27 (lH, td, J=16.9, 4.3), 4.47 (lH, d, J=13.5), 6.71 (lH, d, J=ll l), 6 76-6.96 (3H, m), 7.11-7.19 (2H, m), 7.30-7.42 (2H, m).
(2R,3S~9R)-4-Aza-4-(5-(N.N-dimethvlaminomethvl)- 1,2,3-triazol-4-yl)methyl- 1,7 -dioxa-3-(4-fluoroPhenvl)-9-methoxY-9- (2-methoxy-5-(trifluoromethvl)phenvl)spiro r5.41 decarle The title compound was prepared from the azide of Description 8 according to the method of Example 19 to yield a foam (86mg, 76%).
lH NMR (360MHz, CDCl3) ~ 2.24 (lH, d, J=14.0), 2.50 (6H, s), 2.55 (lH, d, J=14.0), 2.76 (lH, br d, J=11.2), 2.97 (3H, s), 3.24 (lH, d, J=13.9), 3.50 (lH, s), 3.55 (lH, d, J=14.0), 3.68 (lH, m), 3.69 (3H, s), 3.86 (3H, m), 4.19 (lH, dt, J=11.8, 2.1), 4.47 (lH, d, J=9.8), 6.8~ (IH, d, J=8.6), 6 95 (2H, t, J=8.5), 7.21 (lH, d, J=l.9), 7.47 (lH, dd, J=8.7, 1.9), 7.5 (~2H, br s), 7.8-8.4(~lH, br s); m/x ~ES+) 580 (M+1, 100%).
~XAMPLE 36 (2R,3S,9R)-4-Aza-4-(5-(N,N-dimethYlaminomethvl)- 1~2,3-tctrazol-4-vl)methyl- 1,7-dioxa-3-(4-fluoroPhenvl)-9-methoxY-9-(2-(trifluoromethvl)phenyl)spiro~5.41decane The title compound was prepared from the azide of Description 10 according to the method of Example 19 to vield a yellow foam (124mg, 69%). lH NM:R (3~0MHz, CDC13) ~ 2.19-2.27 (7H, m). 2.50-2 61 (2H, m), CA 0224~78 l998-08-0~
2.82 (lH~ br d, J=11.6), 2.96 (3H, s~, 3.20 (lH, d, J=14.0), 3.41 (lH, s), 3.48 (2H, s), 3.61 (lH, d, J=14.0), 3.64 (IH, br d, J=l.0), 4.16 (lH, dt, J=9.4, 2.3), 4.25 (lH, d, J=9.8), 4.29 (lH, d, J=4.3), 6.64 (lH, d, J=7.9), 6.79 (lH, br s), 7.10 (lH, t, J=7.6), 7.23 (lH, t, J=7.7), 7.60 (lH, d, J=7.9); m/z (ES+) 550 (M+l, 100%).
EXAMPLES 37A and 37B
(2R.3S~9R)-4-Aza-1,7-dioxa-3-~4-fluoroPhenvl)-9-methoxv-4-(1-(S~-phenvlethYl)-9-(2-methoxY-5-(trifluoromethYl)phenyl)sl~iror5~4~decane; and 10 (2R~3S,9R~-4-Aza-1.7-dioxa-3-(4-fluoroPhenvl)-9-methoxY-4-(l-(R)-phenvlethYl)-9-(2-methoxY-5-(trifluoromethYl)Phenyl)spiro r5.41decane The morpholine of Example 32 was reacted according to the method of Example 20 to yield the less polar title compound (Example 37A) as an oil (39mg, 25%),1H NMR (360MHz, CDC13) ~ 1.14 (3H, d, J=6.9), 2.32 (lH, 15 d, J=14.0), 2.36 (IH, d, J=11.7), 2.53 (lH, d, J=14.2), 2.62 (lH, dt, J=11.7,3.3), 2.97 (3H, s), 3.60 (lH, dd, J=ll.l, 1.7), 3.67 (lH, q, J=6.8), 3.69 (3H, s), 3.83 (2H, m), 4.17 (lH, dt, J=11.4, 2.1), 4.3 (lH, d, J=9.7), 6.81 (lH, d, J=8.6), 6.88 (2H, t, J=8.7), 7 17-7.42 (7H, m), 7.46 (lH, dd, J=8.7, 1.6), 7.58 (~2H, br s); m/z (;ES+) 546 (M+l, 100%); and the morepolar title 20 compound (Example 37B) as an oil (47mg, 30%), lH NMR (360MHz, CDCl3) ~ 1.35 (3H, d, J=7.1), 2.19-2.34 (~3H, m), 2.42 (lH, d, 14.0), 2.90 (3H, s), 2.96 (lH, d, J=11.4), 3.37 (lH, s), 3.69 (3H, s), 3.70-3.77 (3H, m), 4.28 (lH, dt, J=11.4, 2.4), 4.35 (lH, d, J=10.0), 6.80 (lH, d, J=8.6), 6.88-6.99 (4H, m), 7.16 (lH, d, J=l.9), 7.20-7.29 (3H, m), 7.41-7.49 (~4H, m);
25 1~1 /z (;~S+) 546 (M+ 1, 100%).
(2R~3S,9R)-4-Aza- 1,7-dioxa-3-(4-fluoroPhenvl)-9-methoxY-9-(2-methoxv-5-(tri~Luoromethyl)phenvl)-4-((2-(trifluorometh~tl)PhenYl)methyl)-30 s~iror~i.41 decane The title compound was prepared from the morpholine of Example 32 according to the method of F',~m~le 21 to yield a glass (67mg, 73%).
lH NMR (360MHz, CDCl3) ~ 2.32-2 43 (2H, m), 2.57 (lH, d, J=14.1), 2.71 (lH, br d, J=11 6), 2.99 (3H, s), 3.18 (lH, dd, J=14.7, 1.7) 3.50 (lH, d, J=14.9), 3.54 (lH, s), 3.65 (lH, dt, J=11.5, 1.6), 3.69 (3H, s), 3.83 (lH, d, J=9.8), 4.29 (lH, dt, J=11.8, 2.2), 4.45 (lH, d, J=9.7), 6.81-6.91 (3H, m), 7.24-7.30 (2H, m), 7.45-7.55 (~5H, m), 7.95 (lH, d, J=7.7); m/~ (ES+) 600 (M+l, 100%).
:E~AMPkE 39 (2R~3S,9R)-4-Aza-1~7-dioxa-3-(4-fluorophenvl)-9-methoxv-9-(2-methoxv-5-(trifluoromethYl)phenvl)-4-((3-(trifluoromethYl)PhenYl)methyl) spiror5.41decane The title compound was prepared from the morpholine of Example 32 according to the method of Example 21 to yield a glass ~54mg, 59%).
lH NMR (360MHz, CDCl3) ~ 2.26 (lH, d, J=14.0), 2.28 (lH, m), 2.47 (lH, d, J=14.0), 2.67 (lH, br d, J=11.4), 2.77 (lH, d, J=13.5), 2.90 (3H, s), 3.38 (lH, s), 3.54 (lH, d, J=13.6), 3.59 (lH, m), 3.62 ~3H, s), 3.76 (lH, d, J=9.8), 4.20 (lH, dt, J=11.8, 2.2), 4.35 (lH, d, J--9.8), 6.75 (lH, d, J=8.6), 6.81 (2H,t, J=8.7), 7.15 (lH, d, J=2 1), 7.28-7.41 (5H, m), 7.44 (~2H, br s): m/~ (ES~) 600 (M+l, 100%) (2R,3S~9R)-4-Aza-1,7-dioxa-3-(4-fluoro~henvl)-9-methoxv-9-(2-methoxy-5-(trifluoromethvl)Phenvl)-4-((4-(trifluoromethYl)phenvl)methYl)-spiror6.41decane The title compound was prepared from the morpholine of Example 32 according to the method of Example 21 to yield a glass (63mg, 69%).
lH NMR (360MHz, CDC13) ~ 2.34 (lH, d, J=14.0), 2.36 (lH, dt, J=ll 7, 3.4), 2.55 (lH, d, J=14.0), 2.74 (lH, br d, J=11.5), 2.84 (lH, d, J=13.7). 2.98 (3H, s), 3.46 (lH, s~, 3.62 (lH, d, J=14.3), 3.68 (lH, m), 3.70 (3H. s), 3.83 CA 0224~78 1998-08-0~
WO 97/30056 PCT/G~97/00404 (lH, d, J=9.8), 4.27 (lH, dt, ~=12.0, 2.6), 4.44 (lH, d, J=9.8), 6.83 (lH, d, J=8.6), 6.88 (2H, t, J=8.7'?, 7.23 (lH, d, J=2.1), 7.36 (2H, d, J=8.0), 7.47 (lH, dd, J=9.0, 1.9), 7.51 (4H, m); m/z (ES~) 600 (M+l, 100%).
EXA3!.!1PLE 41 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-methoxv-4-¢(2-methoxyphenvl)methvl)-9-(2-methoxv-5-(trifluoromethvl~PhenYl) s~iror5.41decane The title compound was prepared from the morpholine of Example 32 according to the method of Example 21 to yield an oil (63mg, 74%).
lH NMR (360MHz, C~DCl3) ~? 2.32-2.40 (2H, m), 2.53 (lH, d, J=13.9), 2.86 (lH, br d, J=11.7), 2.97 (3H, s), 3.03 (lH, d, J=13.8), 3.40 (lH, d, J=13.8), 3.46 (lH, s), 3.65 (lH, dd, J=11.4, 2.13, 3.67 ~lH, m), 3.69 (3H, s), 3.72 (3H, s), 3.81 (lH, d, J=9.8), 4.27 (lH, dt, J=11.8, 2.1), 4.41 (lH, d, J=9.8), 6.76-6.91 (5H, m), 7.15-7.25 (2H, m), 7.38 (lH, br d, J=6.g), 7.46 (lH, dd, J=8.6, 1.8), 7.50 (~2H, br s); m/z (ES+) 562 (M+l, 100%).
(2R,3S,9R)-9-Allvloxy-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-phenvl-s~iro~5.4]decane The title compound was prepared from the alcohol of Example 1 and allyl bromide according to the method of Example 22 to yield an oil (62mg, 59%). lH NMR (36(!MH~, CDCl3) ~? 2.24 (lH, d, J=14.2), 2.32 (lH, dt, J=11.8, 3.5), 2.47 (lH, d, J=14.2), 2.78 (lH, d, J=13.3), 2.78 (lH, m), 3.43 (lH, s), 3.61-3.84 (5H, m), 4.23 (lH, dt, J=11.7, 2.5), 4.28 (lH, d, J=9.2), 5.10 (lH, dq, J=10.4, 1.6), 5.28 (lH, dq, J=17.2, 1.7)? 5.83-5.93 (lH, m), 6.77-6.81 (2H, m), 6.96 (2H, t, J=8.7~?, 7.08-7.28 (8H~ m), 7.55 (~2H, br s);
m/z (ES+) 460 (M+l, 100%).
(2R,3S,9R)-4-Aza-4-benzvl- 1,7-dioxa-3-(4-fluorophenyl) -9-Phenvl-9-(phenylmethvloxY)spiror5.4~decane The title compound was prepared from the alcohol of l~ mI~le 1 and benzyl bromide according to the method of Example 22 to yield an oil which solidified on st~n~ing (99mg, 77%). lH NMR (360MHz, CDCl3~ ~
2.29 (lH, d, J=14.2), 2.35 (lH, dt, J=ll.9, 3.3), 2.58 (lH, d, J=14.2), 2.80 (2H, m), 3.45 (lH, s~, 3.64 (lH, m), 3.68 (lH, d, J=13.8), 3.79 (lH, d, J=9.3), 4.16 (lH, d, J=11.6), 4.26 (lH, dt, J=11.5, 1.7), 4.33-4.38 (2H, m), 10 6.85-6.89 (2H, m), 6.95 (2H, t, J=8.6), 7.11-7.32 (13H, m), 7.56 (~2H, br s); m/z (ES+) 510 (M+1, 100%).
(2R,3S.9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-PhenYl-9-propyloxy-15 spiror5.41decane The benzyl~rnin~ of F'.~r~mple 42 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (27mg, 67%).
H NMR (360MHz, CDCl3) ~ 0.84 (3H, t, J=7.3), 1.54 (2H, sx, J=7.2), 1.84 (~lH, br s), 1.98 (lH, m), 2.15 (lH, d, J=14.1), 2.31 (lH, d, J=13.9), 2.40 20 (lH, d, ~=14.1), 2.94-3.23 (~4H, m), 3.66-3.70 (~lH, m), 3.82 (lH, d, J=9.2),3.93 (lH, s), 4.18-4.25 (lH, m), 4.29 (1~, d, J=9.1), 6.71-6.92 (~3H, m), 7.04-7.11 (3H, m), 7.20-7.41 (~2H, m); m/~ (ES+) 372 (M+1, 100%).
25 (2R~3S.9R~-4-Aza-4-benzYl-1.7-dioxa-9-fluoro-3-(4-fluoroPhenYl)-9-Phen sPiro ~5.41 decane Nitrogen was bubbled through a solution of the alcohol of Example 1 (250mg, 0.60mmol) in dichloromethane (6ml) in a NalgeneT~ flask for 5 minutes before cooling to -78~C. Diethylaminosulfur trifluoride (83,u1, 30 0.63mmol) was added dropwise and the solution stirred at -78~C for 4 hours. The reaction mixture was quenched at -78~C by the addition of WO 97/30056 PCT/GB97/~0404 water (20ml), diluted with dichloromethane (20ml), separated and the organic layer dried (MgSO4) and concentrated to a gum (317mg). The crude residue was purified by medium pressure silica gel chromatography eluting with 5:1 hexane:ethyl acetate to yield the title compound (~3:1 mixture of diastereomers) as the least polar component as an oil (65mg, 26%); lH NMR (360MHz, CDCl3) ~ 2.23-2.59 (~3H, m), 2.75-2.92 (~3H, m), 3.50 and 3.54 (lH total, 3:1, 2 x s), 3.61-3.78 (~21~I, m), 3.98-4.42 (~2H, m), 6.96-7.36 (12H, m), 7.54-7.68 (~2H, br s); 13C NMR (90.6MHz, CDCl3, DEPT) ~ 24.66 (CHz), 35.83 (CH2), 45.41 and 45.46 (CH2), 46.41, 46.46, 10 46.53, 46.68 and 46.83 (CH2), 54.69, 55.14, 55.83 and 56.41 (C~2), 66.88, 66.98 and 67.45 (CH), 73.25 and 73.54 (CH7), 75.33 and 75.65 (CH2), 109.6~, 109.88 and 110.63 (CH), 118.47, 118.58, 118.99, 119.46 and 119.56 (C~H), ~20.81, 121.99, 122.03, 122.59, 122.76, 123.16, 123.19, 123.23, 123.30, 123.80, 123.83 and 123.92 (CH~, 127.01, 127.09, 127.27 and 127.36 15 (CH), 13~.90 (CH); m/z (ES+) 422 (M+l, 100%), 402 ~M-19, 28).
(2R,3S~9R)-4-Aza-1,7-dioxa-9-fluoro-3-(4-fluoroPhenYl)-9-phenyl-spiro[5.41decane The benzyl~mine of Example 45 was hydrogenated according to the method of l~ mple 9 to yield the title compound as an oil (18mg, 46%);
m/~ (ES+) 332 (M+1, 18%), 102 (100) 25 (2R,3S,9R~-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluoroPhenYl)-9-hYdroxy-9-(2 (hvdroxymethvl)phenyl)spiro~5.41decane The product of Description 12 (350mg) was heated at ref~ux in a solution of 1~.01 HCl (2ml) and water:ethanol (lOml, 1:1) The ethanol was removed by distillation and the aqueous residue basified (NaHCO~) and 30 extracted with ethyl acetate ~3x30ml~. The combinecl organic cxtracts were washed with water and saturated brine (lx30ml cach), dried W0971300~i6 - 71 - PCT/GB97100404 ~MgSO4) and eoneentrated to a erude oil whieh was purified by flash silica gel ehromatography eluting with 9:1 to 4:1 hexane:ethyl aeetate to yield ~ the title eompound as an oil (136mg, 52%). m/z (ES+) 450 (M+1, 100%).
~0 ~ ~0/
F~
[2'R-r2'a(5*),4'a]1-3"-(4-~uoroPhenYl)-4"-(phenvlmethvl)dispiro-risobenzofuran-1(3H3~4'(5'~)-furan-2'(3EO,2"-morpholine]
Methanesulfonyl~hlori-l~ (23~L1, 0.29mmol) was added to a solution of the diol of Example 47 (130mg, 0.29mmol) and triethylamine (81~
0.58mmol) in diehloromethane (5ml) eooled to 0~C. The resulting mixture was allowed to warm to 20~C and stirred for 18 hours. The reaetion mixture was washed sequentially with l.OM citric acid, water and saturated brine, dried (MgSO4) and concentrated to a yellow oil which was purified by flash siliea gel ehromatography eluting with 19:1 to 4:1 hexane:ethyl acetate to yield the title compound as white foam (9Omg, 72%). lH NMR (360MH~, CDCl3) ~ 2.12 (lH, d, J=14.2), 2.28-2.36 (lH, m), 2.37 (lH, d, J=14.2), 2.82 (lH, d, J=12.7), 2.77-2.88 (lH, m), 3.50 (lH, s), 3.62-3.76 (3H, m), 4.24 (lH, d, J=9.7), 4.20-4.30 (lH, m), 5.03 (2H, s), 6.09 (lH, d, J=7.4), 7.02-7.30 (lOH, m), 7.65 (2H, br s); 771/~ (ES+) 432 (M+1, 100%) .
~fo~ , F ~
r2'R-r2'a(5*).4'a]1-3"-(4-fluoroPhenYl)disPirorisobenzofuran-1(3H~.4'(~i'H)-furan-2'(3H),2"-morpholinel The benzylamine of Example 48 was hydrogenated according to the method of ~,~rnple 9 to yield the title compound as a foam (15mg, 38%).
lH NMR (360MHz, CDCl3) ~ 2.02 ~lH, d, J=14.2), 2.23 (lH, d, J=14.2), 3.05 (lH, dd, J=9.~i, 2.7), 3.21 (lH, td, J=12.3, 3.6), 3.77 (~H, d, J=9.8), 3.74-3.82 (lH, m), 4.01 (lH, s), 4.28 (lH, d, J=9.8), 4.25-4.33 (lH, m), 5.04 (2H, s), 6.19 (lH, d, J=7.5), 7.02-7.13 (4H, m), 7.17 (lH, d, J=6.6), 7.48-7.54 (2H, m); m/z (~S+) 342 (M~l, 100%).
EXA~PLL 3 (2R.3S.9R)-4-Aza-4-benzvl- 1,7-dioxa-3-(4-fluorophenvl)-9-hvdroxy-9-(2-(tri~luoromethYl)PhenYl)spiro~r5.4~decane n-Butyl lithium (3.5ml of a 1.6M solution in hexanes, 5.6mmol) was added dropwise over 15 minutes to a solution of 2-(trifluoromethyl)-iodobenzene (1.47g, 5.4mmol) in ether (15mV cooled to -10~C. A~ter stirring for 1 hour, a 1.2M solution of tributoxyzirconium chloride in ether (4.7ml, 5.6}nmol) (Helv. Chr;m. Acta, 1981, 64, 1552) was added and stirring continued at 0~C for 2.5 hours. Benzyl ketone of Description 4 (616mg, 1.8mmol) as a solution in dichloromethane (6ml) was added and the reaction mixture allowed to warm to 20~C overnight. The reaction was quenched by the addition of 1.0M HCl solution (50ml), extracted with ether (3x30ml), dried (MgSO4) and concentrated to dryness. The crude oil (200mg) was purified by flash silica gel chromatography eluting with 2:1 hexane:ether to yield the title compound as a yellow oil (55mg, 6%).
lH Nl~R (CDC13) ~ 2.28 (lH, d, J=13.3), 2.22-2 40 (2H, m), 2.45 (lH, d, J=13.3), 2.81 (2H, t, J=11.8), 3.54 (lH, s), 3.66 (2H, d, J=12.8), 3.77 (lH, d, J=9.3), 4.32 (2H, m), 4.43 (l~I, d, J=9.2), 7.00 (2H, t, J-8.7), 7.13 (lH, d, J=7.4), 7.21-7.38 (7H, m), 7.58 (2H, br s), 7.68 (lH, d, J=7.3); r~l/3 (:E~S+) 488 (M+l, 100%).
EXAMPLES 4A and 4B
(2R~3S,9R)-4-Aza-4-benzvl-1,7-dioxa-3-(4-~uoroPhenYl)-9-hYdroxY-9-(2 ~ methoxv-6-(tri~1uoromethYl)PhenYl)sPiro~5 4~dccane; and ¢2R,3$,9S~-4-Aza-4-benzvl-1,7-dioxa-3-(4-~luQrophenvl)-9-hYdroxv-9-(2-methoxY-6-30 (tri~1uoromethvl)phenvl)sPiror6.4~decane CA 0224~78 1998-08-0~
2-Methoxy-5-(trifluoromethyl)iodobenzene (1.51g, 5.0mmol) and the benzyl ketone of Description 4 (1.53g, 4.5mmol) were reacted according to the method of Example 2 which gave after work up a crude oil (2.2g). The crude concentrate was purified by flash silica gel chromatography eluting 5 with 6:1 to 4:1 hexane:ethyl acetate to yield the title compound (~"rz~m~le 4A) as a white foam (846mg, 36%); lH NMR (360MHz, CDCl3) ~ 1.92 (lH, d, J=13.0), 2.33 (lH, dt, J=12.0, 3.5), 2.65 (lH, d, J=13.0), 2.76 (lH, d, J=13.2), 2.82 (lH, d, J=11.5), 3.30 (3H, s), 3.54 (lH, s), 3.64 (lH, d, J=13.0), 4.03 (lH, d, J=8.8), 4.18 (lH, d, J=8.8), 4.33 (lH, dt, J=11.8, 2.3), 4.66 (lH, s), 6.72 (lH, d, J=8.6), 7.07 (2H, t, J=8.7), 7.16-7.28 (5H, m~, 7.42 (lH, dd, J=8.9, 2.2), 7.63 (2H, br s), 7.98 (lH, d, J=2.3); 7n/z (ES+) 518 (M+l, 100%);
and the title compound (F',~mple 4B) as an oil ~170mg, 7%); 'H NMR
(360MHz, CI~Cl3) ~ 2.22 (lH, dd, J=14.3, 1.2), 2.33 (lH, dt, J=ll.9, 3.5), 2.73 (lH, d, J=14.3), 2.81 (lH, d, J=13.2), 3.52 (lH, s), 3.57 (lH, m), 3.70 (lH, d, J=13.2), 3.84 (3H, s), 3.85 (lH, d, J=9.0), 4.22 (lH, dt, J=11.8, 2.4), 4.35 (lH, d, J=9.0), 6.88 (lH, d, J=8.6), 7.12 (2H, t, J=8.7), 7.18-7.30 (5H, m), 7.48 (lH, dd, J=8.4, 1.8), 7.65 (lH, d, J=2.1), 7.71 (2H, br s); ~7t/~ (ES+)518 (M+l, 100%).
EXAMPI,E 5 (2R,3S,9R)-4-Aza-4-benzvl-1.7-dioxa-3-(4-fluoroPhenYl)-9-hvdroxy-9-(2-(trifluoromethoxy)phenyl)spiro ~5.41 decane The title compound was prepared according to the method of Example 3 to yield a yellow oil (9lmg, 10%). IH NMR (360MHz, CDCl3) ~ 2.21 (lH, d, J=13.0), 2.35 (lH, dt, J=ll.9, 3.3), 2.40 (lH, d, J=13.2), 2.77 (lH, d, J=13.3), 2.83 (lH, d, J=11.7), 3.56 (lH, s), 3.62-3.70 (2H, m~, 3.83 (lH, d, J=9.3), 4.34 (lH, dt, J=11.6, 2.1), 4.47 (lH, d, J=9.3), 4.55 (lH, s), 7.00 (2H,t, J=8.7), 7.14-7.35 (9H, m~, 7.57 (2H, br s); 77t/~ (E~+) 504 (M+l, 100%).
CA 02245578 l998-08-05 (+/-)-(2R~,3S*,9R*)-4-Aza-4-benzvl-1~7-dioxa-3-(4-fluoroPhenYl)-9-hYdroxy-~ 9-(2-methylphenyl~spiro~5.41decane The title compound was prepared according to the method of ~,~mI)le 1 to yield a white foam (355mg, 47%). Analysis Found: C, 74.64; H, 6.39;
N, 3.40. C27H2sFN03 requires C, 74.81; H, 6.51; N, 3.23%. lH NMR
(360MHz, CDC13) ~ 2.14 (3H, s), 2.27 (lH, d, J=13.2), 2.33 (lH, d, J=13.6), 2.35 (lH, dt, J=ll.9, 3.3), 2.80 (lH, d, J=13.4), 2.83 (lH, d, J=14.4), 3.57 (lH, s), 3.67 (lH, d, J=13.3), 3.86 (lH, d, J=9.3), 4.28 (lH, s), 4.33 (lH, dt, J=11.8, 2.4), 4.43 (lH, d, J=9.3), 7.00 (2H, t, J=8.8), 7.04-7.31 (9H, m), 7.58 (2H, br s); m/z (ES+) 434 (M+l, 100%).
(2R,3S.9R)-4-Aza-4-benzvl- 1,7-dioxa-9-(2-ethYlPhenYl)-3-(4-fluoroPhenyl) -9-hydroxY-spiro~5.41decane The title compound was prepared according to the method of Example 2 to yield an oil (180mg, 28%). IH NMR (360MHz, ~DCl3) ~ 1.07 (3H, t, J=7.5), 2.26-2.48 (4H, m), 2.77-2.88 (2H, m), 3.57 (lH,s), 3.64-3.72 (2H, m), 3.82 (lH, d, J=9.3), 4.32-4.38 (2~, m), 4.41 (lH, d, J=9.3), 6.98-7.08 (3H, m), 7.14-7.30 (8H, m), 7.54-7.64 (2H, br s); m/z (ES+) 449 (M+l, 100%).
(2R.3S,9R)-4-Aza-4-benzYl-9-t2-chlorophenYl)-1.7-dioxa-3-(4-fluoroPhenyl)-9-hvdroxy-spiror5.4~decane The title compound was prepared according to the method of Example 1 to yield an oil (280mg, 51%). ~ (ES+) 454 (M+l, 100%).
(2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxy-9-Phenylspirol5.41decane CA 02245C~78 1998-08-05 The benzylamine of h'.~mple 1 (255mg, 0.61mmol) as a solution in methanol (15ml) was hydrogenated at 40 psi of hydrogen with 10% Pd-C
catalyst (160mg) for 2l/2 hours The reaction mixture was filtered through a pad of Hyflo~M and concentrated to a crude gum which was purified by flash silica gel chromatography eluting with 5% methanol in dichloromethane to yield the title compound as a glass ~76mg, 38%).
lH NMR (360MHz, CDCl3) ~i 1.7-1.9 (~2H, br s), 2.09 (lH, d, J=13.5), 2.20 (lH, dd, J--13.5, 0.9), 3.06 (lH, dd, J=12.4, 2.4), 3.22 (lH, dt, J=12.3, 3.6), 3.73 (lH, dd, J=11.2, 3 0), 3 78 (lH, d, J=9 3), 4 03 (lH, s), 4.27 (lH, d, 10 J=9.3), 4.36 (lH, dt, J=11.7, 2.7), 7.03 (2H, t, J=8.7), 7.12 (2H, m), 7.16-7.26 (3H, m), 7.47 (2H, m); m/z (E:S+) 330 (M+l, 100%), 312 (M-17, 30).
EXAMPLl~ 10 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorophenvl)-9-hYdroxv-9-(2-15 methox~henvl)sPiro~;.41decane The benzyl~mine o~~ mple 2 was hydrogenated according to the method of Example 9 to yield the title compound as a glass (9Omg, 68%).
~H NMR (360MHz, CDCl3) ~ 1.98 (lH, d, J=13.1), 2.56 (lH, d, J=13.1), 3.04 (lH, dd, J=11.6, 2.1), 3.20 ~lH, dt, 3=12.3, 3.7), 3.34 (3H, s), 3.71 (lH, dd, 20 J=ll.O, 2.6), 4.03 (lH, s), 4.17 (2H, s), 4.33 (lH, dt, 3=11.6, 3.1), 6.72 (lH, dd, J=8.2, 0.9), 6.89 (lH, dt, J=7.6, 1.1), 7.02 (2H, t, J=8.7), 7.18 (lH, dt, J=7.8, 1.8), 7.44-7.55 (3H, m); m/~ (ES+) 360 (M+1, 100%), 342 (M-17, 72), 192 (75).
(2R,3S.9R)-4-A~a-1.7-dioxa-3-(4-fluorophenvl)-9-hYdroxy-9-(2-(trifluoromethyl)phenvl~spiror5.41decane The benzylamine of Example 3 was hydrogenated according to the method of l~xample 9 to yield the title compound as a glass (21mg, 53%).
30 lH NMR (360MHz, CDCl3) ~ 2.21 (lH, d, J=13.3), 2.42 (lH, d, J=13.3), 3.0 (lH, dd, J=12.4, 2 0), 3.22 (lH, dt, J=12.3, 3.6), 3.73 (lH, dd, ~=11.2, 2.8), CA 0224~78 1998-08-0~
- 55 - .
3.89 (~H, d, J=9.4), 4.05 (lH, s), 4.34 (lH, dt, J=11.7, 2.6), 4.48 (lH, d, J=9.4), 6.94-7.00 (2H, m), 7.20 (lH, d, J=7.3), 7.31-7.47 (4H, m), 7.68 (lH, dd, J=7.5, 1.6); m/z (ES+) 398 (M+l, 100%).
(2R,3$~9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxY-9-(2-methoxY-5 (trifluoromethyl)phenYl)sPiro ~5.4l decane The benzylamine of Example 4A was hydrogenated according to the method of Example 9 to yield the title compound as an oil (80mg, 70%).
lH NMR (360MHz, CDC13) ~ 1.7-2.1 (~lH, br s), 1.91 (lH, d, J=13.1), 2.59 (lH, d, J=13.0), 3.06 (lH, dd, J=12.4, 2.0), 3.22 (lH, dt, J=12.3, 3.6), 3.32 (3H, s), 3.73 (lH, dd, J=ll.l, 2.7), 4.04 (lH, s), 4.07 (lH, d, J=8.9), 4.34 (lH, dt, J=11.7, 2.9), 6.75 (lH, d, J=8.6), 7.04 (2H, t, J=8.6), 7.43-7.52 (3H, m), 7.92 (lH, d, J=2.3); m/z (ES+) 428 (M+l, 100%).
(2R.3S,9$)-4-Aza-1,7-dioxa-3-~4-fluorophenYl)-9-hvdroxY-9-(2-methoxY-5-(trifluoromethyl3phenyl)spiror5.41decane The benzylamine of Example 4B was hydrogenated according to the mthod of ~xample 9 to yield the title compound as an oil (79mg, 68%).
H NMR (360MHz, CDCl3) ~ 2.14 (lH, d, J=14.3), 2.16 (~lH, br s), 2.64 (lH, d, J=14.4), 3.02 (lH, dd, J=12.3, 2.2), 3.18 (lH, dt, J=12.2, 3.6), 3.62 (lH, dd, J=11.4, 2.8), 3.86 (3H, s), 3.91 (lH, dd, J=9.2, 1.3), 3.99 (lH, s), 4.22 (lH, dt, J=11.8, 2.6), 4.36 (lH, d, J=9.0), 6.90 (lH, d, J=8.6), 7.07 (2H, t, J=8.7), 7.49 (lH, dd, J=8.2, 1.8), 7.54-7.63 (3H, m); m/z (ES+) 428 (M+l, 100%).
E~MPLE 14 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-~luorophenvl3-9-hvdroxY-9-(2-(tri~luoromethoxY)Phcnvl)sPiror5~4ldecane The benzyl~3mine of ~,~mple 5 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (46mg, 66%).
lH NMR (360MHz, CDCls) ~ 1.7-2.1 (lH, br s), 2.18 (lH, d, J=13.1), 2.33 (lH, d, J=13.2), 3.06 (lH, dd, ~=I2.4, 2.2), 3.22 (lH, dt, J=12.3, 3.6), 3.74 (lH, dd, J=11.3, 2.9), 3.97 (lH, d, J=9.4), 4.06 (lH, s), 4.35 (lH, dt, J=11.7, 2.4), 4.48 (lH, d, J=9.5), 6.97 (2H, t, J=8.8), 7.14-7.19 (2H, m), 7.24-7.30 (lH, m), 7.39-7.46 (3H, m); m/z (ES+) 414 (M+1, 100%).
(+/-)-(2R~,3S~.9R*)-4-Aza-1.7-dioxa-3-(4-fluoroPhenvl)-9-hYdroxv-9-(2-methylphenvl)sl)iror5.4~decane The benzyl~mine of ~"c:~m~le 6 was hydrogenated according to the method~of F,~r~m~le 9 to yield the title compound as glass (105mg, 78%).
lH NMR (360MHz, CDCl3) ~ 2.19 (lH, d, J=12.9), 2.21 (3H, s), 2.31 (lH, d, 15 J=13.2), 2.9-3.3 (~2H, br s), 3.06 (lH, dd, J=11.7, 2.0), 3.21 (lH, dt, J=12.3, 3.6~, 3.72 (lH, dd, J=10.5, 2.7), 3.95 (1E~, d, J=9.3), 4.06 (lH, s), 4.34 (lH, dt, J=11.7, 3.0), 4.49 (1H, d, J=9.2~, 6.94-7.18 (6H, m), 7.42-7.47 (2H, m);
m /z (ES+) 344 (M+ 1, 100%) .
EXAMPLl~ 16 (2R,3S,9R)-4-Aza-4-(2,3-dihvdro-3-oxo-1.2.4-triazol-5-YllmethYl-1,7-dioxa-3-(4-fluoro~henYl)-9-hYdroxY-9-(2-methoxvPhen~l)spiro~5.4ldecane The morpholine of Example 10 (81mg, 0.23mmol) was heated with N-methylcarboxy-2-chloroacetamidrazone (see European Patent 25 Specification No. 0 577 394-A) (45mg, 0.271mmol) and potassium carbonate (125mg, 0.904mmol) in DMF (5ml) at 60~C for 1 hour. The cooled solution was diluted with water (25ml), extracted with ethyl acetate (3xl5ml), dried (MgSO~) and concentrated to dryness. The crude gum (110mg) was purified by flash silica gel chromatog~aph~r eluting with 6-8%
30 methanol in dichloromethane to yield the intermcdiate imidiazone, which was redissolved in xylene (2ml~ and heated at reflux for 2 hours. The CA 0224~78 1998-08-0~
crude concentrate was purified by flash silica gel chromatography eluting with 6% methanol in dichloromethane to yield the title compound as a glass (42mg, 41%). IH NMR (360MHz, CDCl3) ~ 2.05 (lH, d, J=13.1), 2.57 (lH, d, J=13.2), 2.61 (lH, m), 2.89 (lH, br d, ~=11.2), 2.95 (lH, d, J=14.~;), 3.35 (3H, s~, 3.45 (lH, d, J=14.5), 3.62 (lH, s), 3.75 (lH, br d, J=8.9), 4.14 (lH, d, J=9.0), 4.18 (lH, d, J=9.0), 4.36 (lH, dt, J=11.7, 2.1), 4.47 (lH, s), 6.71 (lH, d, J=8.2), 6.89 (lH, t, J=7.5), 7.05 (2H, t, J=8.6), 7.19 (lH, t, J=7.5), 7.50 (lH, dd, J=7.8, 1.6), 7.56 (2H, vbr s), 9.90 (lH, br s), 10.45 (lH, br s); m/z (ES+) 457 (M:~l, 32%), 439 (M-17, 15), 382 (100).
(2R,3S,9R)-4-Aza-4-(2,3-dihvdro-3-oxo-1.2.4-triazol-5-Yl)methYl-1,7-dioxa-3-(4-fluoro~henyl)-9-hYdroxY-9-(2-(trifluoromethvl)phenYl)-spiro r5.4] decane The title compound was prepared from the morpholine of ~z~mple 11 according to the method of Example 16 to yield a glass (60mg, 48%).
H NMR (360MHz, CDCl3) ~ 2.2-2.5 (lH, br s), 2.23 (lH, d, J=13.5), 2.47 (lH, d, J=13.4), 2.61 (lH, dt, J=ll 9, 3.3), 2.90 (lH, d, ~=11.3), 3.00 (lH, d, J=14.4), 3.47 (lH, d, ~=14.5), 3.61 (lH, s), 3.75 (lH, d, J=8.9), 3.81 (lH, d, J=9.3), 4.26 (lH, s), 4.35 (lH, dt, J=11.7, 2.0), 4.45 (lH, d, J=9.3), 6.99 (2H,t, J=8.6), 7.11 (lH, d, J=8.6), 7.31-7.37 (2H, m), 7.52 (2H, br s), 7.67 (lH, d,J=9.3), 10.41 (lH, s), 10.95 (lH, br s); ~ (ES+) 495 (M~l, 100%).
~2R,3S,9R)-4-~za-4-(4-(N.N-dimethYlamino)-but-2-vnvl)-1.7-dioxa-3-(4-fluorphenyl)-9-hYdroxy-9-(2-methoxv-5-(trifluoromethvl)~henvl)-spiror{;.4~decane The chloride of Description 5 (60mg, 0.12mmol) dissolved in dioxan (3mV was added to condensed dimethylamine (3ml) in a sealed tube and 30 heated at 90~C for 7 hours. The crude concentrate was purified by flash silica gel chromatography eluting with 5% methanol in dichloromethane to yield the title compound as an oil (42mg, 69%). IH NMR (360MHz, CD~13) o 1.92 (lH, d, J=13.0), 2.31 (6H, s), 2.32 (2H, s), 2.~6 (lH, d, J=13.1), 2.83 (lH, br d, J=11.6), 3.03 (lH, dt, J=12.0, 3.7), 3.29 f2H, s), 3.32 (3H, s), 3.75 (lH, s), 3.79 (lH, dd, J=11.3, 3.7), 4.06 (lH, d, J=8.9), 4.19 (lH, d, J=8.9), 4.46 (lH, dt, J=ll.~i, 2.3), 4.61 (~lH, br s), 6.75 (lH, d, J=8.6), 7.05 (2H, t, J=8.5), 7.44 (lH, dd, J=9.0, 2.6), 7.53 (2H, br s), 7.92 (lH, d, J=2.2); m/z (ES+) ~23 (M+l, 100%).
(2R.3S.9R)-4-Aza-4-(~-(N.N-dimethYlaminomethYl)-1.2~3-triazol-4-yl)methyl- 1.7-dioxa-3-(4-fluoro~henYl)-9-hvdroxY-9-(2-methoxY-5-(trifluoromethYl)phenvl)spiror5.41decane The azide of Description 6 (230mg, 0.44mmol) dissolved in tli~ n (6ml) was added to condensed dimethylamine (6ml) in a sealed tube and heated at 90~C for 7 hours. The crude concentrate was purified by ~lash silica gel chromatography eluting with 10% methanol in dichloromethane to yield the ~itle compound as a foam (155mg, 62%). lH NMR (360MHz, CDCl3) o 1.94 (lH, d, J=13.0), 2.23 ~6H, s), 2.55 (lH, m), 2.58 (lH, d, J=13.1), 2.87 (lH, d, J=11.5), 3.20 (lH, d, J=13.8), 3.34 (3H, s), 3.51 (2H, s), 3.61 (2H, t, J=6.9), 3.71 (lH, dd, J=11.3, 2.1), 4.05 (lH, d, J=8.9), 4.18 (lH, d, J=8.9), 4.32 (lH, dt, J=11.7, 2.0), 6.75 (lH, d, J=8.6), 7.09 (2H, t, J=8.6), 7.45 (lH, dd, J=8.3, 2.1), 7.62 (2H, br s). 7.91 (lH, d, J=2.2); 77~/-fES+) 566 fM+l~ 82%), 165 (100).
EXAMPLES 20A and 20B
(2R,3S,9R)-4-Aza-1~7-dioxa-3-f4-fluoloPhenYl)-9-hYdrox~r-4-(1($)-~henvlethYl)-9-(2-(trifluoromethYl)~henYl)spilor~4ldecane; and (2R,3S,9R)-4-Aza-1,7-dioxa-3-f4-fluoloPhenYl)-9-hYdroxv-4-(l(R)-phenylethvl)-9-(2-(trifluoromethvl)phenYl)sPiro~5.41decane (l-Bromoethyl)benzene (103,ul, 0.76mmol) and potassium carbonate (208mg, 1.5mmol) were added to the mo~pholine of Example 11 (150mg, CA 0224~78 1998-08-0~
0.38mmol) as a solution in DMF (7ml) and stirred for 18 hours at 20~C, then 4 hours at 75~C. The cooled reaction mixture was diluted with water (50ml), extracted with ether (3x25ml), dried (MgS04) and concentrated to a yellow oil (194mg). The crude isomers were separated by medium pressure chromatography eluting with 2:1 hexane:ether to yield the less polar title compound (Example 20A) as a white solid (39mg, 21%);
lH NMR (360MHz, CDC13) ~ 1.17 (3H, d, J=6.8), 2.24 (lH, d, J=13.3), 2.41 (lH, d, J=11.6), 2.45 (lH, d, ~=13.3), 2.65 (lH, dt, J=11.8, 3.3), 3.6~ (lH, m), 3.75 (1~, ~, J=6.8), 3.77 (lH, d, J=9.2), 3.93 (lH, s), 4.24 (lH, dt, 10 J=11.4, 1.9), 4.3~ (lH, s), 4.44 (lH, d, J=9.2), 6.99 (2H, t, J=8.8), 7.15 (lH, d, J=7.3), 7.18-7.40 (4H, m), 7.43 (2H, d, J=8.0), 7.64 (2H, br s), 7.68 (lH, dd, J=7.6, 1.6); m/z (ES~) 502 (M+1, 100%); and the morepolar title compound (Example 20B) as a glass (68mg, 36%); lH NMR (360MHz, CDCl3) ~ 1.39 (3H, d, J=7.1), 2.20 (lH, d, J=13.5), 2.30 (lH, d, J=13.4), 2.30 15 (lH, m), 3.00 (lH, d, J=11.5), 3.48 (lH, s), 3.66 (lH, d, J=9.3), 3.71 (l~I, dd, J=ll.O, 1.4), 3.82 (lH, q, ~=7.1), 4.21 (lH, s), 4.36 (2H, m), 6.95 (2H, dd, J=8.0, 1.6), 7.04 (2H, t, J=8.7), 7.05 (lH, m), 7.23-7.36 (5H, m), 7.51 (2H, br s), 7.65 (lH, dd, J=7.3, 2.0); m/~ (ES+) 502 (M+l, 100%).
EXAMPLE ~1 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-hvdroxy-4-((2-(trifluoromethyl)phenyl)methvl)-9-(2-(trifluoromethYl)phenyl)-spiro r5.4l decane The morpholine of Example 11 (lOOmg, 0.25mmol), 2-25 (tri~Luoromethyl)bcnzyl bromide (120mg, 0.50mmol) and potassium carbonate (138mg, l.OOmmol) were stirred in DMF (5ml) for 4 hours. The reaction mixture was diluted with water (50ml), extracted with ether, (3x25mI), dried (MgSO~) and concentrated to a crude oil (244mg) which was purified by ~lash silica gel chromatography eluting with 4:1 30 hexane:ethyl acetate to vield the title compound as a glass (99mg, 71%) WO 97/300~;6 PCT/GB97/00404 lH NMR (360MHz, CDCl3) ~ 2.29 (lH, d, J=13.3), 2.44 (lH, dt, J=12.0, 3.2), 2.47 (lH, d, J=13.3), 2.75 (lH, d, J=11.8), 3.23 (lH, dd, J=14.8, 1.8), 3.58 (lH, d, J=14.8), 3.66 (lH, s), 3.67 (lH, m), 3.79 (lH, d, J=9.3), 4.32 (lH, s), 4.36 (lH, dt, J=11.7, 2.4), 4.46 (lH, d, J=9.3), 6.95 (2H, t, J=8.8), 7.15 (lH, d, J=7.3), 7.24-7.39 (3H, m), 7.51-7.65 (~4H, m), 7.68 (lH, dd, J=7.5, 1.6), 7.96 (lH, dd, J=7.7); m/z (ES+) 556 (M+l, 100%).
EXAMPL:~ 22 (+/-)-(2R*,3S~9R~)-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluorophenYl)-9-methoxY-9-PhenYl-spiro[5.41decane Sodium hydride (80mg, 60% dispersion in oil, 2.0mmol) was added to a racemic mixture of the alcohol of F,~mple 1 (250mg, 0.60mmol) dissolved in DMF (5mV. After stirring for 30 minutes, methyl iodide (370,u1, 5.96mmoV was added and the reaction stirred for between 2 and 24 hours. The reaction mixture was quenched by the addition of water (50ml, care!) extracted with ether (3x25ml), dried (MgSO4) and concentrated to a yellow solid (254mg) which was purified by flash silica gel chromatography eluting with 5:1 hexane: ethyl acetate to yield the title compound as a glass (197mg, 76%). Analysis Found: C, 75.10; H, 6.51; N, 3.38.
Cz7H2gFNO3 requ~res C, 74.81; H, 6.51; N, 3.23%~. IH NMR (360MHz, ~DGl3) ~ 2.22 (lH, d, J=14.2), 2.33 (lH, dt, J=11.9, 3.4), 2.45 (lH, d, J=14.2), 2.79 (2H, m), 3.09 (3H, s), 3.45 (lH, s), 3 64-3.70 (3H, m), 4.24 (lH, dt, J=11.7, 2.2), 4.28 (lH, d, J=9.3), 6.77-6.83 (2H, m), 6.97 (2H, t, J=8.7), 7.11-7.26 (8H, m), 7.57 (~2H, br s); m/~ (ES+) 434 (M+l, 100%), 402 (M-31, 42).
(2R.3S.9R~-4-Aza-4-benzyl- 1.7-dioxa-3-(4-fluoroPhenvl)-9-methoxv-9-(2- .
methoxvphenyl~spiror5.41decane The alcohol of Example 2 was reacted accol-ding to the method of Example 22 to yield the title compound as a pale vellow foam (466mg, CA 0224~78 1998-08-0~
71%). lH NMR (360MHz, CDC13) ~ 2.25 (lH, d, J=13.9), 2.31 (lH, dt, J=ll.9, 3.4), 2.58 (lH, dd, J=13.8, 1.0), 2.75 (lH, d, J=13.1), 2.78 (lH, br d, J=11.3), 2.97 (3H, s), 3.45 (lH, s), 3.60 (lH, d, J=13.3), 3.62-3.69 (2H, m), 3.66 (3H, s), 4 28 (lH, dt, J=11.8, 2.2), 4.52 (lH, dd, J=9.8, 0.8), 6.77-6.83 (2H, m), 6.88-6.97 (3H, m), 7.17-7.27 (6H, m), 7.56 (~2H, br s); m/z (ES+) 464 (M+l, 100%).
EXAMPL~ 4 (2R,3S.9R)-4-Aza-4-benzYl-1.7-dioxa-3-(4-iluoroPhenYl)-9-methoxv-9-(2-(trifluoromethYl)phenvl)spiror5.41decane The alcohol of ~ m~le 3 was reacted according to the method of Example 22 to yield the title compound as a solid after recrystallisation from 60/80 petrol (9lOmg, 82%). Mp. 155-157~C (petrol). lH NMR
(360MHz, CDCl3) ~ 2.29 (lH, d, J=14.7), 2.27-2.41 (lH, m), 2.56 (lH, d, J=14.7), 2.72-2.83 (2H, m), 2.96 (3H, s), 3.35 (lH, s), 3.69-3.70 (2H, m), 4.18 (lH, br t, J=11.8), 4.27 (2H, s), 6.63 (lH, d, J=7.9), 6.75 (lH, br s), 7.08 (lH, t, J=7.4), 7.16-7.46 (8H, m), 7.59 (lH, d, J=7.9).
(2R,3S,9R)-4-Aza-4-benzvl-1~7-dioxa-3-(4-fluoroPhenvl)-9-methoxv-9-(2-methoxy-a-(trifluoromethYl)phenYl)s~iroL5.4~dccane The alcohol of Example 4A was reacted according to the method of Example 22 to yield the title compound as a foam (430mg, 67%). lH NMR
(360MHz, CDCl3) ~ 2.32 (lH, dt, J=ll.9, 3.5), 2.35 (lH, d, J=14.0), 2.53 (lH, d, J=14.0), 2.75 (lH, d, J=13.1), 2.79 (IH, d, J=ll.O), 2.97 (3H, s), 3.43 (lH, s), 3.a9 (lH, d, J=13.3), 3.64 (lH, m), 3.69 (3H, s), 3.82 (lH, d, J=8.6), 6.88 (2H. t, J=8.7), 7.17-7.29 (6H, m), 7.46 (lH, dd, J=8.4, 1.6), 7.51 (~2H, br s); r7t/~ (ES+) 532 (M+l, 100%).
(+/-)-(2R~,3S*,9R~)-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluorophenvl)-9-methoxY-9-(2-methvlphenyl)spiror5.41decane The alcohol of ~,~m~le 6 was reacted according to the method of Example 22 to yield the title compound as an oil (175mg, 39%) IH NMR
(360~Hz, CDCl3) ~ 2.28-2.36 (2H, m~, 2.31 (3H, s), 2.54 (lH, d, J=13.8), 2.76 (lH, d, J=13.1~, 2.79 (lH, d, J=1~.6), 2.87 (3H, s), 3.42 (lH, s), 3.63 (lH, d, J=13.2), 3.65 (lH, m), 3.89 (lH, d, J=9.3~, 4.26 (lH, dt, J=11.8, 2.5), 4.42 (lH, d, J=9.3), 6.65 (lH, d, J=7.7), 6.84 (2H, t, J=8.9), 6.90 (lH, m), 7.05 (2H, m), 7.15-7.27 (5H,m), 7.49 (~2H, br s); m/z (~S+) 448 (M+l, 100%).
(2R,3S,9R)-4-Aza-4-benzvl-1.7-dioxa-9-(2-ethvlphenvl)-3-(4-iluoro~henvl)-9-methoxy-spiro[5.41decane The alcohol of Example 7 was reacted according to the method of Example 22 to yield the title compound as a white solid (135mg, 77%).
lH NMR (360MHz, CDCl3) ~ 1.14 (l~I, t, J=7.5), 2.28-2.37 (2H, m), 2.54 (lH, d, J=13.8), 2.67-2.84 (4H, m), 2.89 (3H, s), 3.42 (lH, s), 3.60-3.69 (2H, m), 3.85 (lH, d, J=9.4), 4 25 (lH, td, J=10.6, 2.2), 4 ~1 (lH, d. J=9.4), 6.67 (lH, d, J=7.9), 6.80-6.93 (3H, m), 7.11-7.28 (7H, m), 7.47 (2H~ br s); m/_ (ES+) 462 (M~1, 100%) (2R~3S~9R)-4-Aza-4-benzvl-9-(2-chloroPhen~7l)-1.7-dioxa-3-(4-fluoroPhen~rl)-9-~ethoxy-s~iro r5.4~ decane The alcohol of F.~,qm~le 8 was reacted according to the method of ml?le 22 to yield the title compound as an oil (150mg, 51%). lH N~IR
(360MHz, CDCl3) ~ 2.31 (lH, td. J=11.9, 3.3), 2.45 (lH, d, J=1~.1), 2~68 (lH, d, J=14.1), 2.73-2~84 (2H, ~ , 2~92 (3H, s), 3.41 (lH, s), 3.60-3.69 (2H, m), 4.05 (lH, d, J=9.7), 4.23 (lH. td, J=11.7, 2.2), 4.45 (lH, d. J=9.7), 6.78-CA 02245578 lsss-os-05 wo 97/300s6 PCT/GB97/Oû404 6.86 (2H, m), 6.98 ~lH, td, J=7.5, 1.3), 7.10 (lH, td, J=7.7, 1.6), 7.16-7.28 (7H, m), 7.41-7.54 (2H, m); m/z (ES+) 468 (M+l, 100%).
(+/-)-(2R* .3S~,9R*)-4-Aza- 1,7-dioxa-3-(4-fluoroPhenYl)-9-methoxY-9-phenyl-spiror5.41decane The (+/-)-benzyl~min~? of Example 22 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (138mg, 100%). lH ~MR (360MHz, CDC13) ~ 2.14 (lH, d, ~=14.2), 2.40 (lH, d, J=14 2), 3.03 (lH, dd, J=12.3, 2.2), 3.08 (3H, s), 3.20 (lH, dt, J=12.2, 3.6), 3.72 (lH, br d, J=12.1), 3.75 (lH, d, J=9.3), 3.95 (lH, s), 4.26 (lH, dt, J=12.0, 2.7), 4.31 (lH, d, J=9.7), 6.81-6.86 (2H, m), 6.90-6.96 (2H, m), 7.11-7.15 (3H, m), 7.39-7.45 (2H, m); m/z (ES+) 344 (M+l, 60%), 312 (M-31, 100).
EXAMPI,E 30 2R,3S,9R)-4-Aza-1~7-dioxa-3-~4-fluorophenvl)-9-methoxy-9-(2-methoxyphenYl)spiro ~5.4~decane The benzylamine of E~xample 23 was hydrogenated according to the method of Example 9 to yield the title compound as a yellow oil (265mg, 84%). lH NMR (360MHz, CDC13) ~ 2.18 (lH, s), 2.18 (lH, d, J=13.9), 2.54 (lH, d, J=13.9), 2.99 (3H, s), 3.00 (lH, m), 3.16 (lH, dt, J=12.2, 3.6), 3.63 (3H, s), 3.70 (lH, dd, J=11.4, 2.9), 3.82 ~lH, d, J=9.8), 3.95 (lH, s), 4.30 (lH, dt, J=11.8, 2.7), 4.55 (lH, d, J=9.8), 6.77-6.93 (4H, m), 6.98 (lH, dd, J=7.6, 1.6), 7.19 (lH, dt, J=7.8, 1.7), 7.39-7.45 (2H, m); m/~ ~ES+) 374 (M~l, 100%), 342 (M-31, 93).
(2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl~-9-methoxY-9-(2-30 (trifluoromethyl)phenYl)sPiror5.4~decane WO 97/300!;6 PCT/GB97/00404 The benzylamine of Example 24 was hydrogenated according to the mthod of ~,~m~le 9 to yield the title compound as a white solid (603mg, 90 %3. l H N M R (360 M H z, C D Cl3) ~ 2.01 (lH, br s, NH), 2.26 (lH, d, J=14.6), 2.52 (lH, d, J=14.6), 2.96 (3H, s), 3.03 (lH, dt, J=14.0, 2.0), 3.17 (lH, td, J=12.1, 4.0), 3.70 (lH, dd, J=11.4, 3.0), 3.46 (lH, s), 4.21 (lH, td, J=ll.9, 2.9), 4.30 (2H, s), 6.66-6.78 (3H, m), 7.06 (lH, t, J=7.6), 7.18-7.31 (3H, m), 7.58 (lH, d, J=7.9); m/z (ES+) 412 (M+l, 100%).
E~AMPLE 32 10 ~2R~3S,9R)-4-Aza-1,7-dioxa-3-(4-fluorophenYl)-9-methoxv-9-(2-methoxy-5-(trifluoromethylh~henyl)sPiro ~5.41 decane The benzylamine of F"r~mple 25 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (272mg, 88%).
lH NMR (360MHz, CDCl3) ~ 2.26 (lH, d, J=13.9), 2.2-2.5 (~2H, br s), 2.49 15 (lH, d, J=13.7), 3.00 (3H, s), 3.03 (lH, m), 3.16 (lH, dt, J=12.2, 3.7), 3.64(3H, s), 3.71 (lH, dd, J=11.5, 2.8), 3.93 (lH, d, J=9.8), 3.96 (lH, s), 4.31 (lH, dt, J=ll.9, 2.9), 4.44 (lH, d, J=9.7), 6.81 (lH, d, J=8.6), 6.88 (2H, t, J=8.7), 7.25 (lH, d, J=2.1), 7.39-7.47 (3H, m); 771/Z ~ES+) 442 (M+l, 100%).
(2R~3S,9R)-4-Aza-1,7-dioxa-3-~4-fluorophenyl)-9-methoxy-9-(2-rnethvlphenyl)sT)iro~5.41decane The benzylamine of 33xarnple 26 was hydrogenated accor ding to the method of Example 9 to yield the title compound as a glass (35mg, 47%).
25 lH NMR (360MHz, CDCl3) ~ 2.14 (lH, d, J=13.9), 2.16 (lH, m), 2.28 (3H, s), 2.56 (lH, d, J=13.9), 2.86 (3H, s), 3.05-3.20 (2H, m), 3.76 (lH, dd, J=12.2, 2.9), 4.05 (lH, d, J=9.a), 4.13 (lH, m), 4.46 (lH, m), 4.49 (lH, d, J=9.5), 6.64 ~lH, d, J=7.6), 6.84 (2H, t, J=8.5), 6.88- ~lH, m), 7.03-7.10 (2H, m), 7.49 (2H, dd, J=8.5, 5.3); ~71/~, (ES+) 358 (M+l, 100%).
CA 0224~78 1998-08-0~
EXAMPI.E 34 (2R,3S,9R)-4-Aza-1.7-dioxa-9-(2-ethYlphenyl)-3-(4-fluorophenvl)-9-methoxv-sPiror6.41decane The benzylz~lmine of Example 27 was hydrogenated according to the method of Example 9 to yield the title compo~nd as an oil (85mg, 81%).
lH NMR (250MHz, CDCl3) ~ 1.14 (3H, t, J=10.7), 2.07 (lH, br s), 2.22 (lH, d, J=l9.9), 2.49 (lH, d, J=l9.9), 2.68 ~2H, q, J=10 8), 2.90 (3H, s), 3.02 (lH, dd, J=17.5, 3.4), 3.18 (lH, td, .,T=17.3, 5.0), 3.72 (lH, td, J=16.5, 4.2), 3.92-3.99 (2H, m), 4.27 (lH, td, J=16.9, 4.3), 4.47 (lH, d, J=13.5), 6.71 (lH, d, J=ll l), 6 76-6.96 (3H, m), 7.11-7.19 (2H, m), 7.30-7.42 (2H, m).
(2R,3S~9R)-4-Aza-4-(5-(N.N-dimethvlaminomethvl)- 1,2,3-triazol-4-yl)methyl- 1,7 -dioxa-3-(4-fluoroPhenvl)-9-methoxY-9- (2-methoxy-5-(trifluoromethvl)phenvl)spiro r5.41 decarle The title compound was prepared from the azide of Description 8 according to the method of Example 19 to yield a foam (86mg, 76%).
lH NMR (360MHz, CDCl3) ~ 2.24 (lH, d, J=14.0), 2.50 (6H, s), 2.55 (lH, d, J=14.0), 2.76 (lH, br d, J=11.2), 2.97 (3H, s), 3.24 (lH, d, J=13.9), 3.50 (lH, s), 3.55 (lH, d, J=14.0), 3.68 (lH, m), 3.69 (3H, s), 3.86 (3H, m), 4.19 (lH, dt, J=11.8, 2.1), 4.47 (lH, d, J=9.8), 6.8~ (IH, d, J=8.6), 6 95 (2H, t, J=8.5), 7.21 (lH, d, J=l.9), 7.47 (lH, dd, J=8.7, 1.9), 7.5 (~2H, br s), 7.8-8.4(~lH, br s); m/x ~ES+) 580 (M+1, 100%).
~XAMPLE 36 (2R,3S,9R)-4-Aza-4-(5-(N,N-dimethYlaminomethvl)- 1~2,3-tctrazol-4-vl)methyl- 1,7-dioxa-3-(4-fluoroPhenvl)-9-methoxY-9-(2-(trifluoromethvl)phenyl)spiro~5.41decane The title compound was prepared from the azide of Description 10 according to the method of Example 19 to vield a yellow foam (124mg, 69%). lH NM:R (3~0MHz, CDC13) ~ 2.19-2.27 (7H, m). 2.50-2 61 (2H, m), CA 0224~78 l998-08-0~
2.82 (lH~ br d, J=11.6), 2.96 (3H, s~, 3.20 (lH, d, J=14.0), 3.41 (lH, s), 3.48 (2H, s), 3.61 (lH, d, J=14.0), 3.64 (IH, br d, J=l.0), 4.16 (lH, dt, J=9.4, 2.3), 4.25 (lH, d, J=9.8), 4.29 (lH, d, J=4.3), 6.64 (lH, d, J=7.9), 6.79 (lH, br s), 7.10 (lH, t, J=7.6), 7.23 (lH, t, J=7.7), 7.60 (lH, d, J=7.9); m/z (ES+) 550 (M+l, 100%).
EXAMPLES 37A and 37B
(2R.3S~9R)-4-Aza-1,7-dioxa-3-~4-fluoroPhenvl)-9-methoxv-4-(1-(S~-phenvlethYl)-9-(2-methoxY-5-(trifluoromethYl)phenyl)sl~iror5~4~decane; and 10 (2R~3S,9R~-4-Aza-1.7-dioxa-3-(4-fluoroPhenvl)-9-methoxY-4-(l-(R)-phenvlethYl)-9-(2-methoxY-5-(trifluoromethYl)Phenyl)spiro r5.41decane The morpholine of Example 32 was reacted according to the method of Example 20 to yield the less polar title compound (Example 37A) as an oil (39mg, 25%),1H NMR (360MHz, CDC13) ~ 1.14 (3H, d, J=6.9), 2.32 (lH, 15 d, J=14.0), 2.36 (IH, d, J=11.7), 2.53 (lH, d, J=14.2), 2.62 (lH, dt, J=11.7,3.3), 2.97 (3H, s), 3.60 (lH, dd, J=ll.l, 1.7), 3.67 (lH, q, J=6.8), 3.69 (3H, s), 3.83 (2H, m), 4.17 (lH, dt, J=11.4, 2.1), 4.3 (lH, d, J=9.7), 6.81 (lH, d, J=8.6), 6.88 (2H, t, J=8.7), 7 17-7.42 (7H, m), 7.46 (lH, dd, J=8.7, 1.6), 7.58 (~2H, br s); m/z (;ES+) 546 (M+l, 100%); and the morepolar title 20 compound (Example 37B) as an oil (47mg, 30%), lH NMR (360MHz, CDCl3) ~ 1.35 (3H, d, J=7.1), 2.19-2.34 (~3H, m), 2.42 (lH, d, 14.0), 2.90 (3H, s), 2.96 (lH, d, J=11.4), 3.37 (lH, s), 3.69 (3H, s), 3.70-3.77 (3H, m), 4.28 (lH, dt, J=11.4, 2.4), 4.35 (lH, d, J=10.0), 6.80 (lH, d, J=8.6), 6.88-6.99 (4H, m), 7.16 (lH, d, J=l.9), 7.20-7.29 (3H, m), 7.41-7.49 (~4H, m);
25 1~1 /z (;~S+) 546 (M+ 1, 100%).
(2R~3S,9R)-4-Aza- 1,7-dioxa-3-(4-fluoroPhenvl)-9-methoxY-9-(2-methoxv-5-(tri~Luoromethyl)phenvl)-4-((2-(trifluorometh~tl)PhenYl)methyl)-30 s~iror~i.41 decane The title compound was prepared from the morpholine of Example 32 according to the method of F',~m~le 21 to yield a glass (67mg, 73%).
lH NMR (360MHz, CDCl3) ~ 2.32-2 43 (2H, m), 2.57 (lH, d, J=14.1), 2.71 (lH, br d, J=11 6), 2.99 (3H, s), 3.18 (lH, dd, J=14.7, 1.7) 3.50 (lH, d, J=14.9), 3.54 (lH, s), 3.65 (lH, dt, J=11.5, 1.6), 3.69 (3H, s), 3.83 (lH, d, J=9.8), 4.29 (lH, dt, J=11.8, 2.2), 4.45 (lH, d, J=9.7), 6.81-6.91 (3H, m), 7.24-7.30 (2H, m), 7.45-7.55 (~5H, m), 7.95 (lH, d, J=7.7); m/~ (ES+) 600 (M+l, 100%).
:E~AMPkE 39 (2R~3S,9R)-4-Aza-1~7-dioxa-3-(4-fluorophenvl)-9-methoxv-9-(2-methoxv-5-(trifluoromethYl)phenvl)-4-((3-(trifluoromethYl)PhenYl)methyl) spiror5.41decane The title compound was prepared from the morpholine of Example 32 according to the method of Example 21 to yield a glass ~54mg, 59%).
lH NMR (360MHz, CDCl3) ~ 2.26 (lH, d, J=14.0), 2.28 (lH, m), 2.47 (lH, d, J=14.0), 2.67 (lH, br d, J=11.4), 2.77 (lH, d, J=13.5), 2.90 (3H, s), 3.38 (lH, s), 3.54 (lH, d, J=13.6), 3.59 (lH, m), 3.62 ~3H, s), 3.76 (lH, d, J=9.8), 4.20 (lH, dt, J=11.8, 2.2), 4.35 (lH, d, J--9.8), 6.75 (lH, d, J=8.6), 6.81 (2H,t, J=8.7), 7.15 (lH, d, J=2 1), 7.28-7.41 (5H, m), 7.44 (~2H, br s): m/~ (ES~) 600 (M+l, 100%) (2R,3S~9R)-4-Aza-1,7-dioxa-3-(4-fluoro~henvl)-9-methoxv-9-(2-methoxy-5-(trifluoromethvl)Phenvl)-4-((4-(trifluoromethYl)phenvl)methYl)-spiror6.41decane The title compound was prepared from the morpholine of Example 32 according to the method of Example 21 to yield a glass (63mg, 69%).
lH NMR (360MHz, CDC13) ~ 2.34 (lH, d, J=14.0), 2.36 (lH, dt, J=ll 7, 3.4), 2.55 (lH, d, J=14.0), 2.74 (lH, br d, J=11.5), 2.84 (lH, d, J=13.7). 2.98 (3H, s), 3.46 (lH, s~, 3.62 (lH, d, J=14.3), 3.68 (lH, m), 3.70 (3H. s), 3.83 CA 0224~78 1998-08-0~
WO 97/30056 PCT/G~97/00404 (lH, d, J=9.8), 4.27 (lH, dt, ~=12.0, 2.6), 4.44 (lH, d, J=9.8), 6.83 (lH, d, J=8.6), 6.88 (2H, t, J=8.7'?, 7.23 (lH, d, J=2.1), 7.36 (2H, d, J=8.0), 7.47 (lH, dd, J=9.0, 1.9), 7.51 (4H, m); m/z (ES~) 600 (M+l, 100%).
EXA3!.!1PLE 41 (2R,3S,9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-methoxv-4-¢(2-methoxyphenvl)methvl)-9-(2-methoxv-5-(trifluoromethvl~PhenYl) s~iror5.41decane The title compound was prepared from the morpholine of Example 32 according to the method of Example 21 to yield an oil (63mg, 74%).
lH NMR (360MHz, C~DCl3) ~? 2.32-2.40 (2H, m), 2.53 (lH, d, J=13.9), 2.86 (lH, br d, J=11.7), 2.97 (3H, s), 3.03 (lH, d, J=13.8), 3.40 (lH, d, J=13.8), 3.46 (lH, s), 3.65 (lH, dd, J=11.4, 2.13, 3.67 ~lH, m), 3.69 (3H, s), 3.72 (3H, s), 3.81 (lH, d, J=9.8), 4.27 (lH, dt, J=11.8, 2.1), 4.41 (lH, d, J=9.8), 6.76-6.91 (5H, m), 7.15-7.25 (2H, m), 7.38 (lH, br d, J=6.g), 7.46 (lH, dd, J=8.6, 1.8), 7.50 (~2H, br s); m/z (ES+) 562 (M+l, 100%).
(2R,3S,9R)-9-Allvloxy-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-phenvl-s~iro~5.4]decane The title compound was prepared from the alcohol of Example 1 and allyl bromide according to the method of Example 22 to yield an oil (62mg, 59%). lH NMR (36(!MH~, CDCl3) ~? 2.24 (lH, d, J=14.2), 2.32 (lH, dt, J=11.8, 3.5), 2.47 (lH, d, J=14.2), 2.78 (lH, d, J=13.3), 2.78 (lH, m), 3.43 (lH, s), 3.61-3.84 (5H, m), 4.23 (lH, dt, J=11.7, 2.5), 4.28 (lH, d, J=9.2), 5.10 (lH, dq, J=10.4, 1.6), 5.28 (lH, dq, J=17.2, 1.7)? 5.83-5.93 (lH, m), 6.77-6.81 (2H, m), 6.96 (2H, t, J=8.7~?, 7.08-7.28 (8H~ m), 7.55 (~2H, br s);
m/z (ES+) 460 (M+l, 100%).
(2R,3S,9R)-4-Aza-4-benzvl- 1,7-dioxa-3-(4-fluorophenyl) -9-Phenvl-9-(phenylmethvloxY)spiror5.4~decane The title compound was prepared from the alcohol of l~ mI~le 1 and benzyl bromide according to the method of Example 22 to yield an oil which solidified on st~n~ing (99mg, 77%). lH NMR (360MHz, CDCl3~ ~
2.29 (lH, d, J=14.2), 2.35 (lH, dt, J=ll.9, 3.3), 2.58 (lH, d, J=14.2), 2.80 (2H, m), 3.45 (lH, s~, 3.64 (lH, m), 3.68 (lH, d, J=13.8), 3.79 (lH, d, J=9.3), 4.16 (lH, d, J=11.6), 4.26 (lH, dt, J=11.5, 1.7), 4.33-4.38 (2H, m), 10 6.85-6.89 (2H, m), 6.95 (2H, t, J=8.6), 7.11-7.32 (13H, m), 7.56 (~2H, br s); m/z (ES+) 510 (M+1, 100%).
(2R,3S.9R)-4-Aza-1,7-dioxa-3-(4-fluoroPhenvl)-9-PhenYl-9-propyloxy-15 spiror5.41decane The benzyl~rnin~ of F'.~r~mple 42 was hydrogenated according to the method of Example 9 to yield the title compound as an oil (27mg, 67%).
H NMR (360MHz, CDCl3) ~ 0.84 (3H, t, J=7.3), 1.54 (2H, sx, J=7.2), 1.84 (~lH, br s), 1.98 (lH, m), 2.15 (lH, d, J=14.1), 2.31 (lH, d, J=13.9), 2.40 20 (lH, d, ~=14.1), 2.94-3.23 (~4H, m), 3.66-3.70 (~lH, m), 3.82 (lH, d, J=9.2),3.93 (lH, s), 4.18-4.25 (lH, m), 4.29 (1~, d, J=9.1), 6.71-6.92 (~3H, m), 7.04-7.11 (3H, m), 7.20-7.41 (~2H, m); m/~ (ES+) 372 (M+1, 100%).
25 (2R~3S.9R~-4-Aza-4-benzYl-1.7-dioxa-9-fluoro-3-(4-fluoroPhenYl)-9-Phen sPiro ~5.41 decane Nitrogen was bubbled through a solution of the alcohol of Example 1 (250mg, 0.60mmol) in dichloromethane (6ml) in a NalgeneT~ flask for 5 minutes before cooling to -78~C. Diethylaminosulfur trifluoride (83,u1, 30 0.63mmol) was added dropwise and the solution stirred at -78~C for 4 hours. The reaction mixture was quenched at -78~C by the addition of WO 97/30056 PCT/GB97/~0404 water (20ml), diluted with dichloromethane (20ml), separated and the organic layer dried (MgSO4) and concentrated to a gum (317mg). The crude residue was purified by medium pressure silica gel chromatography eluting with 5:1 hexane:ethyl acetate to yield the title compound (~3:1 mixture of diastereomers) as the least polar component as an oil (65mg, 26%); lH NMR (360MHz, CDCl3) ~ 2.23-2.59 (~3H, m), 2.75-2.92 (~3H, m), 3.50 and 3.54 (lH total, 3:1, 2 x s), 3.61-3.78 (~21~I, m), 3.98-4.42 (~2H, m), 6.96-7.36 (12H, m), 7.54-7.68 (~2H, br s); 13C NMR (90.6MHz, CDCl3, DEPT) ~ 24.66 (CHz), 35.83 (CH2), 45.41 and 45.46 (CH2), 46.41, 46.46, 10 46.53, 46.68 and 46.83 (CH2), 54.69, 55.14, 55.83 and 56.41 (C~2), 66.88, 66.98 and 67.45 (CH), 73.25 and 73.54 (CH7), 75.33 and 75.65 (CH2), 109.6~, 109.88 and 110.63 (CH), 118.47, 118.58, 118.99, 119.46 and 119.56 (C~H), ~20.81, 121.99, 122.03, 122.59, 122.76, 123.16, 123.19, 123.23, 123.30, 123.80, 123.83 and 123.92 (CH~, 127.01, 127.09, 127.27 and 127.36 15 (CH), 13~.90 (CH); m/z (ES+) 422 (M+l, 100%), 402 ~M-19, 28).
(2R,3S~9R)-4-Aza-1,7-dioxa-9-fluoro-3-(4-fluoroPhenYl)-9-phenyl-spiro[5.41decane The benzyl~mine of Example 45 was hydrogenated according to the method of l~ mple 9 to yield the title compound as an oil (18mg, 46%);
m/~ (ES+) 332 (M+1, 18%), 102 (100) 25 (2R,3S,9R~-4-Aza-4-benzYl-1.7-dioxa-3-(4-fluoroPhenYl)-9-hYdroxy-9-(2 (hvdroxymethvl)phenyl)spiro~5.41decane The product of Description 12 (350mg) was heated at ref~ux in a solution of 1~.01 HCl (2ml) and water:ethanol (lOml, 1:1) The ethanol was removed by distillation and the aqueous residue basified (NaHCO~) and 30 extracted with ethyl acetate ~3x30ml~. The combinecl organic cxtracts were washed with water and saturated brine (lx30ml cach), dried W0971300~i6 - 71 - PCT/GB97100404 ~MgSO4) and eoneentrated to a erude oil whieh was purified by flash silica gel ehromatography eluting with 9:1 to 4:1 hexane:ethyl aeetate to yield ~ the title eompound as an oil (136mg, 52%). m/z (ES+) 450 (M+1, 100%).
~0 ~ ~0/
F~
[2'R-r2'a(5*),4'a]1-3"-(4-~uoroPhenYl)-4"-(phenvlmethvl)dispiro-risobenzofuran-1(3H3~4'(5'~)-furan-2'(3EO,2"-morpholine]
Methanesulfonyl~hlori-l~ (23~L1, 0.29mmol) was added to a solution of the diol of Example 47 (130mg, 0.29mmol) and triethylamine (81~
0.58mmol) in diehloromethane (5ml) eooled to 0~C. The resulting mixture was allowed to warm to 20~C and stirred for 18 hours. The reaetion mixture was washed sequentially with l.OM citric acid, water and saturated brine, dried (MgSO4) and concentrated to a yellow oil which was purified by flash siliea gel ehromatography eluting with 19:1 to 4:1 hexane:ethyl acetate to yield the title compound as white foam (9Omg, 72%). lH NMR (360MH~, CDCl3) ~ 2.12 (lH, d, J=14.2), 2.28-2.36 (lH, m), 2.37 (lH, d, J=14.2), 2.82 (lH, d, J=12.7), 2.77-2.88 (lH, m), 3.50 (lH, s), 3.62-3.76 (3H, m), 4.24 (lH, d, J=9.7), 4.20-4.30 (lH, m), 5.03 (2H, s), 6.09 (lH, d, J=7.4), 7.02-7.30 (lOH, m), 7.65 (2H, br s); 771/~ (ES+) 432 (M+1, 100%) .
~fo~ , F ~
r2'R-r2'a(5*).4'a]1-3"-(4-fluoroPhenYl)disPirorisobenzofuran-1(3H~.4'(~i'H)-furan-2'(3H),2"-morpholinel The benzylamine of Example 48 was hydrogenated according to the method of ~,~rnple 9 to yield the title compound as a foam (15mg, 38%).
lH NMR (360MHz, CDCl3) ~ 2.02 ~lH, d, J=14.2), 2.23 (lH, d, J=14.2), 3.05 (lH, dd, J=9.~i, 2.7), 3.21 (lH, td, J=12.3, 3.6), 3.77 (~H, d, J=9.8), 3.74-3.82 (lH, m), 4.01 (lH, s), 4.28 (lH, d, J=9.8), 4.25-4.33 (lH, m), 5.04 (2H, s), 6.19 (lH, d, J=7.5), 7.02-7.13 (4H, m), 7.17 (lH, d, J=6.6), 7.48-7.54 (2H, m); m/z (~S+) 342 (M~l, 100%).
Claims (27)
1. A compound of the formula (I):
wherein R represents hydroxy, C1-6alkoxy, C3-6alkenyloxy, C3-6-alkynyloxy, fluoroC1-6alkoxy, C3-7cycloalkoxy, C3-7cycloalkylC1-4alkoxy, phenoxy, benzyloxy or halogen, wherein the phenyl moiety of said phenoxy or benzyloxy is optionally substituted by one, two or three substituents selected from C1-6alkyl, C1-6alkoxy, halogen and trifluoromethyl;
R 1 represents hydrogen, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, C1-6alkoxy, fluoroC1-6alkyl, fluoroC1-6alkoxy, C1-4alkyl substituted by a C1-4alkoxy or hydroxy group, hydroxy, trimethylsilyl, nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONR aR b, NR aR b, SO2NR aR b, or OC1-4alkylNR aR b, where R a and R b are each independently hydrogen or C1-4alkyl;
R 2 and R3 each independently represent hydrogen, halogen, C1-6alkyl, C1-6alkoxy substituted by C1-4alkoxy or trifluoromethyl;
or R and R 1 may be joined such that -R-R1- is a linkage selected fLom -O-CH2- and -O-CH2CH2-:
or, where R 1 and R 2 are attached to adjacent carbon atoms, they may be joined such that, together with the carbon atoms to which they are attached, there is formed a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms selected from oxygen, sulfur or nitrogen, or 1 or 2 groups selected from S(O), S(O)2 and NR a, which ring may also contain 1 or 2 double bonds, where R a is as previously defined;
R 4 represents hydrogen, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, C1-6alkoxy, C1-4alkyl substituted by a C1-4alkoxy group, trifluoromethyl, nitro, CN, SR a, SOR a, SO2R a, COR a, CO2R a, CONR aR b where R a and R b are as previousiy defined;
R 5 represents hydrogen, halogen, C1-6alkyl, C1-6alkoxy substituted by C1-4alkoxy or trifluoromethyl;
R 6 represents hydrogen, COR a, CO2R a, COCONR aR b, COCO 2R a, C1-6alkyl optionally substituted by a group selected from (CO 2R a, CONR aR b, hydroxy, CN, COR a, NR aR b, C(NOH)NR aR b, CONHphenyl(C1-4alkyl), COCO 2R a, CONHNR aR b, C(S)NR aR b, CONR aC1-6alkylR 12, CONR 13C2-6alkenyl, CONR 13C2-6alkynyl, COCONR aR b, CONR aC(NR b)NR aR b, CONRaheteroaryl, and phenyl optionally substituted by one, two or three substituents selected from C1-6alkyl, C1-6alkoxy, halogen and trifluoromethyl);
or R 6 represents a group of the formula -CHaC~CCH2NR 7R 8 where R 7 and R 8 are as defined below;
or R 6 represents C1-6alkyl, optionally substituted by oxo, substituted by a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O or =S and optionally substituted by a group of the formula ZNR 7R 8 where Z is C1-6alkylene or C3-6cycloalkyl;
R 7 is hydrogen or C1-4alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or C2-4alkyl substituted by C1-4alkoxy or hydroxyl;
R 8 is hydrogen or C1-4alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or C2-4alkyl substituted by C1-4alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O
and S;
or R 7, R 8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy optionally substituted by a C1-4alkoxy or hydroxyl group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH
or NR c moiety where R c is C1-4alkyl optionally substituted by hydroxy or C1-4alkoxy;
or R7, R8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
or Z, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring to 4 to 7 ring atoms which may optionally contain an oxygen ring atom;
R9a and R9b each independently represent hydrogen or C1-4alkyl, or R9a and R9b are joined so, together with the carbon atoms to which they are attached, there is formed a C5-7 ring;
R12 represents ORa, CONR aRb or heteroaryl;
R13 represents H or C1-6alkyl;
m is zero, 1, 2 or 3; and n is zero, 1, 2 or 3; with the proviso that the sum total of m and n is 2 or 3;
or a pharmaceutically acceptable salt thereof.
wherein R represents hydroxy, C1-6alkoxy, C3-6alkenyloxy, C3-6-alkynyloxy, fluoroC1-6alkoxy, C3-7cycloalkoxy, C3-7cycloalkylC1-4alkoxy, phenoxy, benzyloxy or halogen, wherein the phenyl moiety of said phenoxy or benzyloxy is optionally substituted by one, two or three substituents selected from C1-6alkyl, C1-6alkoxy, halogen and trifluoromethyl;
R 1 represents hydrogen, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, C1-6alkoxy, fluoroC1-6alkyl, fluoroC1-6alkoxy, C1-4alkyl substituted by a C1-4alkoxy or hydroxy group, hydroxy, trimethylsilyl, nitro, CN, SRa, SORa, SO2Ra, CORa, CO2Ra, CONR aR b, NR aR b, SO2NR aR b, or OC1-4alkylNR aR b, where R a and R b are each independently hydrogen or C1-4alkyl;
R 2 and R3 each independently represent hydrogen, halogen, C1-6alkyl, C1-6alkoxy substituted by C1-4alkoxy or trifluoromethyl;
or R and R 1 may be joined such that -R-R1- is a linkage selected fLom -O-CH2- and -O-CH2CH2-:
or, where R 1 and R 2 are attached to adjacent carbon atoms, they may be joined such that, together with the carbon atoms to which they are attached, there is formed a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms selected from oxygen, sulfur or nitrogen, or 1 or 2 groups selected from S(O), S(O)2 and NR a, which ring may also contain 1 or 2 double bonds, where R a is as previously defined;
R 4 represents hydrogen, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, C1-6alkoxy, C1-4alkyl substituted by a C1-4alkoxy group, trifluoromethyl, nitro, CN, SR a, SOR a, SO2R a, COR a, CO2R a, CONR aR b where R a and R b are as previousiy defined;
R 5 represents hydrogen, halogen, C1-6alkyl, C1-6alkoxy substituted by C1-4alkoxy or trifluoromethyl;
R 6 represents hydrogen, COR a, CO2R a, COCONR aR b, COCO 2R a, C1-6alkyl optionally substituted by a group selected from (CO 2R a, CONR aR b, hydroxy, CN, COR a, NR aR b, C(NOH)NR aR b, CONHphenyl(C1-4alkyl), COCO 2R a, CONHNR aR b, C(S)NR aR b, CONR aC1-6alkylR 12, CONR 13C2-6alkenyl, CONR 13C2-6alkynyl, COCONR aR b, CONR aC(NR b)NR aR b, CONRaheteroaryl, and phenyl optionally substituted by one, two or three substituents selected from C1-6alkyl, C1-6alkoxy, halogen and trifluoromethyl);
or R 6 represents a group of the formula -CHaC~CCH2NR 7R 8 where R 7 and R 8 are as defined below;
or R 6 represents C1-6alkyl, optionally substituted by oxo, substituted by a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O or =S and optionally substituted by a group of the formula ZNR 7R 8 where Z is C1-6alkylene or C3-6cycloalkyl;
R 7 is hydrogen or C1-4alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or C2-4alkyl substituted by C1-4alkoxy or hydroxyl;
R 8 is hydrogen or C1-4alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or C2-4alkyl substituted by C1-4alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O
and S;
or R 7, R 8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy optionally substituted by a C1-4alkoxy or hydroxyl group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH
or NR c moiety where R c is C1-4alkyl optionally substituted by hydroxy or C1-4alkoxy;
or R7, R8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
or Z, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring to 4 to 7 ring atoms which may optionally contain an oxygen ring atom;
R9a and R9b each independently represent hydrogen or C1-4alkyl, or R9a and R9b are joined so, together with the carbon atoms to which they are attached, there is formed a C5-7 ring;
R12 represents ORa, CONR aRb or heteroaryl;
R13 represents H or C1-6alkyl;
m is zero, 1, 2 or 3; and n is zero, 1, 2 or 3; with the proviso that the sum total of m and n is 2 or 3;
or a pharmaceutically acceptable salt thereof.
2. A compound as claimed in claim 1 wherein R represents hydroxy, C1-3alkoxy, C3-5alkenyloxy, phenoxy or halogen.
3. A compound as claimed in claim 1 or claim 2 wherein R1 represents hydrogen, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, C1-6alkoxy, C1-4alkyl substituted by a C1-4alkoxy group, OCF3, hydroxy, trifluoromethyl, trimethylsilyl, nitro, CN, SR a, SOR a, SO2R a, COR a, CO2R a, CONR a R b where R a and R b are each independently hydrogen or C1-4alkyl; and R2 and R3 each independently represent hydrogen, halogen, C1-6alkyl, C1-6alkoxy substituted by C1-4alkoxy or trifluoromethyl.
4. A compound as claimed in any one of claims 1 to 3 wherein R 1 is hydrogen, C1-4alkyl, C1-4alkoxy, halogen, fluoroC1-3alkyl or fluoroC1-3alkoxy.
5. A compound as claimed in any one of claims 1 to 4 wherein R 2 is hydrogen, C1-4alkyl, C1-4alkoxy, halogen or CF3.
6. A compound as claimed in any one of claims 1 to 5 wherein R 3 is hydrogen, fluorine, chlorine or CF3.
7. A compound as claimed in any one of claims 1 to 6 wherein R 4 is hydrogen.
8. A compound as claimed in any one of claims 1 to 7 wherein R 5 is hydrogen, fluorine, chlorine or CF3.
9. A compound as claimed in any one of claims 1 to 8 wherein R 9a and R 9b are each independently hydrogen or methyl.
10. A compound as claimed in any one of claims 1 to 9 wherein n is 1.
11. A compound as claimed in any one of claims 1 to 10 wherein m is 1 or 2.
12. A compound of formula (Ia) wherein R and R6 are as defined in claim 1;
A1 is hydrogen, C1-3alkyl, C1-3alkoxy, halogen, fluoroC1-3alkyl or fluoroC1-3alkoxy;
A2 is hydrogen, halogen, C1-4alkyl or fluoroC1-3alkyl; and A3 is hydrogen or halogen;
or a pharmaceutically acceptable salt thereof.
A1 is hydrogen, C1-3alkyl, C1-3alkoxy, halogen, fluoroC1-3alkyl or fluoroC1-3alkoxy;
A2 is hydrogen, halogen, C1-4alkyl or fluoroC1-3alkyl; and A3 is hydrogen or halogen;
or a pharmaceutically acceptable salt thereof.
13. A compound as claimed in any one of claims 1 to 12 wherein R6 is hydrogen, C1-3alkyl substituted by phenyl wherein said phenyl ring is optionally substituted by C1-3alkoxy or CF3, or R6 is a group of formula -CH2C~CCH2NR7R8, or R5 is C1-3alkyl substituted by a 5-membered heterocyclic ring selected from:
; ; ;
; ;
and
; ; ;
; ;
and
14. A compound selected from:
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-f1uorophenyl)-9-hydroxy-9-phenyl-spiro [5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro [5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydloxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4] decane;
(2R,3S,9S)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethoxy)phenyl)spiro[5.4]decane;
(+/-)-(2R*.3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methylphenyl)spiro[5.4]decane;
(2R,3S.9R)-4-aza-4-benzyl- 1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-hydroxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-spiro[5.4] decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-phenylspiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3 -(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4] decane;
(2R,3S,9S)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethoxy)phenyl)spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methylphenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(4-(N,N-dimethylamino)-but-2-ynyl)-1,7-dioxa-3-(4-fluorphenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)- 1,2,3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-(1(S)-phenylethyl)-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-(1(R)-phenylethyl)-9-(2-(trifluoromethyl)phenyl)spiro[5.4] decane:
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-((2-(trifluoromethyl)phenyl)methyl)-9-(2-(trifluoromethyl)phenyl)-spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro[5.4]decane;
(2R, 3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methylphenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-methoxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro [5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methylphenyl)spiro[5.4]decane:
(2R.3S,9R)-4-aza-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-methoxy-spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-tetrazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(S)-phenylethyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(R)-phenylethyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((2-(trifluoromethyl)phenyl)methyl)-spiro[5.4] decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl)phenyl)methyl)-spiro[5.4] decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((4-(trifluoromethyl)phenyl)methyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-((2-methoxyphenyl)methyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl) spiro[5.4]decane;
(2R,3S,9R)-9-allyloxy-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-phenyl-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-phenyl-9-(phenylmethyloxy)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-propyloxy-9-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-9-fluoro-3-(4-fluorophenyl)-9-phenyl-spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-9-fluoro-3-(4-fluorophenyl)-9-phenylspiro[5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(hydroxymethyl)phenyl)spiro[5.4]decane;
[2'R-[2'.alpha.(S*),4'.alpha.]]-3"-(4-fluorophenyl)-4"-(phenylmethyl)dispiro-[isobenzofuran-1(3H),4'(5'H)-furan-2'(3H),2"-morpholine];
[2'R-[2'.alpha.(S*),4'.alpha.]]-3"-(4-fluorophenyl)dispiro[isobenzofuran- 1(3H),4'(5'H)-furan-2'(3H),2"-morpholine];
or a pharmaceutically acceptable salt thereof.
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-f1uorophenyl)-9-hydroxy-9-phenyl-spiro [5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro [5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydloxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4] decane;
(2R,3S,9S)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethoxy)phenyl)spiro[5.4]decane;
(+/-)-(2R*.3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methylphenyl)spiro[5.4]decane;
(2R,3S.9R)-4-aza-4-benzyl- 1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-hydroxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-spiro[5.4] decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-phenylspiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3 -(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4] decane;
(2R,3S,9S)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethoxy)phenyl)spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methylphenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxyphenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(trifluoromethyl)phenyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(4-(N,N-dimethylamino)-but-2-ynyl)-1,7-dioxa-3-(4-fluorphenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)- 1,2,3-triazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-(1(S)-phenylethyl)-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-(1(R)-phenylethyl)-9-(2-(trifluoromethyl)phenyl)spiro[5.4] decane:
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-4-((2-(trifluoromethyl)phenyl)methyl)-9-(2-(trifluoromethyl)phenyl)-spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro[5.4]decane;
(2R, 3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methylphenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-methoxy-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl-9-(2-chlorophenyl)-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-spiro[5.4]decane;
(+/-)-(2R*,3S*,9R*)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-phenyl-spiro [5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxyphenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4] decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methylphenyl)spiro[5.4]decane:
(2R.3S,9R)-4-aza-1,7-dioxa-9-(2-ethylphenyl)-3-(4-fluorophenyl)-9-methoxy-spiro[5.4] decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-(5-(N,N-dimethylaminomethyl)-1,2,3-tetrazol-4-yl)methyl-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(S)-phenylethyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-(1-(R)-phenylethyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((2-(trifluoromethyl)phenyl)methyl)-spiro[5.4] decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl)phenyl)methyl)-spiro[5.4] decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-9-(2-methoxy-5-(trifluoromethyl)phenyl)-4-((4-(trifluoromethyl)phenyl)methyl)-spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-methoxy-4-((2-methoxyphenyl)methyl)-9-(2-methoxy-5-(trifluoromethyl)phenyl) spiro[5.4]decane;
(2R,3S,9R)-9-allyloxy-4-aza-4-benzyl-1,7-dioxa-3-(4-fluorophenyl)-9-phenyl-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-phenyl-9-(phenylmethyloxy)spiro[5.4]decane;
(2R,3S,9R)-4-aza-1,7-dioxa-3-(4-fluorophenyl)-9-propyloxy-9-spiro[5.4]decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-9-fluoro-3-(4-fluorophenyl)-9-phenyl-spiro[5.4]decane;
(2R,3S,9R)-4-aza- 1,7-dioxa-9-fluoro-3-(4-fluorophenyl)-9-phenylspiro[5.4] decane;
(2R,3S,9R)-4-aza-4-benzyl- 1,7-dioxa-3-(4-fluorophenyl)-9-hydroxy-9-(2-(hydroxymethyl)phenyl)spiro[5.4]decane;
[2'R-[2'.alpha.(S*),4'.alpha.]]-3"-(4-fluorophenyl)-4"-(phenylmethyl)dispiro-[isobenzofuran-1(3H),4'(5'H)-furan-2'(3H),2"-morpholine];
[2'R-[2'.alpha.(S*),4'.alpha.]]-3"-(4-fluorophenyl)dispiro[isobenzofuran- 1(3H),4'(5'H)-furan-2'(3H),2"-morpholine];
or a pharmaceutically acceptable salt thereof.
15. A compound as claimed in any preceding claim for use in therapy.
16. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 14 in association with a pharmaceutically acceptable carrier or excipient.
17. A method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound according to claim 1.
18. A method according to claim 17 for the treatment prevention of pain or inflammation.
19. A method according to claim 17 for the treatment prevention of migraine.
20. A method according to claim 17 for the treatment prevention of emesis.
21. A method according to claim 17 for the treatment or prevention of postherpetic neuralgia.
22. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of a physiological disorder associated with an excess of tachykinins.
23. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of pain or inflammation.
24. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of migraine.
25. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of emesis.
26. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of postherpetic neuralgia.
27. A process for the preparation of a compound as claimed in Claim 1 which comprises:
(A), where R is a hydroxy group, reacting a compound of formula (II) wherein R4, R5, R6, R 9a, R 9b, m and n are as defined in claim 1 with a Grignard or organolithium compound of formula (IIIA) or (IIIB) wherein R1, R2 and R3 are as defined in claim 1 and Hal is a halogen atom;
or (B), where R is a group selected from C1-6alkoxy, C3-6alkenyloxy, C3-6alkynyloxy, fluoroC1-6alkoxy, C3-7cycloalkoxy, C3-7cycloalkylC1-4alkoxy, phenoxy or benzyloxy, reacting a compound of formula (IV) with a suitable alkyl halide, alkenyl halide, alkynyl halide, fluoroalkyl halide, cycloalkyl halide, cycloalkylalkyl halide, phenyl halide or benzyl halide; or (C), where R is a halogen atom, reacting a compound of formula (IV) with a suitable halogenating reagent; or (D), where R 6 is H, debenzylating the corresponding compound of formula (I) in which R 6 is a benzyl group; or (E), reacting a compound of formula (V) wherein R, R1, R2, R3, R4, R5, R 9a, R 9b, m and n are as defined in claim 1, with a compound of formula (VI) where R 6a is a group of the formula R 6 as defined in claim 1 or a precursor therefor and LG is a leaving group; and, if R 6a is a precursor group, converting it to a group R 6; or (F), where R 6 represents a 1,2,3-triazol-4-ylmethyl group substituted by CH2NR7R8, reacting a compound of formula (VII) with an amine of formula NHR 7R 8; or (G), where R 6 represents a C1-6alkyl group which is substituted by an unsubstituted or substituted 1,2,4-triazolyl group, reacting a compound of formula (V) with a compound of formula (VIII) wherein Hal is a halogen atom, p is an integer from 1 to 6 and R 18 is H, CONH 2 or OCH 3 (which is converted to an oxo substituent under the reaction conditions), in the presence of a base, followed where necessary by conversion to a compound of formula (I) by reduction of the CONH 2 group to CH 2NH2; or (II). interconversion of a compound of formula (I) into another compound of formula (I); or (J), where R 6 represents the group -CH2C~CCH 2NR 7R 8, reacting a compound of formula (X) wherein Hal is a halogen atom, with an amine of formula HNR 7R 8 in the presence of a base;
each process being followed, where necessary, by the removal of any protecting group where present;
and when the compound of formula (I) is obtained as a mixture of enantiomers or diastereoisomers, optionally resolving the mixture to obtain the desired enantiomer;
and/or, if desired, converting the resulting compound of formula (I) or a salt thereof, into a pharmaceutically acceptable salt thereof.
(A), where R is a hydroxy group, reacting a compound of formula (II) wherein R4, R5, R6, R 9a, R 9b, m and n are as defined in claim 1 with a Grignard or organolithium compound of formula (IIIA) or (IIIB) wherein R1, R2 and R3 are as defined in claim 1 and Hal is a halogen atom;
or (B), where R is a group selected from C1-6alkoxy, C3-6alkenyloxy, C3-6alkynyloxy, fluoroC1-6alkoxy, C3-7cycloalkoxy, C3-7cycloalkylC1-4alkoxy, phenoxy or benzyloxy, reacting a compound of formula (IV) with a suitable alkyl halide, alkenyl halide, alkynyl halide, fluoroalkyl halide, cycloalkyl halide, cycloalkylalkyl halide, phenyl halide or benzyl halide; or (C), where R is a halogen atom, reacting a compound of formula (IV) with a suitable halogenating reagent; or (D), where R 6 is H, debenzylating the corresponding compound of formula (I) in which R 6 is a benzyl group; or (E), reacting a compound of formula (V) wherein R, R1, R2, R3, R4, R5, R 9a, R 9b, m and n are as defined in claim 1, with a compound of formula (VI) where R 6a is a group of the formula R 6 as defined in claim 1 or a precursor therefor and LG is a leaving group; and, if R 6a is a precursor group, converting it to a group R 6; or (F), where R 6 represents a 1,2,3-triazol-4-ylmethyl group substituted by CH2NR7R8, reacting a compound of formula (VII) with an amine of formula NHR 7R 8; or (G), where R 6 represents a C1-6alkyl group which is substituted by an unsubstituted or substituted 1,2,4-triazolyl group, reacting a compound of formula (V) with a compound of formula (VIII) wherein Hal is a halogen atom, p is an integer from 1 to 6 and R 18 is H, CONH 2 or OCH 3 (which is converted to an oxo substituent under the reaction conditions), in the presence of a base, followed where necessary by conversion to a compound of formula (I) by reduction of the CONH 2 group to CH 2NH2; or (II). interconversion of a compound of formula (I) into another compound of formula (I); or (J), where R 6 represents the group -CH2C~CCH 2NR 7R 8, reacting a compound of formula (X) wherein Hal is a halogen atom, with an amine of formula HNR 7R 8 in the presence of a base;
each process being followed, where necessary, by the removal of any protecting group where present;
and when the compound of formula (I) is obtained as a mixture of enantiomers or diastereoisomers, optionally resolving the mixture to obtain the desired enantiomer;
and/or, if desired, converting the resulting compound of formula (I) or a salt thereof, into a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9603136.4 | 1996-02-15 | ||
GBGB9603136.4A GB9603136D0 (en) | 1996-02-15 | 1996-02-15 | Therapeutic agents |
PCT/GB1997/000404 WO1997030056A1 (en) | 1996-02-15 | 1997-02-13 | Spiro-ketal derivatives and their use as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2245578A1 true CA2245578A1 (en) | 1997-08-21 |
Family
ID=29422170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2245578 Abandoned CA2245578A1 (en) | 1996-02-15 | 1997-02-13 | Spiro-ketal derivatives and their use as therapeutic agents |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2245578A1 (en) |
-
1997
- 1997-02-13 CA CA 2245578 patent/CA2245578A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5728695A (en) | Spiroketal derivatives, compositions containing them and their use as therapeutic agents | |
US6096766A (en) | 3-benzylaminopiperidines as tachykinin receptor antagonists | |
AU710873B2 (en) | Morpholine derivatives and their use as therapeutic agents | |
US5962485A (en) | N-(2-benzyloxy-1-phenethyl)-N-(2'-methoxyethyl)amino-methane compounds are useful as tachykinin antagonists | |
US5985896A (en) | Piperidine and morpholine derivatives and their use as therapeutic agents | |
US5885999A (en) | Serine derivatives and their use as therapeutic agents | |
US6172077B1 (en) | Spiro-azacyclic derivatives and their use as therapeutic agents | |
US5830892A (en) | Piperidine and morphonline derivatives and their use as therapeutic agents | |
EP0880528B1 (en) | Spiro-ketal derivatives and their use as therapeutic agents | |
US5922744A (en) | Ethane-1-2-diamine derivatives and tachykinin antagonists | |
AU717414B2 (en) | Spiro-ketal derivatives and their use as therapeutic agents | |
CA2245578A1 (en) | Spiro-ketal derivatives and their use as therapeutic agents | |
CA2245579A1 (en) | Spiro-ketal derivatives and their use as therapeutic agents | |
CA2235855A1 (en) | Morpholine derivatives and their use as therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |